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This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented, but is described in less detail than the key studies. The profile is not intended to be an
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile
begins with a public health statement that describes, in nontechnical language, a substance's relevant
toxicological properties.  Following the public health statement is information concerning levels of
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of
significance to the protection of public health are identified by ATSDR.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or
levels of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and
local levels; interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR.
Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry











     
    
    
  
   
  
   
   
   
vi1-BROMOPROPANE
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise








   
  
  






     
   
     
  
 
    
    
 
   
   
 
    
     




    
      
   
   
 
 
   









   
  
   
 
vii1-BROMOPROPANE
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances may find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (e.g., death, systemic, immunologic, reproductive), by route of exposure, and by 
length of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies
are reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet:  http://www.atsdr.cdc.gov
The following additional materials are available online:
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary
health care providers’ knowledge of a hazardous substance in the environment and to aid in the





















   
 
   
 
 
   
  
  

















   
    
 
    
 
 
    
    
viii1-BROMOPROPANE
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides
to assist first responders and hospital emergency department personnel in planning for incidents
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp).
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:
https://www.cdc.gov/nceh/.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page:
https://www.niehs.nih.gov/.
Clinical Resources (Publicly Available Information)
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:
http://www.acoem.org/.
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with






    
 
 
   
  
     
   
 
   
  




Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX:  844-226-8333 • Web Page:
http://www.acmt.net.
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the 
public about the impact of environmental factors on the health of children and reproductive-aged
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html.
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA
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ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA
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Peter McClure, Ph.D., D.A.B.T.
Kimberly Zaccaria, Ph.D.
Courtney Hard, B.A.
SRC, Inc., North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to
assure consistency across profiles and adherence to instructions in the Guidance.






























   




   
    
     
   
 
  




A peer review panel was assembled for 1-bromopropane.  The panel consisted of the following members:
1. Xiaozhong (John) Yu MD, Ph.D., Department of Environmental Health Science, College of
Public Health, University of Georgia, Athens, Georgia;
2. James V. Bruckner, Ph.D., Professor of Pharmacology and Toxicology, Department of
Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens,
Georgia; and
3. Gaku Ichihara, M.D., Ph.D., Department of Occupational and Environmental Health Faculty of
Pharmaceutical Sciences, Tokyo University of Science, Japan.
These experts collectively have knowledge of 1-bromopropane’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1. PUBLIC HEALTH STATEMENT FOR 1-BROMOPROPANE
This Public Health Statement summarizes the Agency for Toxic Substances and Disease Registry’s 
(ATSDR) findings on 1-bromopropane, including chemical characteristics, exposure risks, possible health
effects from exposure, and ways to limit exposure.
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the
nation.  These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal
clean-up activities.  1-Bromopropane has not been reported at any EPA NPL sites; however, it is
unknown how many of the 1,832 current or former NPL sites have been evaluated for the presence of
1-bromopropane.  But the possibility remains that as more sites are evaluated, the sites where 
1-bromopropane is found may increase.  This information is important because these future sites may be
sources of exposure, and exposure to 1-bromopropane may be harmful.
If you are exposed to 1-bromopropane, many factors determine whether you’ll be harmed.  These include
how much you are exposed to (dose), how long you are exposed (duration), how often you are exposed 
(frequency), and how you are exposed (route of exposure).  You must also consider the other chemicals
you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.
WHAT IS 1-BROMOPROPANE?
1-Bromopropane is a colorless liquid.  Commercial 1-bromopropane includes not only 1-bromopropane, 
but also additives that improve its performance in the desired application and stabilizers to inhibit
decomposition.
1-Bromopropane was originally used in the production of pesticides, flavors and fragrances,
pharmaceuticals, and other chemicals.  It is currently used as a solvent in the adhesives, dry cleaning,
vapor degreasing, and electronic and metal cleaning industries. 1-Bromopropane production has increased
over the last 10 years due to its use as a replacement for other more harmful substances.
More information regarding the identity of 1-bromopropane can be found in Chapters 4 and 5.
WHAT HAPPENS TO 1-BROMOPROPANE WHEN IT ENTERS THE ENVIRONMENT?
1-Bromopropane quickly evaporates into the air when released to the environment.  In air, it is broken 
down quickly. Half of 1-bromopropane will be broken down in 2 weeks.  1-Bromopropane has been 
   
 




   
     




   
 
 
    
   
   
  
    
 




   
 
   
 
     
     
  
     
        
      
     
     
 
    
 
  
      
21-BROMOPROPANE
1.  PUBLIC HEALTH STATEMENT
detected in ambient air.  1-Bromopropane that enters surface water is slowly broken down.  Most of it
evaporates into air.  1-Bromopropane released to soil can enter surface water.  It is not bound to soil
particles, so it may enter groundwater.  1-Bromopropane is not likely to concentrate in the food chain. 
More information regarding the levels 1-bromopropane in the environment can be found in Chapter 6.
HOW MIGHT I BE EXPOSED TO 1-BROMOPROPANE?
Exposure to 1-bromopropane is mainly an occupational problem.  Use of 1-bromopropane in aerosol
applications can lead to dermal and inhalation exposure of workers. Workers using 1-bromopropane as a
spray adhesive have the highest exposures.  Workers involved in the production of 1-bromopropane, as
well as those using it in commercial applications, such as adhesive sprays, degreasing operations for
cleaning metals, plastics, and electronic components, dry cleaning, asphalt production, aircraft
maintenance, and synthetic fiber manufacturing, also have potential for high exposure.
You may be exposed to 1-bromopropane in air when it is used during aerosol applications, specifically at
locations in close proximity to facilities where it is used, processed, or manufactured, where vapor may
migrate.
More information regarding exposure and 1-bromopropane can be found in Sections 6.5–6.7.
HOW CAN 1-BROMOPROPANE ENTER AND LEAVE MY BODY?
When you breathe or touch 1-bromopropane (or products containing 1-bromopropane), it can be taken
directly into your blood through your lungs and skin.  There is no information available to show whether
1-bromopropane can enter the bloodstream if you swallow this substance in liquid form, but based on 
studies in animals, some of it will likely enter the bloodstream. Factors such as your age, sex, body 
composition, and overall health will affect what happens to 1-bromopropane once it is in your body.  The
majority of 1-bromopropane is removed from your body within a day.  1-Bromopropane may leave your
body unchanged in the air you breathe or in your urine after it has been changed to breakdown products. 
More information on how 1-bromopropane can enter and leave your body can be found in Chapter 3.
HOW CAN 1-BROMOPROPANE AFFECT MY HEALTH?
1-Bromopropane may have an effect on your nervous system (brain and nerves).  Day-after-day exposure
to low concentrations in workplace air has been associated with minor effects, such as headache, 
   
 





   
   
      
  
 
   
   
    
  
 
    
 
    
    








     
     
 
    
   
    
        
 
 
   
       
        
31-BROMOPROPANE
1.  PUBLIC HEALTH STATEMENT
decreased sensation in the fingers and toes, and a drunk-like feeling.  However, workers exposed to 
higher levels for weeks, months, or years have experienced severe effects requiring hospitalization, 
including incoordination, weakness, loss of feeling, inability to walk, and damage to nerves.  Damage to
the nervous system may not be reversible, resulting in long-term effects even after 1-bromopropane
exposure is stopped.  
Breathing 1-bromopropane may also lead to irritation of your nose and throat.  Studies in animals suggest
that high 1-bromopropane exposure may damage the liver or kidney, decrease your ability to resist
infection, or impair your ability to get pregnant (or get someone pregnant).  Evidence for these effects is
limited.  It is not known whether the same effects will happen in humans.  
We do not know if 1-bromopropane causes cancer in humans.  1-Bromopropane has caused tumors in 
animal studies. Based on the findings in animals, the American Conference of Industrial Hygienists 
(ACGIH) has assigned 1-bromopropane a classification of “A3 – Confirmed animal carcinogen with 
unknown relevance to humans” and the Department of Health and Human Services (DHHS) has 
classified 1-bromopropane as “reasonably anticipated to be a human carcinogen”. The International
Agency for Research on Cancer (IARC) and the EPA have not evaluated the carcinogenicity of
1-bromopropane.  
See Chapters 2 and 3 for more information on health effects of 1-bromopropane.
HOW CAN 1-BROMOPROPANE AFFECT CHILDREN?
This section discusses potential health effects of 1-bromopropane exposure in humans from when they’re
first conceived to 18 years of age.
The health effects of 1-bromopropane exposure in children are not known.  The nervous system is 
expected to be a target based on findings in adults.  Because the nervous system is still developing in
children, they might be more sensitive to nervous system effects seen in adults. However, since exposure 
to 1-bromopropane occurs mainly in worker settings, children are less likely to be exposed to 1-bromo-
propane.  
It is not known if a fetus or infant can be harmed if a woman is exposed to 1-bromopropane during 
pregnancy or breastfeeding. Studies in animals have shown effects when mothers were exposed to high 
levels of 1-bromopropane (500 parts per million [ppm] or higher) during pregnancy and/or nursing.
   
 




    







     
 
 
   
  







     
    
   
      
 






    




1.  PUBLIC HEALTH STATEMENT
However, the exposure levels in these studies were much higher than is expected to occur in human 
exposures. Therefore, the relevance of these findings to humans is unknown.
More information regarding children’s health and 1-bromopropane can be found in Section 3.7.
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1-BROMOPROPANE?
If your doctor finds that you have been exposed to significant amounts of 1-bromopropane, ask whether
your children might also be exposed.  Your doctor might need to ask your state health department to 
investigate.  You may also contact the state or local health department with health concerns.
Unless you live near a factory/business that uses 1-bromopropane, your household exposure to 1-bromo-
propane is expected to be minimal.  If someone in the household works in a factory or business that
produces or uses 1-bromopropane, a change of clothes prior to returning home will decrease the chance of
traces of 1-bromopropane entering the home.  Although the speed of dermal absorption of 1-bromo-
propane is unknown, thorough washing of exposed skin including face and hands should decrease the 
chance of carrying the substance home.  
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
1-BROMOPROPANE? 
1-Bromopropane and its breakdown products (metabolites) can be measured in the urine.  However, the
detection of 1-bromopropane or its metabolites cannot predict the kind of health effects that might 
develop from that exposure.  Because 1-bromopropane and its metabolites leave the body fairly rapidly,
urine tests for these substances need to be conducted within days after exposure.
For more information on the different substances formed by 1-bromopropane breakdown and on tests to
detect these substances in the body, see Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
   
 






   
 
 
    




    
   
 
 
      
 






















1.  PUBLIC HEALTH STATEMENT
public health but are not enforceable by law.  Federal organizations that develop recommendations for
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (e.g., an 8-hour
workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on 
their mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
Currently, there are no federal recommendations or regulations available for 1-bromopropane.
For more information regarding regulations and recommendations pertaining to 1-bromopropane, see 
Chapter 8.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  You may also contact
your doctor if experiencing adverse health effects or for medical concerns or questions.  ATSDR can also
provide publicly available information regarding medical specialists with expertise and experience
recognizing, evaluating, treating, and managing patients exposed to hazardous substances.
• Call the toll-free information and technical assistance number at
1-800-CDCINFO (1-800-232-4636) or
• Write to:
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences
1600 Clifton Road NE
Mailstop F-57
Atlanta, GA 30329-4027
   
 








1.  PUBLIC HEALTH STATEMENT
Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.












   
    
     
   
   
    
   
 
   
    
   
 
 





     
   
   
  
   




2. RELEVANCE TO PUBLIC HEALTH
2.1  BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1-BROMOPROPANE IN 
THE UNITED STATES
1-Bromopropane is a brominated hydrocarbon that was originally used as an intermediate in the
production of pesticides, flavors and fragrances, pharmaceuticals, and other chemicals.  It is currently
used as a solvent in the adhesives, dry cleaning, vapor degreasing, and electronic and metal cleaning
industries. There has been an increased use of 1-bromopropane in the last decade due to its application as 
a substitute for ozone-depleting substances and suspected carcinogens in various industrial and 
commercial applications.  Due to the increased use of 1-bromopropane, exposure to workers has been 
increasing, and this has caused some human health concern, such as neurological alterations and
reproductive toxicity.  Therefore, its use in certain industries is being reevaluated.
The dominant process affecting the overall environmental fate and transport of 1-bromopropane is
volatilization.  In water, estimated volatilization half-lives for a model river and a model lake were 
reported as 1.2 hours and 4.4 days, respectively.  1-Bromopropane in air will be degraded by
photochemically produced hydroxyl radicals, with 1-bromopropane having a half-life of 14 days.  
Hydrolysis and biodegradation by microorganisms have also been shown to break down 1-bromopropane
in aquatic and terrestrial environments.  1-Bromopropane is not expected to bioaccumulate in aquatic
organisms.
Exposure to 1-bromopropane occurs mainly in occupational settings.  Use of 1-bromopropane in aerosol
applications can lead to dermal and inhalation exposure of workers. Workers using 1-bromopropane as a 
spray adhesive have the highest dermal and inhalation exposures.  Workers involved in the production of
1-bromopropane, as well as those using it in commercial applications, such as adhesive sprays, degreasing
operations for cleaning metals, plastics, and electronic components, dry cleaning, asphalt production, 
aircraft maintenance, and synthetic fiber manufacturing, also have potential for high exposure.  The
general population may be exposed to 1-bromopropane in air when it is used during aerosol applications 
due to potential vapor migration, particularly at locations in close proximity to the emissive use of
1-bromopropane.
   
 






     
  
   
   
 





     
   
  
   
  
     
 
 
      
     
 
  
    
 
 
       
   
  
81-BROMOPROPANE
2. RELEVANCE TO PUBLIC HEALTH
2.2  SUMMARY OF HEALTH EFFECTS 
The preponderance of health effects information on 1-bromopropane is from studies of laboratory animals
and human studies in which the main exposure route is inhalation, but dermal exposure may have also 
occurred in the human studies.  As summarized below and detailed in Chapter 3 (Health Effects), the 
main target organ of concern following 1-bromopropane exposure in humans is the nervous system.  
Reported health effects in workers exposed to 1-bromopropane for months or years range from subtle
neurological deficits (e.g., decreased vibration sense and paresthesias) at workplace air concentrations as 
low as 1.28 ppm to frank neurotoxic effects (e.g., ataxia, spastic paraparesis, and symmetric 
demyelinating polyneuropathy) in workers exposed to concentrations ≥100 ppm. Although the principal
route of exposure was likely inhalation, dermal exposure could have been significant since often no 
gloves were used when handling 1-bromopropane, or the use of gloves, as noted in some reports, may
have enhanced dermal uptake of 1-bromopropane by occlusion effect.  Evidence of alterations of the
autonomic nervous system has also been presented.  A study that followed workers as outpatients for
2 years post-exposure reported persistent symptoms including headache, decreased memory, decreased
mood, lower extremities numbness, cramping, paresthesias, weakness, and difficulty walking/poor
balance.  Clinical signs noted in these individuals included decreased cognition, lower extremities
spasticity and weakness, gait ataxia, hyperreflexia, and decreased lower extremities sensation.  It was 
suggested that the pathogenesis of 1-bromopropane neurotoxicity in humans may reflect a central distal
axonopathy syndrome.
Results from animal studies support the conclusion that exposure to 1-bromopropane can result in
neurotoxicity.  Reported effects in acute- and intermediate-duration inhalation studies at concentrations
≥50 ppm 1-bromopropane included changes in neurobehavior, electrophysiological parameters, and in 
morphology and biochemistry of the central and peripheral nervous systems.  Impaired learning and 
memory, sedation, and biochemical changes were also reported in rats after 12 days of ingestion of doses
of 200 mg 1-bromopropane/kg/day in oral studies that assessed neurological end points in laboratory 
animals.
Various in vivo and in vitro mechanistic studies have been conducted to investigate the mechanism(s)
involved in the neurotoxic action of 1-bromopropane in animals (see Section 3.5.2, Mechanisms of
Toxicity).  Proposed mechanisms include changes in neurotransmitter systems, electrophysiological
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alterations, decreased neurogenesis, glial activation, inhibition of anti-apoptotic processes, and oxidative
stress; however, no definitive mechanism of action has yet been determined.
Limited data are available regarding non-neoplastic health effects in humans exposed to 1-bromopropane
other than neurological effects.  Preliminary health surveys and occupational case studies suggest that
1-bromopropane may be a respiratory tract irritant.  These data are supported by findings of respiratory
tract lesions in rats and mice exposed to ≥125 or ≥62.5 ppm 1-bromopropane, respectively, for
intermediate-duration periods.  Limited human clinical chemistry data do not indicate that the liver or
kidney are sensitive targets of 1-bromopropane, although animal studies suggest that liver and/or kidney
damage may occur with repeated exposure to concentrations ≥50 ppm.  Limited reproductive data
available in two NIOSH Health Hazard Evaluation reports and two preliminary health surveys are 
inadequate to assess the reproductive toxicity of 1-bromopropane in humans. The available animal data,
however, show that 1-bromopropane exposure can adversely affect the male and female reproductive 
systems (sperm damage, altered hormone concentrations, altered estrous cycles, altered reproductive
development) at exposure concentrations ≥50 ppm. 
There are no developmental studies in humans exposed to 1-bromopropane.  Studies in rats suggest that
maternal exposure to ≥500 ppm 1-bromopropane can result in reduced body weight in the offspring.  
1-Bromopropane was not teratogenic in animal studies. No human data are available regarding immune 
system effects, but one inhalation and one oral study in animals suggest that 1-bromopropane exposure
can suppress immune responses.  Available data do not provide consistent evidence for exposure-related
effects in other organ systems (cardiovascular, dermal, endocrine, gastrointestinal, hematological, or
ocular); therefore, non-neoplastic effects in these systems following exposure to 1-bromopropane are
unlikely to occur. 
There are no cancer studies in humans exposed to 1-bromopropane.  The potential carcinogenicity of
1-bromopropane has been examined in 2-year inhalation bioassays with F-344 rats and B6C3F1 mice.  
1-Bromopropane was a multi-site carcinogen in rats, significantly increasing the incidence of large 
intestine adenomas in females (500 ppm), skin keratoacanthoma in males (≥250 ppm), skin 
keratoacanthoma, basal cell adenoma, or squamous cell carcinoma in males (≥125 ppm), malignant
mesothelioma in males (500 ppm), and pancreatic islet adenoma in males (≥125 ppm).  In mice, exposure
to 1-bromopropane significantly increased the incidence of combined alveolar/bronchiolar adenoma or
carcinoma in females (≥62.5 ppm).  Based on the findings from the NTP bioassay, ACGIH has assigned 
1-bromopropane a classification of “A3 – Confirmed animal carcinogen with unknown relevance to
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humans,” and the Department of Health and Human Services has classified 1-bromopropane as
“reasonably anticipated to be a human carcinogen”. IARC and the EPA have not evaluated the
carcinogenicity of 1-bromopropane.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been established for
1-bromopropane.  An MRL is defined as an estimate of daily human exposure to a substance that is likely
to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
• An MRL of 1 ppm (5 mg/m3) has been derived for acute-duration inhalation exposure (14 days or
less) to 1-bromopropane.
The MRL is based on a BMCL1SD of 97.40 ppm for neurological effects in rats exposed intermittently to 
1-bromopropane for 14 days (Honma et al. 2003).  No adequate data in humans are available. The only
acute-duration inhalation studies in humans were a few case studies reporting subjective symptoms in
workers within 2 weeks of 1-bromopropane introduction into the workplace.  Symptoms included
respiratory irritation, headache, nausea, and lower extremity numbness, pain, and weakness; the
geometric mean air concentration was 107 ppm for glue sprayers (range 58–254 ppm) (Raymond and 
Ford 2007).  Acute animal inhalation studies included two single-exposure studies evaluating lethality
(Elf AtoChem S.A. 1997; Kim et al. 1999), a single-exposure study evaluating sperm motility (Garner et 
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al. 2007), a 1-week study evaluating neurogenesis and endocrine end points (Zhang et al. 2013), a 1-week
study evaluating morphological and biochemical changes in the brain (Wang et al. 2002), and a 3-week
study that also provided results of neurobehavioral tests conducted in rats during the first 2 weeks of
exposure (Honma et al. 2003).  Garner et al. (2007) reported significantly reduced sperm motility in mice
following a single 6-hour exposure to 800 ppm 1-bromopropane for 6 hours. It should be noted, however, 
that because the initial concentration of 800 ppm 1-bromopropane decreased steadily during the 6-hour
exposure period, the true LOAEL may have been somewhat lower. Wang et al. (2002) reported 
morphological changes in the medulla oblongata and posterior tibial nerve in rats exposed to 800 ppm
1-bromopropane, but not ≤400 ppm, for 1 week (Wang et al. 2002).  However, only one rat/group was
assessed for morphological alterations.  Wang et al. (2002) also reported several biochemical changes in
the central nervous system of rats following exposure to ≥200 ppm 1-bromopropane. The toxicological 
significance of these changes is unknown because there were no clear associations between biochemical
and morphological changes.  Other reported neurological effects included decreased activity and ataxia
after single exposures to ≥1,800 ppm, but not 300 ppm; however, only qualitative data were provided in 
that study (Kim et al. 1999).  In the Zhang et al. (2013) study, there were no exposure-related changes in
hippocampal neurogenesis, adrenal weight, or plasma corticosterone levels in male rats intermittently
exposed to 1,000 ppm 1-bromopropane (the highest exposure concentration tested) for 1 week.  Honma et
al. (2003) conducted several neurobehavioral tests in male F-344 rats following exposure to ≤1,000 ppm
1-bromopropane 8 hours/day, 7 days/week for 3 weeks.  All tests were conducted at various times after
the 3-week exposure period except a traction test that was also conducted on exposure days 1, 7, and 14.  
The traction test was used to measure forelimb grip strength. No statistically significant differences in
grip strength were observed between exposed rats (10, 50, 200, 1,000 ppm 1-bromopropane) and controls
on days 1 or 7.  On day 14, however, rats exposed to 1,000 ppm 1-bromopropane showed a statistically
significant decrease in grip strength compared to lower exposure groups and controls, thus defining a no-
observed-adverse-effect level (NOAEL) and LOAEL of 200 and 1,000 ppm, respectively, for
neurological effects in an acute-duration inhalation study.  Because all data were presented graphically,
the means and standard errors (standard deviations [SDs] were subsequently calculated) for traction time 
(assessed on day 14) were extracted digitally using GrabIt! software (version XP2) for benchmark dose
(BMD) analysis. The BMCL1SD of 97.40 ppm from the selected model (Exponential model 4) was
duration-adjusted (8/24 hours) to calculate a BMCL[HEC] of 32.3 ppm.  Applying an uncertainty factor of
30 (3 for extrapolation from animals to humans with dosimetric adjustment and 10 for human variability)
to the BMCL[HEC] of 32.3 ppm yields an acute-duration inhalation MRL of 1 ppm for 1-bromopropane.  A
duration adjustment (8/24 hours) seemed appropriate in the absence of information regarding whether
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Haber’s Law is applicable under the experimental conditions of the study. Further details of the MRL
derivation are presented in Appendix A.
• An MRL of 0.1 ppm (0.5 mg/m3) has been derived for intermediate-duration inhalation exposure
(15–364 days) to 1-bromopropane.
Adequate human data are not available. There are three publications of human cases exposed for
intermediate durations (from weeks to months) that provide exposure levels.  A case discussed by
Ichihara et al. (2002) (case 3) was a woman who showed signs of staggering and numbness and 
paresthesias in the feet, thighs, lower back, and hips, and complained of headaches after 2 months of
using 1-bromopropane as a solvent with a spray gun.  Estimates of the exposure levels using a passive 
sampler indicated that the daily time-weighted average (TWA) concentration ranged from 60 to 261 ppm
with an average of 133±67 ppm (SD).  An MRL cannot be based on a single case.  Raymond and Ford 
(2007) reported that four workers developed severe ataxia, sensory motor, and cognitive impairments
soon after the introduction of 1-bromopropane into their workplace as a furniture adhesive.  A survey
conducted by the National Institute of Occupational Safety and Health (NIOSH) 9 months after the four
workers became ill showed that the workers could have been exposed to a mean concentration of
1-bromopropane of 107 ppm (range 58–254 ppm).  This study is not suitable for MRL derivation because
of the small size of the cohort, the fact that the workers studied had elevated urinary arsenic 
concentrations from unknown sources, a major confounder, and lack of exposure data at the time of the
illnesses. In a brief communication, Wang et al. (2015) reported that 6 out of 20–25 workers in a golf-
club cleaning business in Taiwan developed neurological symptoms, including tingling pain, soreness in
the lower extremities, and paresthesia after exposure to 1-bromopropane for 3–10 months.  Workers were
assigned to wash and dry golf clubs with the solvent. The mean of three measurements of
1-bromopropane in air over the platform of the washing tank was 128.8 ppm (range 97.3–188.6 ppm).  
Because only qualitative data were presented, no personal air sampling was available, and dermal contact
with 1-bromopropane may have been considerable (no data on the use of gloves were provided), this
study is inadequate for MRL derivation.
Examination of the intermediate-duration inhalation database in animals suggests that the liver and the
nervous system might be targets for 1-bromopropane toxicity. Four studies identified the lowest LOAEL
of 50 ppm 1-bromopropane.  At this exposure concentration, Kim et al. (1999) reported hepatocyte
vacuolization in Sprague-Dawley rats exposed intermittently for 8 weeks; Liu et al. (2009) reported
hepatocellular degeneration and focal necrosis and alterations in sperm parameters in BALB/cA mice 
exposed intermittently for 4 weeks, Zong et al. (2016) reported mild hepatocyte degeneration in rats
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exposed intermittently for 4 weeks, and Honma et al. (2003) reported increased spontaneous locomotor
activity in Fischer-344 rats exposed intermittently for 3 weeks.  The 50 ppm exposure concentration was
the lowest concentration tested in the Kim et al. (1999), Liu et al. (2009), and Zong et al. (2016) studies, 
whereas Honma et al. (2003) identified a NOAEL of 10 ppm for neurological effects.  Of these three 
studies, the Honma et al. (2003) study appears to be the most appropriate for MRL derivation for the
following reasons: (1) the nervous system is the most sensitive target for 1-bromopropane in humans as
evidenced in studies in workers and case reports (no adverse hepatic effects have been reported in
individuals showing clear signs of neurotoxicity) and (2) it identified a NOAEL for neurological effects.  
In the Honma et al. (2003) study, spontaneous locomotor activity was monitored in groups of male F-344 
rats (4/group) following 3 weeks of daily 8-hour whole-body exposures to 0, 10, 50, or 200 ppm
1-bromopropane vapors.  After the 3-week exposure period, rats were tested once per day for
6 consecutive days.  Significant increases in spontaneous locomotor activity relative to controls occurred
in the groups exposed to 50 ppm 1-bromopropane on post-exposure days 1, 2, and 3 and in the group 
exposed to 200 ppm on post-exposure days 1, 2, 3, and 4.  No significant difference from controls was
observed in rats exposed to 10 ppm 1-bromopropane. The spontaneous locomotor activity results were
presented graphically; however, the data were not amenable for extraction using GrabIt! Software
(version XP2).  Thus, the NOAEL/LOAEL approach was used to identify the point of departure (POD)
for the MRL. The data (Figure 3 in the study) are presented as changes in spontaneous locomotor activity
relative to pre-exposure levels (assigned as 100% activity) for each day post-exposure that the test was 
performed (up to 6 days post-exposure).  The selection of which post-exposure day (1 to 6) to model to 
compare treated and controls would have been entirely arbitrary. The NOAEL of 10 ppm was duration-
adjusted (8/24) to calculate the NOAEL[HEC] of 3.33 ppm.  Applying an uncertainty factor of 30 (3 for 
dosimetric adjustment and 10 for human variability) resulted in an intermediate-duration inhalation MRL
of 0.1 ppm for 1-bromopropane.  A duration adjustment (8/24 hours) seemed appropriate in the absence
of information regarding whether Haber’s Law is applicable under the experimental conditions of the
study.  Further details of the MRL derivation are presented in Appendix A.
• An MRL of 0.02 ppm (0.1 mg/m3) has been derived for chronic-duration inhalation exposure
(365 days or more) to 1-bromopropane.
This MRL was based on a minimal LOAEL of 1.28 ppm for mild neurological impairment (increased 
vibration sense threshold in toes, indicating decreased vibration sense) in female workers from three
1-bromopropane production facilities in China employed for an average duration of ~40 months (Li et al. 
2010).  The study examined a number of neurological parameters in a population of workers and age-, 
sex-, and region-matched controls in three 1-bromopropane production plants in China. The final analysis 
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comprised 120 women (60 exposed and 60 referents) and 52 men (26 exposed and 26 referents). Median
individual TWA exposure to 1-bromopropane ranged from 0.07 to 106.4 ppm for females and from 0.06 
to 114.8 ppm for males.  After conducting multiple analyses, the vibration sense threshold showed the
clearest dose-related effect, with significant increases (indicative of decreased vibration sense) in all 
exposed female groups.  No significant differences between controls and individual male groups were 
seen regarding neurological parameters in this analysis.  The minimal LOAEL of 1.28 ppm for increased
vibration sense threshold (decreased vibration sense) in females was adjusted for continuous exposure
(1.28 ppm x 5 days/7 days x 12 hours/24 hours = 0.46 ppm) and was divided by an uncertainty factor of
30 (3 for use of minimal LOAEL and 10 to account for human variability) to derive the MRL of 0.02 ppm
(0.1 mg/m3).  However, the confidence in the MRL is low due to a number of limitations of the principal
study, most notably potential underestimation of 1-bromopropane exposure levels and concerns regarding
the sensitivity of the vibration sense measurement method utilized in the study.  However, after careful
review of limitations and criticisms, as well as the available human and animal data, this study was 
considered to be the best available study on which to base the chronic MRL.  In support, basing an MRL
on the most sensitive animal study identifying a LOAEL for respiratory lesions (Morgan et al. 2011; NTP
2011) would yield an MRL of 0.03 ppm (0.15 mg/m3), which is essentially equivalent to the MRL based
on the selected human study.  The rationale for selecting the Li et al. (2010) study as the principal study
for the derivation of the chronic inhalation MRL, despite acknowledged limitations, is discussed in detail 
in Appendix A.
ACGIH (2014, 2016) has recommended a Threshold Limit Value (TLV) of 0.1 ppm 1-bromopropane
based on the same end point from the Li et al. (2010) study.  This value is designed to be protective for
healthy adult workers exposed daily over a working lifetime.
Oral MRLs
• An MRL of 0.2 mg 1-bromopropane/kg/day has been derived for acute-duration (14 days or less)
oral exposure to 1-bromopropane
This MRL was based on a BMDL1SD of 19.75 mg 1-bromopropane/kg/day for impaired memory in the
Morris water maze test in Wistar rats exposed to 0, 200, 400, or 800 mg 1-bromopropane/kg/day via
gavage for 12 days (Zhong et al. 2013).  On days 8–12, cognitive function (spatial learning and memory)
was assessed with the Morris water maze test and dose-related impairments were observed in learning and
memory measures. On day 5, when the escape platform was removed to assess memory, all exposure
groups showed a significant decrease in the number of times they crossed the former location of the
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escape platform.  A LOAEL of 200 mg/kg/day was identified for this study based on impaired spatial
learning and memory (increased swimming distance, altered search pattern, decreased number of
crossings of the escape platform); no NOAEL was identified.  All data were presented graphically. The
SDs could not be extracted from day 1–4 figures, either because they overlapped between dose groups
(total swimming distance) or they were not reported (distribution of search patterns); therefore, these data 
could not be used for BMD analysis. However, the means and standard deviations for the number of
crossings of the escape platform (assessed on day 5) were extracted digitally using GrabIt! software 
(version XP2) for BMD analysis. Alternate data extraction of the means and SDs using DigitizeIt
software resulted in BMDLs that differed by <17% on average, which would yield the same MRL. The
BMDL1SD of 19.75 mg 1-bromopropane/kg/day from the selected model (Hill) was divided by an 
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 to account for human 
variability) to derive an MRL of 0.2 mg 1-bromopropane/kg/day. Further details regarding the Zhong et
al. (2013) study can be found in Appendix A. A more recent study by the same groups of investigators
confirmed the previous results and reported that treatment of male Wistar rats with ≥200 mg
1-bromopropane/kg/day for 12 days impaired spatial memory and spatial learning ability (Guo et al.
2015). In this study, rats exposed to ≥200 mg 1-bromopropane/kg/day in the Morris Water Maze showed
a significantly dose-related decreased percent of time at the target platform; the NOAEL was 100 mg
1-bromopropane/kg/day. Modeling of these data yielded a BMDL1SD (POD) of 77.94 mg
1-bromopropane/kg/day, which is higher than the BMDL1SD of 19.75 mg 1-bromopropane /kg/day used to 
derive the current MRL. Therefore, it is still more appropriate (more protective) to use data from Zhong
et al. (2013) to derive an acute-duration oral MRL for 1-bromopropane.
No intermediate-duration oral MRL was derived for 1-bromopropane due to a lack of adequate studies.  
No chronic-duration oral MRL was derived for 1-bromopropane due to a lack of oral studies for chronic
durations. 
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of 1-bromopropane.  
It contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, 
reproductive, developmental, and carcinogenic effects).  These data are discussed in terms of three 
exposure periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 1-bromopropane
are indicated in Table 3-1 and Figure 3-1.  
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
Unless otherwise stated, all animal studies mentioned in Section 3.2 tested commercial-grade 1-bromo-
propane (purity ≥99%). 
3.2.1 Inhalation Exposure 
In occupational studies and case reports described below, exposure to 1-bromopropane occurred primarily
via the inhalation route, but dermal exposure may have also occurred. Since (in most cases) it is not
known whether the workers were using protective clothing and/or respirators, the specific contribution of
each route of exposure is not possible to determine.  Therefore, the reader should keep in mind that both 
inhalation and dermal routes combined may have contributed to the effects described.
3.2.1.1  Death 
No reports of deaths in humans following inhalation exposure to 1-bromopropane were located in the 
available literature.
Lethal exposure concentrations have been identified in rats in acute-duration studies and in mice in 
intermediate-duration studies.  In male and female rats exposed for 4 hours to concentrations of 1-bromo-
propane vapors ranging from 11,000 to 17,000 ppm, the combined LC50 was 14,374 ppm (95%
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confidence interval [CI], 13,624–15,596) (Kim et al. 1999).  No rats died in the 11,000-ppm exposure
group, and all rats exposed to 17,000 ppm 1-bromopropane died during the 14-day observation period.  
Necropsy did not reveal gross alterations. Light microscopy showed that some exposed rats had 
cytoplasmic vacuolization of hepatocytes. In another study of male and female rats exposed for 4 hours 
to concentrations of 1-bromopropane vapors ranging from 6,040 to 8,500 ppm, the combined LC50 was 
7,000 ppm (Elf AtoChem S.A. 1997). At necropsy, pulmonary lesions consisting of edema and 
“emphysema” were observed.
In intermediate-duration studies, exposure to 500 ppm 1-bromopropane vapors 6 hours/day, 5 days/week
resulted in significant lethality in male and mice during the first 2 weeks of exposure (Anderson et al. 
2010; NTP 2011).  No deaths occurred in mice exposed to 250 ppm 1-bromopropane. The cause of death
was not specified in these studies, but NTP stated that in the 14-week study, lethargy and abnormal
breathing were observed in moribund mice on week 1. Since the 16-day and 14-week NTP studies also
tested rats exposed up to 2,000 and 1,000 ppm 1-bromopropane, respectively, and there were no
compound-related deaths, mice appear to be considerably more sensitive than rats to the acute toxicity of
1-bromopropane. 
The LC50 from Kim et al. (1999) and the lethal doses from Anderson et al. (2010) and NTP (2011) are
listed in Table 3-1 and plotted in Figure 3-1.
3.2.1.2  Systemic Effects
The highest NOAEL values and all LOAEL values for each reliable study for systemic effects in each
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
Respiratory Effects. One preliminary health survey and several case reports of workers experiencing
frank neurotoxicity following exposure to 1-bromopropane indicate that occupational exposure to 
1-bromopropane can cause mild respiratory irritation. In a preliminary health survey, 10/24 female and 
6/13 male workers from a Chinese 1-bromopropane factory reported nose and/or throat irritation; workers 
were exposed to 1–171 ppm 1-bromopropane for 1–115 months (Ichihara et al. 2004a).  In three female 
workers from a cushion company who were hospitalized for neurological symptoms following exposure
to 1-bromopropane for 8–9 hours/day for ≥3 months, two of the women complained of sore throat, 
hoarseness, and/or sinus irritation (Ichihara et al. 2002).  The mean daily time-weighted exposure level
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation 
Exposure/ LOAEL 
Duration/



































Bd Wt 100 F 498 F (14.3% reduction in net 





(3/8 died in the first 
week) 
(4/5 deaths during first 
week) 
(4/10 males and 5/10 
females died in the first 2 
weeks) 
(24.6% reduction in net 
body weight change on 
Gd 6-20) 
Reference 
Chemical Form Comments 
Elf AtoChem S.A. 1997 
1-Bromopropane 
Kim et al. 1999 
1-Bromopropane 
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Less Serious Serious 
(ppm) (ppm) 
6920 (pulmonary edema and 
emphysema) 
1000 M (11% reduction in final 
body weight) 
107 F (subjective complaints of 
headache, dizziness, 
numbness, weakness) 




Elf AtoChem S.A. 1997 
1-Bromopropane 
Wang et al. 2002 
1-Bromopropane 
Zhang et al. 2013 
1-Bromopropane 
Raymond and Ford 2007 
1-Bromopropane 
Honma et al. 2003 
1-Bromopropane 
Comments 
Endocrine NOAEL is 
for adrenal gland 
weight and plasma 
corticosterone. 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
a 
































4 hr 11000 (decreased activity, 
ataxia) 
Kim et al. 1999 
1-Bromopropane 
1 hr 300 1800 (decreased activity; mild 
ataxia) 
Kim et al. 1999 
1-Bromopropane 
7 d 





996 F BSOC 2001b 
1-Bromopropane 
4 hr 8500 M Elf AtoChem S.A. 1997 
1-Bromopropane 
6 hr 800 M (37% reduced sperm 
motility) 
Garner et al. 2007 
1-Bromopropane 
Comments 
NOAEL is for 
neurogenesis in the 
hippocampus. 
NOAEL is for 
histopathology of the 
testes. 
CYP2E1-null mice 
showed only a 12% 
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Key to Species Frequency 
Figure (Strain) (Route) 
Developmental 









NOAEL Less Serious Serious 
System (ppm) (ppm) (ppm) 







Hepatic 400 M 600 M (vacuolation of 
centrolobular 
hepatocytes and 











Albemarle Corporation 1997 
1-Bromopropane 
Comments 
NOAELs are for clinical 
chemistry, urinalysis, 
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Cardio 400 M 1000 M (15-20% increase in 
systolic blood pressure) 
Banu et al. 2007 
1-Bromopropane 
Bd Wt 400 M 1000 M (Body weight reduced 








Resp 750 BSOC 2001a 
1-Bromopropane 
Hepatic 100 M 250 M (hepatocellular 
vacuolization in F0 and 
F1 males) 
Renal 250 F 500 F (transitional renal 
epithelial hyperplasia and 
pelvic mineralization in 
F0 females) 
Endocr 500 M 750 M (20% decrease absolute 
weight of F1 male 
adrenals and pituitary) 
Bd Wt 250 F 500 F (12-14% reduced body 
weight F0 and F1 dams 




8 hr/d Bd Wt 400 F 800 F (11% reduced maternal body weight on postnatal 
day 21) 
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Bd Wt 200 M 1000 M (12% weight loss during 
exposure period) 







Cardio 1000 M (approximately 15% 
increase in systolic blood 
pressure) 
Huang et al. 2016 
1-Bromopropane 
Hepatic 1000 M (21.8% increase in 
absolute liver weight) 







Resp 800 M Ichihara et al. 2000a 
1-Bromopropane 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
a 









































Chemical Form Comments 
400 M 800 M (alteration in 
myofilaments in soleus 
muscle) 
Ichihara et al. 2000b 
1-Bromopropane 
400 M 800 M (12% reduction in 
terminal body weight) 
700 M (47-49% decrease 
plasma ALT activity) 
Ishidao et al. 2002 
1-Bromopropane 
No microscopic 
examination of the liver 
was conducted. 
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Hepatic 125 F (increased relative and 
absolute liver weight) 
NTP 2011 
1-Bromopropane 
Renal 125 F (increased relative kidney 
weight) 
Bd Wt 1000 M 2000 M (final body weight 
reduced 27%) 
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Key to Species Frequency 
Figure (Strain) (Route) 
30 Rat 14 wk 
5 d/wk(Fischer- 344) 
6 hr/d 
31 Rat 20 d 






















Chemical Form Comments 
1000 NTP 2011 
1-Bromopropane 










62.5 F 125 F (significant increase in 
absolute and relative liver 
weight) 
500 F 1000 F (increased absolute and 




500 M 1000 M (12% reduction in final 
body weight) 
1000 F Sekiguchi et al. 2002 
1-Bromopropane 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
a 

































Bd Wt 800 M 1000 M (15% reduction in 
terminal body weight) 





Bd Wt 400 M 800 M (12% reduction in 
terminal body weight) 





Hepatic 200 F (significant increase in 
absolute and relative liver 
weight) 
Yamada et al. 2003 
1-Bromopropane 
Renal 200 F (significant increase in 





400 F 800 F (final body weight 
reduced 30%) 
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1000 M (19% reduced body 
weight) 
1000 M (19% reduced terminal 
body weight) 







Yu et al. 1998 
1-Bromopropane 
Yu et al. 2001 
1-Bromopropane 
Zhang et al. 2013 
1-Bromopropane 
Comments 
Hepatic and renal 
NOAELs are for organ 
histopathology. 
NOAELs are for tissue 
histopathology 
Endocrine NOAEL is 
for adrenal gland 
weight and serum 
corticosterone. 
















3.  HEALTH EFFECTS
31













































Less Serious Serious 
(ppm) (ppm) 
50 M (hepatocellular 
degeneration and focal 
necrosis) 
100 M (liver necrosis) 
125 (minimal grade necrosis 
and regeneration in 
bronchioles) 
1000 M (decreased absolute and 
relative heart weight) 
500 M (moderate to marked 
centrilobular necrosis) 
1000 F (increased absolute and 
relative kidney weight) 
Reference 
Chemical Form 
Liu et al. 2009 
1-Bromopropane 





Nfr2-null mice were 
more susceptible than 
the wild type to 
1-BP-induced liver 
toxicity. 
Nasal lesions observed 
in olfactory and 
respiratory epithelium 
at 500 ppm and 
higher. 
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Resp 250 500 (cytoplasmic 
vacuolization in nasal 
respiratory epithelium, 
trachea, and bronchioles) 
NTP 2011 
1-Bromopropane 









250 500 (necrosis and hepatocyte 
degeneration) 
Renal 250 500 (increased absolute and 
relative kidney weight) 
Endocr 250 F 500 F (moderate to marked 








8 hr/d Hepatic 50 M (mild centrilobular hepatocyte degeneration) 




Zong et al. 2016 
1-Bromopropane 
Bd Wt 250 M 
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500 F (decreased CD4+/CD8-




Albemarle Corporation 1997 
1-Bromopropane 





































NOAEL is for organ 
weight/histology 
Suppression of IgM 
response to SRBC at 
1,000 ppm (10 wks) 
Increased brown 




NOAEL is for organ 
weight and 
histopathology of the 
spleen and thymus. 
NOAEL is for 
histopathology of 
thymus and spleen. 
NOAEL is for 
histopathology of 
lymphoreticular tissues. 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
a 





































125 F (suppression of IgM 
response to SRBC at 10 
weeks) 





500 NTP 2011 
1-Bromopropane 














400 M 1000 M (decreased hindlimb 
muscle strength) 
Banu et al. 2007 
1-Bromopropane 
Comments 
NOAEL is for weight 
and histopathology of 
spleen and thymus. 
NOAEL is for 
histopathology of 
lymphoreticular tissues. 
Case reports (n=3) 
NOAEL is for FOB, 
motor activity, and 
organ weight/histology 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
Exposure/ LOAEL 
Duration/
a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (ppm) (ppm) (ppm) 
56 Rat 2-gen 75070 d(Sprague-
6 hr/dDawley) 
57 Rat 4 wk 1500 M (ataxic gate, convulsions)5 d/wk(Wistar) 
6 h/d 
58 Rat 8 wk 700 M (increased excitability in5 d/wk(Wistar) hippocampal neurons)6 hr/d 
59 Rat 12 wk 200 M 400 M (increased excitability in5 d/wk(Wistar) hippocampal neurons)6 hr/d 
60 Rat 3 wk c 10 M 50 M (increased spontaneous8 hr/d(Fischer- 344) locomotor activity) 
61 Rat 12 wk 200 M (significantly reduced7 d/wk(Wistar) hindlimb grip strength)8 hr/d 






Fueta et al. 2002 
1-Bromopropane 
Fueta et al. 2004 
1-Bromopropane 
Fueta et al. 2007 
1-Bromopropane 
Honma et al. 2003 
1-Bromopropane 
Ichihara et al. 2000b 
1-Bromopropane 
Kim et al. 1999 
1-Bromopropane 
Comments 
NOAEL is for 
histopathology of the 
brain of the F0 
generation. 
Experiments were 
conducted ex vivo in 
hippocampal slices. 
Experiments were 




in peripheral nerve 
occurred at 800 ppm. 
NOAEL is 
histopathology of the 
brain. 
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400 M 800 M (decrease density of 
noradrenergic axons in 
brain areas) 







400 M (morphological 
alterations in astrocytes 
in cerebellum) 






















800 M 1000 M (morphological 
alterations in cerebellar 
microglia) 







400 M (increased excitability in 
hippocampal neurons) 
Ueno et al. 2007 
1-Bromopropane 
Comments 
NOAEL is for 
histopathology of the 
brain. 
NOAEL is for 
histopathology of 
central and peripheral 
nervous tissues. 
Excitability was tested 
in hippocampal slices. 
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1000 M (hindlimb paralysis) Yu et al. 1998 
1-Bromopropane 
Motor nerve conduction 







1000 M (peripheral nerve 
degeneration) 







600 M 900 M (reduced neurogenesis in 
hippocampus) 
Zhang et al. 2013 
1-Bromopropane 
NOAEL and LOAEL 








500 NTP 2011 
1-Bromopropane 
NOAEL is for 









600 Albemarle Corporation 1997 
1-Bromopropane 







400 M (23% reduced epididymal 
sperm count) 
1000 M (>30% reduced absolute 
reproductive organs 
weight) 
Banu et al. 2007 
1-Bromopropane 
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100 250 M (reduced absolute 
prostate weight in F0 
males) 
750 (100% infertility) BSOC 2001a 
1-Bromopropane 
250 F (increased estrous cycle 






200 M (26-27% reduced 
absolute and relative 
seminal vesicles weight) 








300 F 1800 F (27-30% increased 
relative ovaries weight) 
Kim et al. 1999 
1-Bromopropane 
No effects were 








1000 M (reduced sperm count 
and motility) 







8 hr/d 1000 F Sekiguchi et al. 2002 
1-Bromopropane 
NOAEL is for effects on 
estrous cycles and 
spontaneous ovulation. 
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Table 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (continued) 
a 

































200 F (decreased ovarian antral 
follicle counts) 





1000 M Yu et al. 1998 
1-Bromopropane 





1000 M Yu et al. 2001 
1-Bromopropane 
NOAEL is for 





50 M (decreased sperm count 
and motility; increased 
abnormal sperm) 





250 500 (decreased sperm per 







250 500 (decreased F1 and F2 
pups born and litter size; 
reduced [14-18%] F2 pup 




Male F1 pup weight 
reduced 13.7% on Pnd 
28 at 500 ppm. 
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Fueta et al. 2015 
1-Bromopropane 
700 (7.5 to 9.5% reduced pup 
weights on Pnd 14). 
1-BP suppressed wet 















Furuhashi et al. 2006 
1-Bromopropane 
800 (significantly decreased 
survival during lactation) 
Li et al. 2010 Values listed are 
median exposure 
levels. Hepatic and 







1.28 F 6.6 F (83% increase in serum 
TSH) 
89 Human 4-9 yr 
(Occup) 
Hemato 197 NIOSH 2002 
1-Bromopropane 
The NOAEL listed is 
the geometric mean. 
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Key to Species Frequency 
Figure (Strain) (Route) 
90 Human ~ 29 mo 
(Occup) 
91 Rat 105 wk 























Chemical Form Comments 
45.7 NIOSH 2003a 
1-Bromopropane 
The NOAELs listed are 
the geometric means. 
The kidney NOAEL is 
for serum chemistry. 
45.7 
125 (glandular hyperplasia in 
the nose [both sexes], 
chronic active nasal 
inflammation [females]) 
Morgan et al. 2011; NTP 2011 
1-Bromopropane 
NOAELs are for tissues 
histopathology. 
Various respiratory 
tract lesions in the 
nose, larynx, trachea, 
and lungs were 
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Key to Species Frequency 
Figure (Strain) (Route) 




93 Rat 105 wk 
5 d/wk(Fischer- 344) 
6 hr/d 























62.5 (various histological 
alterations in the nasal 
respiratory epithelium, 
larynx, trachea, and 
bronchioles) 











500 Morgan et al. 2011; NTP 2011 
1-Bromopropane 
250 Morgan et al. 2011; NTP 2011 
1-Bromopropane 
Comments 
NOAELs are for tissue 
histopathology. 
Lesions of the olfactory 
epithelium were 
observed in females at 
125 ppm and higher. 
NOAEL is for 
histopathology of 
lymphoreticular tissues. 
NOAEL is for 
histopathology of 
lymphoreticular tissues. 
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Li et al. 2010 
96 Human > 3 yr 
(Occup) 
108 (inability to walk, spastic 
paraparesis, sensory 
loss, hyperreflexia) 
Majersik et al. 2007 
1-Bromopropane 
97 Human 4-9 yr 
(Occup) 




98 Human ~ 29 mo 
(Occup) 








533 M (severe ataxia, motor and 
sensory impairments, 
axonal damage) 







500 Morgan et al. 2011; NTP 2011 
1-Bromopropane 
Comments 
LOAEL value listed is 
the median exposure 
level. 
Case reports (n=5) 
No referent group was 
included; LOAEL value 
listed is the geometric 
mean. 
The LOAEL listed is for 
the geometric mean. 
Case report 
NOAEL is for 
histopathology of the 
brain. 
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250 Morgan et al. 2011; NTP 2011 
1-Bromopropane 
Reproductive 
102 Human 4-9 yr 
(Occup) 
168.9 NIOSH 2002 
1-Bromopropane 
103 Human ~ 29 mo 
(Occup) 






















125 M (CEL: skin 
keratoacanthoma; basal 
cell adenoma or 
carcinoma) 
Morgan et al. 2011; NTP 2011 
1-Bromopropane 
Comments 
NOAEL is for 
histopathology of the 
brain. 
The NOAEL (geometric 
mean) is for lack of 
self-reported 
reproductive issues. 
The NOAEL (geometric 
mean) is based on a 
lack of self-reported 
reproductive issues. 
NOAEL is for 
histopathology of 
reproductive organs. 
NOAEL is for 
histopathology of the 
reproductive organs. 
125 ppm also CEL for 
pancreatic islet 
adenoma in males. 
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Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (ppm) (ppm) (ppm) Chemical Form Comments 
107 Mouse 105 wk 
(B6C3F1) 5 d/wk 
6 hr/d 
Morgan et al. 2011; NTP 2011 
1-Bromopropane 
62.5 F (CEL: combined 
alveolar/bronchiolar 
adenoma or carcinoma) 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an acute-duration inhalation minimal risk level (MRL) of 1 ppm for 1-BP based on a BMCL1SD of 97.40 ppm. The BMCL1SD was adjusted for intermittent exposure 
and multiplied by the ratio of the animal-to-human blood: gas partition coefficients to calculate a human equivalent concentration (HEC).  The BMCL[HEC] was divided by an 
uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustment and 10 for human variability). 
c Used to derive an intermediate-duration inhalation MRL of 0.1 ppm for 1-BP based on a NOAEL of 10 ppm. The NOAEL was adjusted for intermittent exposure and multiplied by the 
ratio of the animal-to-human blood: gas partition coefficients to calculate a human equivalent concentration (HEC). The NOAEL[HEC] was divided by an uncertainty factor of 30 (3 for 
extrapolation from animals to humans with dosimetric adjustment and 10 for human variability). 
d Used to derive a chronic-duration (365 days or more) inhalation MRL of 0.02 ppm for 1-BP. The minimal LOAEL of 1.28 ppm was adjusted for continuous exposure (1.28 ppm × 5 
days/7 days × 12 hours/24 hours = 0.46 ppm) and was divided by an uncertainty factor of 30 (3 for use of minimal LOAEL and 10 for human variability) to derive the MRL of 0.02 
ppm. 
ALT = alanine aminotransferase; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; F = Female; FOB = functional observation 
battery; Gastro = gastrointestinal; Gd = gestational day; gen = generation; Hemato = hematological; hr = hour(s); IgM = immunoglobulin M; Immuno/Lymphoret = 
immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; Ld = lactation day; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = metabolism; mo = 
month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; Occup = occupational; Resp = respiratory; SRBC = sheep red blood cell; TWA = time-weighted 
average; wk = week(s) 




12r10000 16r7r 7r1r 7r7r7r 
13r 
1000 9r 9r 11r 14r6r 15r 18r
8r 9r 17m























 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans









































Figure 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation 
Acute (≤14 days) 
Systemic 
R  C  G  H   H  ppm 
10000 
28r 28r 28r 
1000 30r 41m 20r 24r 30r 30r 30r 36r 37r 30r 24r 36r 37r 
25r 25r 25r 25r 26r 25r21r 27r19r 19r 19r 19r 19r 19r
42m 41m 42m 42m 42m 42m 41m 42m 
20r 26r 19r 
42m 41m 42m 43m 21r 
35r 
41m 29r 30r 
100 40m 21r 
30r 




















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
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Figure 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (Continued) 
Intermediate (15-364 days) 
Systemic 







41m 29r28r 28r 28r 
32r 
30r 36r 37r 30r 38r 30r 30r 20r 23r 24r 29r 30r 31r 
25r 25r 35r 22r 25r 26r 33r21r 
19r 19r 19r 19r
21r 30r 42m 21r 42m 42m 42m 21r 30r 
20r 22r 25r 26r 
28r 



















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans












33r 36r 37r 38r 
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Figure 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (Continued) 















1000 49r 55r 65r 67r 69r 70r 74r 78r 79r 81r 82r71r47r 50r 63r 67r 87r46r 56r 75r58r 86r19r 44r 54r 71r 73r
52m 45r 72m 84m 78r 85r 
55r 59r 63r 64r 68r 74r 
77r
45r 84m 75r 75r 78r 85r 
59r 61r 76r 80r 
5351m 78r 





















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
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Figure 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (Continued) 
Intermediate (15-364 days) 
Systemic 
ppm 
Re  Ca  Ga  He  Mu  He  Re  En  De  Oc  Bo  Im  Ne  Re  Ca  
          
            
ppm 
1000 
9991r 91r 91r 91r 91r 91r 91r 91r 91r 93r 100r 
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Figure 3-1 Levels of Significant Exposure to 1-Bromopropane - Inhalation (Continued) 
Chronic (≥365 days) 
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developed neurological signs and symptoms 2 weeks after 1-bromopropane was introduced into her
workplace. The geometric mean air concentration of 1-bromopropane was 107 ppm for glue sprayers
(range 58–254 ppm).  It should be mentioned that the woman had been a furniture gluer for 18 months
prior to the introduction of 1-bromopropane into the workplace and had been in good health prior to the
introduction of 1-bromopropane into the workplace.
In general, except for a chronic study, studies in rats and mice have used exposure concentrations higher
than those associated with respiratory irritation in workers and have reported mainly histological
alterations in the respiratory tract, with some inconsistencies between studies. Some studies provided 
data on lung weight.  It also appears that mice are more susceptible than rats. Pulmonary lesions
consisting of edema and “emphysema” were reported in rats exposed to ≥6,920 ppm, a lethal 
concentration, for 4 hours (Elf AtoChem S.A. 1997).  Nasal lesions, including minimal necrosis of the 
respiratory epithelium and suppurative inflammation were observed in 1–2/5 male rats exposed to
≥500 ppm 1-bromopropane for 16 days, but no such lesions were observed in females exposed to doses 
up to 2,000 ppm for 16 days or males or females exposed to concentrations up to 1,000 ppm for 14 weeks
(NTP 2011). No changes were observed in lung weights in the NTP studies in rats. In other 
intermediate-duration rat studies, no exposure-related changes in lung weight or histology were observed 
in rats intermittently exposed to concentrations up to 1,800 ppm 1-bromopropane (Albemarle Corporation 
1997; BSOC 2001a; Ichihara et al. 2000a; Kim et al. 1999).  
In intermediate-duration mouse studies, histopathological changes were observed in various levels of the 
respiratory tract of mice following intermittent exposure to 500 ppm 1-bromopropane for 14 weeks, 
including cytoplasmic vacuolization of the nasal respiratory epithelium and cytoplasmic vacuolization in
the trachea and lung bronchioles (4/10 males, 5/10 females); incidences in the control group were 
0/10 (NTP 2011). Absolute and relative lung weights were also increased in females exposed to 500 ppm
1-bromopropane.  Exposure-related effects were not observed at ≤250 ppm.  In the accompanying 17-day 
study, histopathological changes in the lungs were observed in all mice exposed to ≥125 ppm 1-bromo-
propane (lowest concentration tested), including bronchiole necrosis, regeneration, and vacuolization and 
perivascular inflammation (NTP 2011).  Histopathological changes in the nose were observed at
≥500 ppm, including olfactory epithelium atrophy, necrosis, and regeneration and respiratory epithelial 
necrosis and cytoplasmic vacuolization (NTP 2011).
In a chronic-duration study, respiratory tract lesions were observed in rats exposed to ≥125 ppm and mice
exposed to ≥62.5 ppm 1-bromopropane for 105 weeks (lowest concentrations tested) (Morgan et al. 2011;
   
 




    
  
  
     
 
   
 
       
       




       
    
   
  
    
      
   
 
   
      
     
          
 
     
 
     
  
  




NTP 2011).  Observed lesions in rats included glandular hyperplasia and chronic suppurative
inflammation of the nose; chronic active inflammation of the nose, larynx, and trachea; chronic
suppurative inflammation of the lungs; metaplasia of the olfactory epithelium; squamous metaplasia of
the larynx; and epithelial hyperplasia of the trachea.  In mice, observed lesions included regeneration of
bronchioles; cytoplasmic vacuolization in the nasal respiratory epithelium, bronchioles, larynx, and 
trachea; hyperplasia in nasal respiratory epithelium; and metaplasia and atrophy in nasal olfactory
epithelium.
Limited human data suggest that exposure to 1-bromopropane can cause respiratory tract irritation at
exposure levels that might be found in occupational settings; however, definite levels at which respiratory
lesions might occur in humans are unknown. Studies in animals suggest that mice can develop
respiratory tract lesions at exposure levels reported in some occupational studies and may be a better
animal model than rats for this end point.
Cardiovascular Effects. Only one report was located that provided some information regarding
cardiovascular assessment in humans following likely exposure to 1-bromopropane at work.  Raymond 
and Ford (2007) reported that a woman who developed neurological signs and symptoms 2 weeks after
1-bromopropane was introduced into her workplace had a normal electrocardiogram.  The geometric
mean air concentration was 107 ppm for glue sprayers (range 58–254 ppm). It should be mentioned that
the woman had been a furniture gluer for 18 months prior to the introduction of 1-bromopropane into the
workplace.
No generalizations can be made from the single case report mentioned above, and the available studies in 
animals have examined mostly histology of the heart, but not cardiovascular function. The animal studies
indicate that morphological alterations of the heart are unlikely to occur following exposure to 1-bromo-
propane. Changes in heart weight were reported in one animal study. A significant decrease in absolute 
and relative heart weight was observed in male mice intermittently exposed to ≥1,000 ppm 1-bromo-
propane for 17 days; no exposure-related changes were observed in heart weight in males at ≤500 ppm or
in females at ≤2,000 ppm (NTP 2011).  No exposure-related changes in heart histology were observed in 
mice at concentrations up to 2,000 ppm 1-bromopropane for 17 days or 500 ppm for 14 weeks (NTP
2011).  In rats, no exposure-related changes in heart weight or histology were observed in three strains 
intermittently exposed to concentrations up to 1,800 ppm 1-bromopropane for 8–14 weeks (Albemarle 
Corporation 1997; Ichihara et al. 2000a; Kim et al. 1999; NTP 2011).
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A significant increase (15–20%) in systolic blood pressure (measured with a tail cuff) was reported in 
conscious male Wistar rats exposed to 1,000 ppm 1-bromopropane intermittently for 4–6 weeks (Banu et
al. 2007; Huang et al. 2016).  The blood pressure was still elevated 5 weeks after exposure ceased, but
returned to control values by 8 weeks after exposure terminated.  No significant effects were reported in 
rats exposed to 400 ppm 1-bromopropane. Biochemical assays in homogenates of left ventricle and aortic
tissues showed that markers of oxidative stress were significantly elevated in exposed rats, which led 
Huang et al. (2016) to suggest that oxidative stress, through activation of NADPH oxidase pathways,
might be a mechanism for 1-bromopropane-induced increased blood pressure. 
In the only available chronic-duration study, no exposure-related changes in heart histology were 
observed in rats or mice intermittently exposed to concentrations up to 500 or 250 ppm 1-bromopropane, 
respectively, for 105 weeks (Morgan et al. 2011; NTP 2011).
The limited human data are insufficient to determine if 1-bromopropane exposure causes cardiovascular
effects. While animal studies showed that morphological alterations of the heart did not occur following
exposure to 1-bromopropane, no conclusions can be drawn regarding cardiovascular function that would 
support or refute the findings of the case report.
Gastrointestinal Effects. Several single case reports or reports of a small number of workers 
experiencing frank neurotoxicity following exposure to 1-bromopropane reported gastrointestinal effects,
including diarrhea and nausea/vomiting, at mean air concentrations of 107–133 ppm (Ichihara et al. 2002;
Raymond and Ford 2007). These effects are considered secondary to neurological effects (see
Section 3.2.1.4, Neurological Effects for more details).
No exposure-related histopathological lesions were observed in the gastrointestinal tract in intermediate-
duration studies in rats or mice intermittently exposed to concentrations up to 1,000 or 500 ppm 1-bromo-
propane, respectively, or in chronic-duration studies in rats or mice exposed intermittently to 
concentrations up to 500 or 250 ppm, respectively (Albemarle Corporation 1997; Morgan et al. 2011;
NTP 2011). The limited information from animal studies suggests that the gastrointestinal tract is not a
sensitive target for airborne 1-bromopropane.
Hematological Effects. The available human occupational studies show mixed results regarding
hematological effects in 1-bromopropane workers.  For example, a study was conducted of 60 female and 
26 male Chinese individuals who had been exposed to the chemical in three 1-bromopropane production 
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factories for 3–4 years (Li et al. 2010). Based on assessments of individual exposures, median exposure
concentrations for low-, mid-, and high-dose females were 1.28, 6.60, and 22.58 ppm, respectively;
median exposure concentrations for the low- and high-dose males were 1.05 and 12.5 ppm, respectively.  
The results of hematological tests showed small (8–20%) but significant decreases between exposed 
female groups and matched controls for white blood cell count, red blood cell count, hemoglobin, and 
hematocrit.  However, no clear dose-response relationships were apparent and the effects were not
significant in male workers. Regression analysis adjusting for alcohol exposure and pair-matching for
age, sex, and region in selecting controls showed significant negative trends for red blood cell count, 
hematocrit, and platelets in females; no significant trends were reported in males. The same regression
analysis on the product of exposure levels and duration of exposure (cumulative exposure) showed 
significant increases in mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) and 
significant decreases in red blood cell count and hematocrit in female workers. In a review of the Li et al.
(2010) study, Smith et al. (2011) noted that since hematological parameters experience temporal
fluctuations related to menstrual cycle, lack of control for the latter could have led to misleading results.  
Additionally, reported hematological values in female workers were within reported reference ranges for
hematological parameters (CDC 2005); values for other parameters were not reported by study authors.
The findings of Li et al. (2010) are not supported by findings from two earlier surveys of workers in the
United States exposed to 1-bromopropane during the spray application of solvent-based adhesives 
(NIOSH 2002, 2003a).  Neither survey found exposure-related hematological effects in the workers who 
were exposed to concentrations of 1-bromopropane ranging from 7 to 381 ppm. Although exposure
levels were monitored using full-shift personal breathing zone samples in both studies, these studies are 
limited due to relatively small sample sizes (69 subjects in one study and 13 the other) and lack of control
for potential confounding factors (e.g., age).
Single case reports or reports of a small number of workers experiencing frank neurotoxicity following
exposure to 1-bromopropane suggest that hematological parameters are not particularly sensitive to
1-bromopropane exposure.  For example, Samukawa et al. (2012) stated that routine blood tests
(assuming that included standard hematological parameters) of a worker that may have been exposed to
up to 553 ppm 1-bromopropane for 18 months were within normal limits.  Raymond and Ford (2007)
reported that a woman who developed neurological signs and symptoms 2 weeks after 1-bromopropane
was introduced into her workplace had normal complete blood count. The geometric mean concentration
of 1-bromopropane for glue sprayers was 107 ppm (range, 58–254 ppm).  One of the cases described by
Majersik et al. (2007) was that of a woman who worked as a foam cushion gluer for 4 years prior to 
   
 




   
    




      
  
   
    
    
 
 
    
      
   
  
    
    
    
 
  
    





     
     





showing neurotoxic signs and symptoms.  The investigators stated that a complete blood count showed 
“variant lymphocytes.” However, no further details were provided. The mean concentration of
1-bromopropane in the workplace air during gluing operations was 130 ppm (range 91–176 ppm) and a
TWA of 108 ppm (range 92–127 ppm).  
Studies in rats and mice exposed to 1-bromopropane have described alterations in hematological
parameters of questionable biological significance and at exposure levels considerably higher than those
measured in the human studies mentioned above.  For example, nose-only exposure of male Wistar rats to 
7,280 ppm 1-bromopropane for 4 hours resulted in a significant increase in polymorphonuclear
neutrophils 24 hours after exposure ceased, but not 14 days after exposure (Elf AtoChem S.A. 1997).  
Other hematological parameters were not significantly altered by exposure to 1-bromopropane in this
study. 
Significant hematological alterations observed in male rats exposed intermittently to 1,800 ppm
1-bromopropane for 8 weeks included a 28% decrease in white blood cell count, 8% decrease in red blood
cell count, 12% decrease in hematocrit, 3% decrease in MCV, 8% increase in MCH, and 11% increase in
mean corpuscular hemoglobin concentration (MCHC) (Kim et al. 1999).  Some of these parameters were 
also altered at 50 ppm, but none were altered at 300 ppm.  The study authors did not consider these
changes to be biologically relevant, as they were mostly within the normal range for rats. Similarly, no 
biologically relevant changes were observed in hematological parameters in females exposed to
concentrations up to 1,800 ppm (Kim et al. 1999).  Similarly, significant, but minor changes in 
hematology observed in male rats intermittently exposed to concentrations ≥400 ppm for 12 weeks,
including a 3% increase in MCV and a 2.4–3.5% decrease in MCHC, were not considered biologically
relevant (Ichihara et al. 2000a).  No exposure-related hematological changes were reported in rats or mice 
intermittently exposed to concentrations up to 1,000 or 500 ppm, respectively, for 7–14 weeks (Albemarle
Corporation 1997; NTP 2011; Yu et al. 1998, 2001).
Available human and animal data are limited, but suggest that clinically relevant hematological changes 
are not likely to occur in humans following exposure to 1-bromopropane. Hematological parameters 
were not assessed in the chronic-duration study; therefore, it is unknown whether the findings of Li et al. 
(2010) in 1-bromopropane workers would also occur in animals following prolonged exposure to low 
levels of 1-bromopropane (Morgan et al. 2011).  
   
 




     
 
 
   
 
    
   
    
   
 
 
    
   
   
 
    
  
 
      
  
  
       
  
     
   
 
 
      
   





Musculoskeletal Effects. No information was located regarding musculoskeletal effects in humans 
exposed to 1-bromopropane.
Animal studies provide limited relevant data. Irregular banding of the striated muscle fibers of the soleus 
muscle was observed in male rats intermittently exposed to 800 ppm for 12 weeks, and electron 
microscopy revealed loss of regular linearity in the Z line and zigzag arrangement of the myofilaments;
no changes were observed at ≤400 ppm (Ichihara et al. 2000b).  In other intermediate-duration studies, no 
exposure-related musculoskeletal effects were observed in rats or mice intermittently exposed to
concentrations up to 1,000 or 500 ppm, respectively (Albemarle Corporation 1997; Ichihara et al. 2000a;
NTP 2011).  
In the only available chronic-duration study, no exposure-related musculoskeletal effects were observed
in rats or mice intermittently exposed to concentrations up to 500 or 250 ppm, respectively, for 105 weeks
(Morgan et al. 2011; NTP 2011).
From these limited data, it would appear that neither skeletal muscle nor bone are sensitive targets for
1-bromopropane toxicity. 
Hepatic Effects. Limited information is available regarding hepatic effects in humans exposed to 
1-bromopropane.  No evidence of adverse liver effects was observed in the Chinese cohort of workers 
exposed to 1-bromopropane studied by Li et al. (2010) as described above.  In that study, liver function 
was assessed by clinical chemistry tests. The median exposure level in 60 female workers was 6.6 ppm
with a range of 0.07–106.4 ppm.  The corresponding values for 26 exposed male workers were 4.6 and 
0.06–114.8 ppm.  Raymond and Ford (2007) reported that a woman who developed neurological signs 
and symptoms 2 weeks after 1-bromopropane was introduced into the workplace had hepatic clinical
chemistry parameters within normal ranges. The geometric mean air concentration was 107 ppm for glue 
sprayers (range 58–254 ppm).
Unlike the limited human data, findings from animal studies indicate that the liver might be a target of
1-bromopropane at much higher exposure levels. A study aimed at determining an LC50 for 1-bromo-
propane in rats reported cytoplasmic vacuolization of hepatocytes in some exposed rats exposed to
11,000–17,000 ppm for 4 hours; however, there was no dose-response relationship (Kim et al. 1999).  
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Intermediate-duration studies in rats and mice have reported histological alterations consisting mostly of
hepatocyte vacuolization and occasionally hepatocyte degeneration and necrosis at the higher exposure 
concentrations.  Studies in rats identified LOAELs of 250 ppm (NTP 2011), 800 ppm (Yamada et al. 
2003), and 600 ppm (Albemarle Corporation 1997); corresponding NOAELs were 125, 400, and 400 ppm
1-bromopropane.  In general, male rats appeared to be affected at lower exposure concentrations than 
females.  In these studies, exposure durations were ≥12 weeks.  In an 8-week study, hepatocyte
vacuolization was observed in rats exposed intermittently to 50–1,800 ppm 1-bromopropane; however, 
the study authors stated that findings were not dose-related, but incidence data were not provided (Kim et
al. 1999).  However, hepatocyte vacuolization was observed in parental male rats exposed to 250 ppm
1-bromopropane in a 2-generation reproductive study (BSOC 2001a).  In shorter-duration studies (2– 
7 weeks), no exposure-related changes in liver histology were observed in rats exposed to concentrations 
up to 2,000 ppm (NTP 2011; Yu et al. 1998, 2001). LOAELs reported in mice include 50 ppm (lowest
exposure concentration tested) for mild hepatocyte changes (Zong et al. 2016), 100 ppm (lowest exposure 
concentration tested) for hepatic necrosis (Liu et al. 2010), and 500 ppm for hepatocyte degeneration
(NTP 2011). A NOAEL of 250 ppm 1-bromopropane was identified in NTP (2011).
Significant increases in liver weight (7–48%) have been reported in rats exposed intermittently for 2– 
14 weeks to ≥125 ppm 1-bromopropane but not at ≤62.5 ppm (Albemarle Corporation 1997; Huang et al. 
2016; Kim et al. 1999; NTP 2011; Yamada et al. 2003).  However, a study reported no exposure-related
changes in liver weight in male rats following intermittent exposure to concentrations up to 800 ppm for
12 weeks (Ichihara et al. 2000a).  In BALB/cA mice, which have an increased metabolic capacity for
1-bromopropane, absolute liver weights were significantly increased by 22% following exposure to 
250 ppm 1-bromopropane for 4 weeks; no changes were observed at ≤110 ppm (Liu et al. 2009).  In other
mouse strains, liver weight was significantly increased by 13–43% following intermittent exposure to 
≥300 ppm for 2–14 weeks; no exposure-related changes were observed at ≤250 ppm (Liu et al. 2009, 
2010; NTP 2011). 
The results of monitoring clinical chemistry parameters have been mixed and not always consistent with 
histopathological findings. Early, transient changes in clinical chemistry (decreased albumin, total
protein, and alanine aminotransferase [ALT] activity) that were observed in rats intermittently exposed to
62.5–1,000 ppm for 14 weeks were attributed to the effects of 1-bromopropane on hepatic protein 
metabolism; however, the 25–30% increase in succinate dehydrogenase (SDH) activity in male rats
exposed to ≥500 ppm might have been indicative of mild hepatotoxicity (NTP 2011). Serum activities of
liver enzymes were significantly decreased in male rats exposed to ≥50 ppm for 8 weeks (Kim et al.
   
 




    
  
   
   
   
   
    
   
  
    
 
     
   
      
 
      
     
  
 
        
    
  
 












1999).  In females, aspartate aminotransferase (AST) activity was not significantly affected, ALT was
decreased at ≥300 ppm, and lactic dehydrogenase (LDH) was decreased at 300 ppm but not 1,800 ppm
(Kim et al. 1999). The lack of a dose-response relationship, at least in females, is consistent with an
apparent lack of dose-response reported for histological alterations in this study. No biologically
significant exposure-related changes were observed in hepatic clinical chemistry parameters in male or
female rats exposed up to 600 ppm 1-bromopropane for 13 weeks; this exposure concentration induced 
hepatocyte vacuolization in male rats (Albemarle Corporation 1997).  In male rats, plasma ALT levels 
were significantly decreased by 27–49% following intermittent exposure to ≥700 ppm for 3–12 weeks, 
but no changes were observed in plasma AST; no histological examination of the liver was conducted in 
this study (Ishidao et al. 2002).
In a chronic-duration study, no exposure-related changes in non-neoplastic liver histology were observed
in rats or mice intermittently exposed to concentrations up to 500 or 250 ppm, respectively, for 105 weeks
(Morgan et al. 2011; NTP 2011).
The limited human data available suggest that the liver is not a sensitive target for 1-bromopropane
toxicity. However, animal data suggest that at high enough concentrations, the liver may be a target of
1-bromopropane toxicity.
Renal Effects. The available studies of humans exposed to 1-bromopropane suggest that inhaled
1-bromopropane did not significantly alter renal function under the exposure conditions.  A significant 
trend for increased blood urea nitrogen (BUN) was reported in male and female Chinese workers exposed
to 1-bromopropane in the study conducted by Li et al. (2010); however, all reported values for BUN (as 
well as serum creatinine) were within reported reference values (Ichihara et al. 2011).  In the Li et al.
(2010) study, median exposure concentrations for low-, mid-, and high-dose females (20/group) were 
1.28, 6.60, and 22.58 ppm, respectively; median exposure concentrations for low- and high-dose males 
(13/group) were 1.05 and 12.5 ppm, respectively.  In the 2003 NIOSH survey described earlier under
Hematological Effects, no exposure-related changes were observed in renal clinical chemistry values
between adhesive-spray line workers exposed to a geometric mean (range) of 45.7 ppm (7–281 ppm) and 
30 unexposed workers exposed to a geometric mean (range) of 1.1 ppm (0.1–4.9 ppm) (NIOSH 2003a).  
Similarly, in case studies, two women who developed neurological signs and symptoms 2 weeks after
1-bromopropane was introduced into their workplace had renal clinical chemistry and urinalysis 
parameters within normal ranges; however, one woman developed polyuria (Raymond and Ford 2007).  
The geometric mean air concentration was 107 ppm for glue sprayers (range 58–254 ppm).  It should be
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mentioned that the women had been furniture gluers for ≥40 months prior to the introduction of
1-bromopropane into the workplace.
No information regarding renal effects was located in the available acute-duration studies in animals.  
Intermediate-duration inhalation studies in animals provide information regarding kidneys’ histological
appearance, weight, and urinalysis parameters. Some animal studies suggest that exposure to high 
concentrations of 1-bromopropane may induce adverse renal effects.
Results of microscopic examination of the kidneys have been mixed.  For instance, no significant
alterations have been reported in rats at ≤600 ppm 1-bromopropane (Albemarle Corporation 1997; Kim et
al. 1999; Yamada et al. 2003), but mild dilation of proximal tubules was seen in female rats exposed to 
800 ppm (Yamada et al. 2003), tubule casts were reported in female exposed to 1,800 ppm for 8 weeks
(Kim et al. 1999), and transitional renal epithelial hyperplasia and pelvic mineralization were reported in 
parental generation female rats exposed to 500 ppm 1-bromopropane (BSOC 2001a).  In contrast, no 
exposure-related changes in kidney histology were observed in female rats exposed up to 2,000 ppm
1-bromopropane for 2–14 weeks (NTP 2011). Similarly, no exposure-related changes were observed in 
kidney histology in male rats at up to 2,000 ppm or mice at up to 500 ppm for 2–14 weeks (Albemarle 
Corporation 1997; Ichihara et al. 2000a; Kim et al. 1999; NTP 2011; Yu et al. 1998, 2001).  
Results of monitoring kidney weight were mixed.  The lowest LOAEL in rats was 125 ppm 1-bromo-
propane for a 20% increase in absolute kidneys weight in females in a 16-day study (NTP 2011), whereas
the lowest LOAEL in mice was 500 ppm 1-bromopropane for a 12% increase in kidney weight in a
14-week study (NTP 2011).  No NOAEL was identified in the rat study and the NOAEL in the mouse
study was 250 ppm.  Because other studies did not report significant alterations in kidney weights at
higher exposure concentrations or effects were not dose-related, no generalizations can be made,
suggesting that kidney weight is not a reliable biomarker of 1-bromopropane toxicity.
Two studies provided information regarding urinalysis in rats exposed to 1-bromopropane, and based on 
the results, it seems that exposure to 1-bromopronane did not induce toxicologically significant 
alterations.  One 8-week study reported increased urobilinogen, bilirubin, ketone bodies, and leukocytes
in females exposed to ≥300 ppm and decreased urobilinogen and increased ketone bodies in males 
exposed to 1,800 ppm (Kim et al. 1999). However, no data were shown, and the investigators stated that
most values were within normal limits. In the other study, no exposure-related changes in urinalysis were 
   
 




      
  
 
   
   
    
 
     
   
       
 
 
        
  
    
     
    




   
     
   
    
  
 
    





observed in male or female rats exposed up to 600 ppm 1-bromopropane (the highest concentration 
tested) for 13 weeks (Albemarle Corporation 1997).
In a chronic-duration study, no exposure-related changes in kidney histology were observed in rats or
mice intermittently exposed to concentrations up to 500 or 250 ppm, respectively, for 105 weeks (Morgan
et al. 2011; NTP 2011).
The limited human data available suggest that the kidney is not a sensitive target for 1-bromopropane
toxicity. Results from some animal studies suggest that at high enough concentrations, the kidney may be
a target of 1-bromopropane toxicity. These concentrations, however, are considerably higher than those
reported in occupational studies.
Endocrine Effects. A small number of human studies provide information on endocrine effects after
exposure to 1-bromopropane.  Based on these limited data, it appears that 1-bromopropane does not have
endocrine effects in humans.  In a study of Chinese workers exposed to 1-bromopropane conducted by Li 
et al. (2010), regression analyses that included exposure level and duration showed significant trends for
increased serum TSH and follicle-stimulating hormone (FSH) in female workers. Neither serum estradiol
levels in females nor serum testosterone levels in males were significantly associated with exposure to
1-bromopropane.
In a case study of female foam cushion gluers experiencing frank neurotoxicity following exposure to 
1-bromopropane vapors 30–40 hours/week for ≥3 years, no exposure-related changes in serum TSH were
observed (Majersik et al. 2007). The mean concentration of 1-bromopropane in the workplace air during
gluing operations was 130 ppm (range 91–176 ppm).  Similarly, Raymond and Ford (2007) reported that
a woman who developed neurological signs and symptoms 2 weeks after 1-bromopropane was introduced
into her workplace had normal thyroid function tests.  The geometric mean air concentration in this case 
was 107 ppm for glue sprayers (range 58–254 ppm).
Studies in animals have examined mostly the microscopic appearance and weight of endocrine glands
and, consistent with the limited human data, do not suggest that the endocrine system is a particularly
sensitive target for 1-bromopropane toxicity.
   
 




   




     
 





    
  
   
     
   
 
    
 
    
    
 
    
  
      
 
        
    
   





The only relevant information in an acute-duration study is that no changes in adrenal weight or plasma
corticosterone levels were observed in male rats exposed intermittently to concentrations up to 1,000 ppm
1-bromopropane for 1–4 weeks (Zhang et al. 2013). 
Intermediate-duration studies identified a LOAEL of 500 ppm 1-bromopropane for moderate to marked
necrosis of the adrenal cortex in female mice exposed for 14 weeks; the NOAEL was 250 ppm (NTP 
2011).  No exposure-related non-neoplastic changes were observed in other endocrine glands.  Studies in
several strains of rats exposed intermittently to up to 1,800 ppm 1-bromopropane did not report exposure-
related histopathological lesions in endocrine glands (Albemarle Corporation 1997; BSOC 2001a; 
Ichihara et al. 2000a; Kim et al. 1999; NTP 2011; Yamada et al. 2003).
Several intermediate-duration studies provide information on endocrine gland weight.  The lowest
LOAEL was 50 ppm 1-bromopropane for a 30% increase in relative weight of the left adrenal in male rats 
exposed for 8 weeks (Kim et al. 1999).  However, exposure to higher concentrations did not show a clear
dose-response relationship, and no significant changes occurred in the right adrenal or in the adrenal
gland from females exposed to the same concentrations (Kim et al. 1999).  Therefore, the significance of
the effect is questionable at best.  Other studies in rats that tested exposure concentrations in the range of
200–800 ppm 1-bromopropane also reported increases in adrenal weight in rats, but the results were 
inconsistent between studies, or no dose-response was apparent (Albemarle Corporation 1997; Yamada et
al. 2003).  In other intermediate-duration exposure studies, no exposure-related changes in adrenal or
pituitary weight were observed in rats intermittently exposed to concentrations up to 1,000 ppm (Ichihara 
et al. 2000a; Zhang et al. 2013).
In chronic studies, no exposure-related, non-neoplastic changes were observed in endocrine glands from
rats or mice intermittently exposed to concentrations up to 500 and 250 ppm 1-bromopropane, 
respectively, for 105 weeks (Morgan et al. 2011; NTP 2011).
The limited human data and the animal data available do not suggest that endocrine end points are 
particularly sensitive targets for 1-bromopropane toxicity.
Dermal Effects. No information was located regarding dermal effects in humans following inhalation 
exposure to 1-bromopropane.  
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No exposure-related non-neoplastic skin lesions were observed in intermediate-duration studies in rats or
mice intermittently exposed to concentrations up to 1,000 or 500 ppm, respectively, or in chronic-duration 
studies in rats or mice exposed intermittently to concentrations up to 500 or 250 ppm, respectively
(Albemarle Corporation 1997; Morgan et al. 2011; NTP 2011).
Ocular Effects. No information was located regarding ocular effects in humans following inhalation 
exposure to 1-bromopropane.  However, symptoms of eye irritation were common among Chinese
workers exposed to concentrations ≥56.9 ppm 1-bromopropane (Ichihara et al. 2004a). It is assumed that 
the eye irritation was due to vapors of 1-bromopropane making direct contact with the eye.
No exposure-related changes were observed in ophthalmic or microscopic examinations of the eyes of
rats intermittently exposed to concentrations up to 600 ppm 1-bromopropane for 13 weeks (Albemarle 
Corporation 1997). Similarly, no exposure-related non-neoplastic lesions were observed in the eyes of
rats or mice intermittently exposed to concentrations up to 1,000 or 500 ppm 1-bromopropane, 
respectively, for 14 weeks, or 500 or 250 ppm, respectively, for 105 weeks (Morgan et al. 2011; NTP
2011).
Body Weight Effects. Studies in humans and in rats show that repeated exposure to 1-bromopropane
can produce weight loss.  Several single case reports or reports of a small number of workers 
experiencing frank neurotoxicity following exposure to 1-bromopropane also reported body weight loss
(Ichihara et al. 2002; Raymond and Ford 2007).  In general, weight loss (11–25 pounds in some cases)
occurred in a relatively short period of time prior to hospitalization for neurological symptoms.  In one
case, weight loss was accompanied by diarrhea and nausea/vomiting (Ichihara et al. 2002).  In two 
additional cases, it was noted that the subjects complained of dysphagia (difficulty swallowing), which 
suggested a disorder of the glossopharyngeal nerve, vagus nerve, or medulla oblongata (Ichihara et al. 
2002).  The mean daily time-weighted exposure level in one workplace was 133±67 ppm (range 60– 
261 ppm). In cases reported by Raymond and Ford (2007), the geometric mean air concentration of
1-bromopropane was 107 ppm for glue sprayers (range 58–254 ppm).  
In an acute 4-hour nose-only inhalation study in rats, exposure of males to 7,280 ppm 1-bromopropane or
females to 7,029 ppm 1-bromopropane did not result in significant alterations in body weight over a
14-day observation period following exposure (Elf AtoChem S.A. 1997). Intermittent exposure of
pregnant rats to 498 or 996 ppm 1-bromopropane on gestational days (GDs) 6–19 resulted in 14.3 and
   
 




        
   
 
 
        
   
  
     
   
      
 
    
       
  
       
    
  
     
 









     
    




24.6% reductions in net weight (weight at termination [GD 20] minus weight on GD 6), respectively; the
NOAEL was 100 ppm 1-bromopropane (BSOC 2001b).
In intermediate-duration studies, body weight effects following inhalation exposure to 1-bromopropane
differed between rat strains.  In general, the relative strain susceptibility was Wistar > F-344 > Sprague
Dawley.  In male and female Wistar rats exposed intermittently for 1–14 weeks, final body weight
decreases of 9.8–30% compared to controls were consistently reported at exposure concentrations 
≥1,000 ppm 1-bromopropane, and decreased body weight was also occasionally observed in animals 
exposed to 700–800 ppm 1-bromopropane; no significant body weight effects were observed ≤400 ppm
1-bromopropane (Banu et al. 2007; Furuhashi et al. 2006; Honma et al. 2003; Huang et al. 2016; Ichihara 
et al. 2000a, 2000b; Ishidao et al. 2002; Subramanian et al. 2012; Wang et al. 2002, 2003; Yamada et al.
2003; Yu et al. 2001; Zhang et al. 2013).  Male F-344 rats exposed intermittently to ≥1,000 ppm
1-bromopropane for 2–105 weeks showed decreases in final body weight of 12–27% relative to controls; 
no significant body weight effects were observed in F-344 males exposed to ≤500 ppm or in females 
exposed to ≤2,000 ppm (Morgan et al. 2011; NTP 2011; Sekiguchi et al. 2002).  None of the studies in
Wistar or F-344 rats provided information regarding food consumption.  In Sprague-Dawley rats, no 
significant changes (≤10% compared to controls) in body weight or food consumption were observed in 
males or females intermittently exposed to concentrations up to 1,800 ppm for 8–13 weeks (Albemarle 
Corporation 1997; Kim et al. 1999; Sohn et al. 2002). However, male Sprague-Dawley from the parental 
generation in a 2-generation study exposed to 750 ppm 1-bromopropane were 12.8% lighter at
termination than controls (BSOC 2001a).  In addition, pregnant rats from the parental and F1 generations
exposed to 500 ppm 1-bromopropane had body weights reduced 12–14% on GD 20; no significant effects 
were reported at 250 ppm 1-bromopropane (BSOC 2001).
No body weight effects were observed in four mouse strains intermittently exposed to concentrations up 
to 2,000 ppm for 2–14 weeks (Liu et al. 2009; NTP 2011; Zong et al. 2016).  Similarly, no body weight
effects were observed in mice exposed to concentrations up to 250 ppm for 105 weeks (Morgan et al. 
2011; NTP 2011).
Human and rat studies indicate that exposure to 1-bromopropane can reduce body weight gain.  Observed 
weight effects may be secondary to nausea and anorexia, or other neurological effects in exposed humans
(see Section 3.2.1.4, Neurological Effects, for more details). In Wistar rats, exposure to ≥1,000 ppm
1-bromopropane has been reported to induce a decline in consciousness (Honma et al. 2003), so 
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decreased food intake due to sedation may explain, at least in part, the reported decreased weight gain at
these exposure levels.
Metabolic Effects. Limited data from reports of workers experiencing frank neurotoxicity following
exposure to 1-bromopropane do not suggest metabolic effects of 1-bromopropane. In the 2003 NIOSH
survey previously described in the Hematological Effects section, no exposure-related changes were 
observed in electrolyte levels between adhesive-spray line workers exposed to a geometric mean of
45.7 ppm 1-bromopropane (range, 7–281 ppm) and 30 unexposed workers exposed to a geometric mean 
of 1.1 ppm 1-bromopropane (range, 0.1–4.9 ppm) (NIOSH 2003a).  Similarly, Raymond and Ford (2007)
reported normal electrolyte and glucose levels in four workers who developed neurological signs and 
symptoms 2 weeks after 1-bromopropane was introduced into the workplace. The geometric mean air
concentration was 107 ppm for glue sprayers (range, 58–254 ppm).  It should be mentioned that the
workers had been furniture gluers for up to 18 years prior to the introduction of 1-bromopropane into the
workplace.  In a case study of a female foam cushion gluer experiencing frank neurotoxicity following
exposure to 1-bromopropane vapors for 30–40 hours/week for ≥3 years, no exposure-related changes in
glucose levels were observed (Majersik et al. 2007). The mean concentration of 1-bromopropane in the
workplace air during gluing operations was 130 ppm (range, 91–176 ppm).  
Only one study in animals that assessed metabolic end points was located.  No exposure-related changes 
in electrolyte or glucose levels were observed in male or female rats intermittently exposed up to 600 ppm
1-bromopropane for 13 weeks (Albemarle Corporation 1997).
3.2.1.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans after inhalation exposure to 1-bromo-
propane.
Only one study was located that evaluated immune function in animals exposed to 1-bromopropane via
inhalation.  In that study, the IgM plaque-forming response to immunization with SRBCs was reduced by
up to ~60% in splenocytes harvested from female rats and mice exposed intermittently to 1,000 ppm and 
≥125 ppm, respectively, for 4–10 weeks (Anderson et al. 2010).  Other exposure-related changes 
observed in mice at ≥125 ppm included reduced absolute spleen weight, reduced spleen cellularity, 
decreased CD3+ cells in the spleen, and increased natural killer (NK) cells in the spleen.  No mouse
NOAEL was identified. In rats, several significant changes were observed in spleen cell subpopulations 
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in rats at ≥500 ppm, including decreased CD4−/CD8+, CD45/B220+, and CD3+ cells and increased NK
cells. The NOAEL in rats was 250 ppm.
No other animal studies evaluating immune function were located.  However, several studies examined
immune organ weight or histology following inhalation exposure to 1-bromopropane; however, no 
exposure-related changes were observed in intermediate-duration studies in rats or mice exposed 
intermittently to concentrations up to 1,800 or 500 ppm, respectively, or in chronic-duration studies in 
rats or mice exposed intermittently to concentrations up to 500 or 250 ppm, respectively (Albemarle 
Corporation 1997; BSOC 2001a; Ichihara et al. 2000a; Kim et al. 1999; Morgan et al. 2011; NTP 2011; 
Yamada et al. 2003).
The limited evidence from animal inhalation studies indicates that 1-bromopropane can suppress immune 
responses in two different species, indicating that immune suppression may be a concern following
1-bromopropane exposure in humans.
3.2.1.4  Neurological Effects 
Exposure to 1-bromopropane can induce neurotoxicity in humans as evidenced by reports of exposure at
work and occupational studies involving larger cohorts.
Neurological parameters were evaluated in Chinese 1-bromopropane production workers and unexposed
controls (no monitoring data were available in the control factories, but these factories did not use 
1-bromopropane) from the Li et al. (2010) occupational study described in the Hematological Effects 
section.  Median exposure concentrations for the low-, mid-, and high-exposure females were 1.28, 6.60, 
and 22.58 ppm, respectively; median exposure concentrations for the low- and high-dose males were 
1.05 and 12.5 ppm, respectively. Comprehensive neurological evaluations were conducted that included
measurements of motor and sensory parameters as well as performance in various neurobehavioral tests.
Using regression analysis of median group exposure levels, adjusting for alcohol exposure and pair-
matching for age, sex, and region in selecting controls, significant trends were observed in tibial distal 
latency, vibration sense in the toes, and Benton test in female workers.  Significant increases in tibial 
distal latency and vibration sense threshold were also associated with cumulative exposure in female 
workers. Regression analyses also showed impaired results in a test of motor coordination in males.
When workers were stratified by exposure groups (control, low-, mid-, and high-exposure), analysis of
variance (ANOVA) showed significant decreases in vibration sense, tibial distal latency, and sural
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sensory nerve conduction velocity between exposed females and controls.  The vibration sense threshold 
showed the clearest dose-related effect, with significant increases (indicative of decreased vibration
sense) in all exposed female groups. No significant differences between controls and individual male 
groups were seen regarding neurological parameters in this analysis. No information was provided 
regarding work position, which could have contributed to numbness and decreased sensations.  The
minimal LOAEL of 1.28 ppm for reduced vibration sense in female workers was used as the basis for the 
chronic-duration inhalation MRL. However, the confidence in the MRL is low due to a number of
limitations of the principal study.  Key limitations identified by the investigators or pointed out by others
(Smith et al. 2011) included: (1) the cross-sectional study design; (2) potential selection bias for the 
control group; (3) potential underestimation of 1-bromopropane exposure levels; (4) co-exposure to low
levels of 2-bromopropane in the exposed group of workers; (5) lack of biomonitoring data for controls;
(6) lack of control of the temperature of the skin of the legs may have impacted measurements of nerve 
conduction velocity; (7) abnormally high control values for tibial nerve distal latency; (8) concerns 
regarding the sensitivity of the vibration sense measurement method utilized in the study; and (9) no data
on menstrual cycle of females. However, after careful review of limitations and criticisms, as well as the 
available human and animal data, this study was considered to be the best available study on which to
base the chronic MRL. In support, the most sensitive animal study yielded an MRL of 0.03 ppm
(0.15 mg/m3) based on respiratory lesions (Morgan et al. 2011; NTP 2011), which is essentially
equivalent to the MRL based on the selected human study.  The rationale for selecting the Li et al. (2010)
study as the principal study for the derivation of the chronic inhalation MRL, despite acknowledged
limitations, is discussed in more detail in Appendix A. The results of the neurological testing of
1-bromopropane workers from one of the three factories included in the Li et al. (2010) study had been 
published previously by Ichihara et al. (2004b).
Other occupational studies evaluating neurological effects include two NIOSH Health Hazard Evaluation 
reports of workers exposed to 1-bromopropane during the spray application of solvent-based adhesives 
(NIOSH 2002, 2003a). These studies, however, are limited due to small sample sizes, lack of control for
potential confounding factors (e.g., age), and/or lack of unexposed referent group. In the first report, 
study subjects were exposed to a geometric mean (range) 168.9 ppm (60–381.2 ppm) 1-bromopropane.  
All workers surveyed (n=42) presented with symptoms suggestive of excessive exposure to solvents.
Those exposed to the higher levels of 1-bromopropane (169.8–197 ppm) reported more frequently having
a headache at least once per week, having painful tingling in the hands, having a tremor, and “feeling
drunk” when not drinking than those with the lower exposure levels.  Thirty-two persons were subjected
to further analyses of symptoms.  The results showed that for each of the symptoms evaluated, the 
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concentrations of 1-bromopropane in air were not statistically different between those individuals
reporting the symptom compared to those not reporting the symptom. In the second NIOSH report, the
cohort included 10 female and 3 male workers exposed to a geometric mean (range) of 45.7 ppm (7– 
281 ppm) and 30 unexposed workers exposed to a geometric mean (range) of 1.1 ppm (0.1–4.9 ppm).  
Exposed workers complained more frequently of tremor, headache, feeling "drunk," fatigue, and anxiety;
using personal breathing zone (PBZ) data, employees reporting anxiety, headache, and feeling "drunk"
had statistically significant higher PBZ concentrations of 1-bromopropane compared to those not
reporting those symptoms. Nerve conduction studies performed in 29 individuals were judged by a
physician to be normal, 4 were incomplete but without abnormalities, and 4 were considered borderline.  
The remaining five tests were considered abnormal; two of them were among the workers exposed to
1-bromopropane, but neither one was among the most heavily exposed workers.  This yielded a 
prevalence ratio of 1.5 (95% CI, 0.3–7.9) for abnormal nerve conduction.  Assessment of the combined 
(n=9) borderline tests (n=4) and abnormal tests (n=5) showed that only two of them were exposed to 
1-bromopropane and seven were not.  Overall, the results of this survey found no relationship between 
abnormal nerve conduction and exposure to 1-bromopropane.
Case reports have described neurological effects in subjects exposed to 1-bromopropane for periods
ranging from a few weeks to years.  In most cases, dermal exposure could have been significant since 
often no gloves were used when handling 1-bromopropane, or the use of gloves, as noted in some reports, 
may have enhanced dermal uptake of 1-bromopropane by occlusion effect.  In an early case described by
Sclar (1999), a subject exposed for 2 months to a solvent containing mainly 1-bromopropane developed 
numbness and progressive weakness of the extremities.  Nerve conduction studies showed evidence of
primary, symmetric demyelinating polyneuropathy.  Samukawa et al. (2012) reported that a subject who 
used 1-bromopropane as a cleaning agent for metal parts for 18 months complained of numbness and pain 
of the lower extremities, weakness, and gait disturbance.  Conduction velocity was decreased in motor
and sensory nerves.  Examination of a biopsy of the sural nerve showed axonal damage.  The mean TWA
level of exposure for this subject was estimated to be 553 ppm 1-bromopropane (range, 353–663 ppm). 
Others have reported similar effects (Ichihara et al. 2002; Majersik et al. 2007; MMWR 2008; Raymond 
and Ford 2007; Wang et al. 2015).  Diarrhea, urinary incontinence, and abnormal sweating were signs 
reported in the three cases described by Ichihara et al. (2002), suggesting alterations in the autonomic
nervous system. The daily exposure concentration measured with a passive sampler attached to one 
subject for 11 days was 133±67 ppm (mean ± SD). Majersik et al. (2007) reported six cases of
neurotoxicity occurring in foam cushion gluers exposed to 1-bromopropane vapors from spray adhesives.
Five patients were exposed 30–40 hours/week over a period of 3 years, whereas the sixth patient had been
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employed for 3 months; none used protective clothing. Lower extremity pain or paresthesias developed
subacutely in all of the patients.  Five of them complained of difficulty walking and, upon examination,
had spastic paraparesis, distal sensory loss, and hyperreflexia. Analysis of air samples collected at the 
workplace during gluing operations revealed a mean concentration of 1-bromopropane of 130 ppm
(range, 91–176 ppm) with a 7-hour TWA of 108 ppm (range, 92–127 ppm). A 2-year follow-up of three 
of the patients revealed persistent symptoms that included headache, decreased memory, decreased mood, 
lower extremities numbness, cramping, paresthesias, weakness, and difficulty walking/poor balance.  
Clinical signs noted in these individuals included decreased cognition, lower extremities spasticity and 
weakness, gait ataxia, hyperreflexia, and decreased lower extremities sensation. Majersik et al. (2007)
suggested that the pathogenesis of 1-bromopropane neurotoxicity in humans may reflect a central distal 
axonopathy syndrome. It should be noted that decreased vibration sense, particularly in the lower
extremities, was reported in several of the cases described above (Ichihara et al. 2002; Majersik et al.
2007; Raymond and Ford 2007; Samukawa et al. 2012; Sclar 1999).  Vibration sense in the toes appeared
to be the most sensitive neurological end point in 1-bromopropane workers studies by Li et al. (2010), and
was significantly decreased in workers exposed to a median concentration ≥1.28 ppm 1-bromopropane.  
Many studies have examined the effects of 1-bromopropane on the nervous system of animals. These 
studies have provided information regarding biochemical, morphological, and physiological aspects of
both the peripheral nervous system and the central nervous system. For the most part, these studies 
support the findings in humans. 
A study aimed at determining an LC50 for 1-bromopropane in rats reported decreased activity and ataxia 
within 1 hour after a 4-hour exposure to ≥11,000 ppm 1-bromopropane (Kim et al. 1999). The same
investigators reported that male and female rats exposed to 1,800 ppm 1-bromopropane for 6 hours
showed decreased activity and mild ataxia after 1 hour of exposure; no such signs were observed in rats
exposed to 300 ppm 1-bromopropane. In another study, daily exposure of male rats to 1,000 ppm
1-bromopropane 8 hours/day for 14 days significantly reduced forelimb grip strength, but no significant
effect was seen at ≤200 ppm 1-bromopropane or at 1,000 ppm when tested following exposure on day 1 
or 7 (Honma et al. 2003). The Honma et al. (2003) study was used to derive an acute-duration inhalation 
MRL for 1-bromopropane. A more detailed description of the Honma et al. (2003) study can be found in 
Appendix A.
An acute-duration study in male rats examined neurochemical (8 rats/group) and morphological effects
(1 rat/group) of 1-bromopropane in rats exposed up to 800 ppm 1-bromopropane 8 hours/day for 7 days
   
 




    
    
  
  
      
     
  
    
     
     
     
     
 
    
     
      
  
 
    
    
      
     
    
   
   
   
    
   
   
     
    




(Wang et al. 2002).  Observed morphological alterations included the preterminal axon swelling with thin
myelin sheath in the gracile nucleus of the medulla oblongata and swelling and masses of myelin sheath,
hypertrophy of Schwann cell cytoplasm, and decreased frequency of Schmidt-Lanterman incisures in the
posterior tibial nerve.  Morphological changes were not observed in the medulla or tibial nerve at
≤400 ppm or the cerebellum, dorsal root ganglion, or thoracic spinal cord at ≤800 ppm. It should be
mentioned, however, that only 1 rat per group (n=9) was used for morphological analyses, therefore, the
findings may not be representative.  Biochemical findings in this study included decreased creatine kinase 
(CK) activity in the brain stem and spinal cord at ≥200 ppm, increased total glutathione through the
central nervous system at ≥200 ppm, and reduced levels of the neuronal marker protein γ-enolase in the
cerebrum and cerebellum at ≥400 ppm.  These findings suggest that biochemical end points are affected
at lower exposures than morphological structures if the morphological findings are representative of the
various exposure groups.
In intermediate-duration studies, the lowest LOAEL for neurological effects was 50 ppm 1-bromopropane
for increased spontaneous locomotor activity in male F-344 rats exposed intermittently for 3 weeks; the
NOAEL was 10 ppm 1-bromopropane (Honma et al. 2003).  The increase in spontaneous locomotor
activity was used to derive an intermediate-duration inhalation MRL for 1-bromopropane.  Other effects 
occurring at higher exposure concentrations included increased ambulation and rearing, altered
performance in a water maze test, and decreased muscle strength; however, concentrations up to 
1,000 ppm did not significantly alter passive avoidance behavior, preening behavior, or motor
coordination (Honma et al. 2003). Other studies in rats have reported reduced limb grip strength at
≥200 ppm 1-bromopropane and altered gait at ≥800 ppm (Ichihara et al. 2000b; Yu et al. 1998, 2001).
Male rats exposed to 1,500 ppm 1-bromopropane intermittently for 4 weeks showed frank effects such as 
ataxic gait and convulsions (Fueta et al. 2002). A study that assessed the reversibility of the effects of
1-bromopropane reported a significant decrease (about 68%) in hindlimb muscle strength in male Wistar
rats following exposure to 1,000 ppm 1-bromopropane for 6 weeks, which was still evident (about 40%
reduction) 14 weeks after exposure terminated (Banu et al. 2007). In a 13-week study in rats, however, 
no exposure-related changes were observed in motor activity or a functional observation battery assessed
during weeks 4, 8, and 13 of exposure to 1-bromopropane at concentrations up to 600 ppm (Albemarle
Corporation 1997). No significant histopathological changes were observed in rats or mice exposed at up 
to 1,800 or 500 ppm, respectively, 1-bromopropane 6 hours/day, 5 days/week for 8–14 weeks (Kim et al.
1999; NTP 2011; Sohn et al. 2002). Neurobehavior was not assessed in these studies.
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Some functional deficits described above could be explained by basic electrophysiological changes such 
as alterations in nerve conduction velocity.  For example, motor nerve conduction velocity was 
significantly decreased and distal latency was increased in male Wistar rats after several weeks of 
exposure to ≥800 ppm 1-bromopropane (Ichihara et al. 2000b; Yu et al. 2001).  In turn, decreased nerve
conduction velocity could be due to morphological changes such as swelling of the axons and alteration 
of the myelin sheath, as observed by Ichihara et al. (2000b) and Yu et al. (1998, 2001).  In Sprague-
Dawley rats, a strain in which no functional deficits or morphological alterations of the brain were found
by Albemarle Corporation (1997) and BSOC (2001a), a study of similar duration and exposure conditions
as those used by Ichihara et al. (2000b) and Yu et al. (2001) reported no morphological alterations in 
peripheral nerves of male or female rats exposed to up to 1,250 ppm 1-bromopropane; however, no nerve
conduction velocity experiments were conducted (Sohn et al. 2002). The mechanism(s) underlying the 
apparent strain differences are unknown.  
Studies have also examined morphological and biochemical alterations in various brain areas following
exposure to 1-bromopropane.  For example, intermittent exposure of male rats to ≥800 ppm 1-bromo-
propane vapors for 4 weeks resulted in a significant reduction in the density of noradrenergic axons in the
dorsal and ventral medial prefrontal cortex and the amygdala but induced no significant changes in the
dentate gyrus in the hippocampus (Mohideen et al. 2011).  In contrast, exposure to 1-bromopropane did 
not affect the density of serotonergic neurons in any of the three areas studied.  A more recent study in 
rats reported that exposure to 1,000 ppm 1-bromopropane for 4 weeks produced pyknosis and shrinkage
of Purkinje cells and nuclei of granular cells of the cerebellum (Mohideen et al. 2013).  Immunostaining
showed that exposure to ≥400 ppm 1-bromopropane significantly increased the number of astrocytes in
the middle cerebellar peduncle, suggesting astrocyte activation.  Exposure to 1-bromopropane also
induced significant elongation of processes in astrocytes in the cerebellum in all exposed groups. There
was no clear demyelination in the cerebellum or hippocampus. Cerebellar glia cells were also affected in
a study in male rats exposed to 1,000 ppm 1-bromopropane 8 hours/day, 7 days/week for 4 weeks
(Subramanian et al. 2012).  In these rats, microglia appeared larger and had longer ramified processes in
the high-dose group.  Microscopy also showed shrinkage of Purkinje cells in the high-dose group.  No 
such effects were reported in rats exposed to 800 ppm 1-bromopropane. Morphological changes were 
paralleled by exposure-concentration-related increases in markers of oxidative stress in the cerebellum, as 
well as reactive oxygen species and nitric oxide content, suggesting that these biochemical changes may
play a role in the neurotoxicity of 1-bromopropane.  Other biochemical changes observed in various brain
regions following exposure to ≥200 ppm 1-bromopropane for 1–4 weeks included alterations in amino 
acids involved in transamination and alterations in levels of neurotransmitters or their metabolites or
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precursors from the gamma-aminobutyric acid (GABA), serotonergic, dopaminergic, noradrenergic, and
glutamatergic systems (Suda et al. 2008; Zhang et al. 2013); see Section 3.4.2, Mechanisms of Toxicity,
for more details, in particular the possible role of the hippocampus in 1-bromopropane-induced 
neurotoxicity.
In a chronic-duration inhalation study of 1-bromopropane, exposure of male and female rats to up to 
500 ppm 1-bromopropane or of male and female mice to up to 250 ppm 1-bromopropane did not induce
gross or microscopic alterations in brain (Morgan et al. 2011; NTP 2011). No other neurological end
points were assessed in these studies.
The available data clearly indicate that the nervous system is a target for 1-bromopropane toxicity in
humans and animals. Data in humans show that 1-bromopropane can induce morphological alterations in 
neurons, which may lead to motor and sensory deficits.  Studies in animals show that 1-bromopropane
can induce biochemical, morphological, electrophysiological, and neurobehavioral alterations by
mechanisms yet to be elucidated.
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. Due to unclear
adversity of biochemical changes in the nervous system, these end points were not used as the basis of
NOAEL/LOAEL determinations unless they were clearly associated with an apical end point (e.g.,
neurobehavioral change, histopathological lesion, etc.).
3.2.1.5  Reproductive Effects
Available information regarding reproductive effects of 1-bromopropane in humans is limited. In two
NIOSH health hazard reports, no exposure-related reproductive effects were reported by workers exposed 
to 1-bromopropane in response to the questions regarding whether they had been diagnosed with a 
reproductive or fertility problem, had ever seen a doctor for reproductive or fertility problems, or had 
failed to have a child after attempting for a full year (NIOSH 2002, 2003a).  The geometric means for 
1-bromopropane exposure levels were 168.9 and 45.7 ppm for the 2002 and 2003 report, respectively. In
the 2003 report, a limited number of individuals (three exposed males, nine unexposed males) were 
evaluated for sperm parameters (NIOSH 2003a).  There was no evidence of exposure-related changes in
sperm count, motility, or morphology.  In preliminary health surveys, female workers from a Chinese 
1-bromopropane factory (n=23) did not report more menstrual abnormalities than age-matched referents 
   
 




      
  
   
 
 
    
   
     
 
 
   
     
     
  
     
     
   
  
  
   
  
   
 
      
     
   
      
   
      
 
   
  




from a beer factory (Ichihara et al. 2004a, 2004b).  The 8-hour shift TWA median exposure was 1.61 ppm
1-bromopropane.  Survey results were not included in the more comprehensive health survey from this
and two other factories in China (Li et al. 2010).
Animal studies that evaluated sperm/estrous cycle parameters, reproductive organ weight and histology, 
and reproductive hormone levels were available for review. While the available human data are 
inadequate to assess the reproductive toxicity of 1-bromopropane, animal data suggest that the
reproductive system may be a potential target of concern for 1-bromopropane toxicity in humans.
Alterations in sperm parameters have been consistently reported in rats and mice following intermittent,
intermediate-duration inhalation exposure to 1-bromopropane at concentrations as low as 250 and
50 ppm, respectively.  Observed effects in F-344 rats exposed to ≥250 ppm and rats exposed to ≥400 ppm
included a 25–70% decrease in sperm count, a 7–58% decrease in sperm motility, and a 7–98.5% increase
in percent of abnormal sperm (including tailless sperm and banana-like sperm heads); no sperm
alterations were observed in rats exposed to ≤200 ppm 1-bromopropane (Ichihara et al. 2000a; NTP
2011).  In Wistar rats, exposure to 400 ppm 1-bromopropane for 6 weeks results in a 23% decrease in 
epididymal sperm count and exposure to 1,000 ppm significantly reduced sperm motility and sperm count
even 14 weeks after the 6-week exposure period ceased (Banu et al. 2007). The investigators suggested
that different mechanisms operate at different exposure concentrations based on the observed failure of
spermiation at 400 ppm 1-bromopropane and spermatogenic cell depletion at 1,000 ppm 1-bromopropane.
In three mouse strains with different capacities to metabolize 1-bromopropane (C57Bl/6J, DBA/2J, and 
BALB/cA), the strain with the highest CYP2E1 protein level and lowest total GSH content and GST
activity in the liver (BALB/cA) was the most susceptible, showing a 27–78% decrease in sperm count, a 
24–39% decrease in percent of motile sperm, and a 15–24% increase in the percent of abnormal sperm
(2-tail sperm, banana-like sperm) at concentrations ≥50 ppm 1-bromopropane (lowest concentration
tested) (Liu et al. 2009).  Garner et al. (2007) had earlier reported that CYP2E1-null mice exposed to 
800 ppm for 6 hours had a lower reduction (12%) in sperm motility than similarly exposed wild mice 
(37%).  In B6C3F1 mice, sperm count was decreased 28% and sperm motility was decreased 3% at
500 ppm 1-bromopropane; no sperm alterations were observed at concentrations ≤250 ppm (NTP 2011).  
Multiple studies reported alterations in the estrous cycle in rats and mice intermittently exposed to 
1-bromopropane vapors at concentrations ≥250 and 500 ppm, respectively, for 12–14 weeks.  Observed 
alterations included an increase in the number of irregular cycles or lack of estrous cycling in rats exposed
to ≥400 ppm (Yamada et al. 2003), extended estrus period and decreased diestrus period during normal-
   
 





    
     
   
    
  
    
 
     
 
 
   
  
      
   
     
  
   
   
    
     
   
  
 
   
     
    
    
  
       





length estrous cycles in F-344 rats exposed to ≥250 ppm for 14 weeks (NTP 2011), and a 10% increase in 
estrous cycle length in mice exposed to 500 ppm 1-bromopropane for 14 weeks (NTP 2011).  No 
significant changes in the estrous cycle were observed in rats at ≤200 ppm or mice at ≤250 ppm (NTP
2011; Yamada et al. 2003).  In a shorter intermediate-duration study in rats exposed intermittently to up to 
1,000 ppm 1-bromopropane for 20 days, there were no exposure-related changes in the number of estrous
cycles per group, number of cycles per rat, cycle days, number of rats with cycles >6 days in duration, or
number of ovulated ova in the oviduct at sacrifice (during estrous) (Sekiguchi et al. 2002). 
An acute inhalation study in male rats did not reveal histological lesions in the testes following a 4-hour
nose-only exposure to up to 8,500 ppm 1-bromopropane (Elf AtoChem S.A. 1997).
Histopathological lesions in the reproductive organs were infrequently reported in longer-term studies.  
One intermediate-duration study reported several alterations in reproductive organ histology in male
Wistar rats following intermittent exposure to 800 ppm 1-bromopropane for 12 weeks (Ichihara et al.
2000a).  Histological alterations were described qualitatively only, and included alterations in the testes
(increased number of degenerated spermatocytes and retention of elongated spermatids in the 
seminiferous tubules), epididymides (decreased diameter of the epididymal duct cavity, increased
interstitial space, increased height of the epithelial cells, and presence of neutrophil leukocytes or
degenerated epithelial cell-like profiles in the epididymal duct), and the prostate and seminal vesicles
(smaller alveoli and many degenerated cells in the vesicular cavity of the seminal vesicles).  With the
exception of retention of elongated spermatids in the seminiferous tubules at 400 ppm, no 
histopathological changes were observed at concentrations ≤400 ppm 1-bromopropane (Ichihara et al.
2000a).  A more recent study from the same group of investigators reported degenerative changes in the 
reproductive organs of male Wistar rats exposed to 1,000 ppm 1-bromopropane for 6 weeks (Banu et al. 
2007).  Fourteen weeks after exposure ceased, the appearance of the prostate and seminal vesicles had 
returned to normal, but the testes and epididymides still showed histological alterations (Banu et al.
2007). In females, one intermediate-duration study reported follicular changes in the ovaries of rats 
intermittently exposed to concentrations ≥200 ppm 1-bromopropane for 12 weeks, including a significant
33–75% decrease in the number of antral and growing follicles (Yamada et al. 2003).  In this study, no 
histological changes were observed in the uterus or vagina at exposures up to 800 ppm 1-bromopropane
(Yamada et al. 2003).  However, no significant histopathological changes were reported in the
reproductive organs in intermediate-duration studies in rats or mice exposed to up to 1,800 or 500 ppm 1-
bromopropane, respectively (Albemarle Corporation 1997; Kim et al. 1999; NTP 2011; Yu et al. 1998, 
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2001), or in chronic duration studies in rats or mice at concentrations up to 1,000 or 500 ppm, 
respectively (Morgan et al. 2001; NTP 2011).  
Reproductive organ weight changes have been inconsistently reported in intermediate-duration studies
with intermittent exposure to 1-bromopropane.  Testes weight was significantly decreased by 12.5% in 
mice exposed to 250 ppm, but not ≤110 ppm 1-bromopropane (Liu et al. 2009); however, no other
intermediate-duration study reported decreased testicular weight in mice or rats exposed to concentrations
up to 500 and 1,800 ppm, respectively (Albemarle Corporation 1997; Ichihara et al. 2000a; Kim et al.
1999; Liu et al. 2009; NTP 2011). A study aimed at determining an LC50 for 1-bromopropane in rats did
not report altered testes weight after the 14-day observation period at up to 8,500 ppm (Elf AtoChem S.A. 
1997). Epididymides weight was significantly reduced by 11–28% in rats exposed to ≥400 ppm 1-bromo-
propane (Ichihara et al. 2000a) and by 14–19% in rats exposed to 1,000 ppm (but not ≤500 ppm) (NTP
2011); however, no changes in epididymides weight were reported in mice exposed to concentrations up 
to 500 ppm (Liu et al. 2009; NTP 2011).  Significant reductions of 18–47% in weight of the seminal 
vesicles have been reported in rats and C57Bl/6J mice at ≥200 and 250 ppm, respectively; however, 
seminal vesicle weights were not altered in DBA/2J or BALB/cA mice exposed to concentrations up to 
250 ppm (Ichihara et al. 2000a; Liu et al. 2009). In addition, one study reported a 32% decreased in 
prostate weight in rats at 800 ppm, but not ≤400 ppm (Ichihara et al. 2000a). A study that examined the 
reversibility of the effects of 1-bromopropane reported significant reductions in absolute weight of the
prostate (56%), seminal vesicles (56%), testes (33%), and epididymides (28%) after 6 weeks of exposure 
to 1,000 ppm 1-bromopropane; no significant changes occurred at 400 ppm 1-bromopropane (Banu et al. 
2007).  Fourteen weeks after exposure ceased, the weight of the testes and epididymides were still
significantly reduced compared to controls (Banu et al. 2007).  One intermediate-duration study reported
a significant 27–30% increase in the relative weight of the right and left ovaries in rats exposed to
1,800 ppm 1-bromopropane for 8 weeks; no changes were observed at concentrations ≤300 ppm (Kim et
al. 1999).  In other intermediate-duration studies, no changes were observed in female reproductive organ 
weights in rats exposed to concentrations up to 1,000 ppm (Albemarle Corporation 1997; Sekiguchi et al.
2002; Yamada et al. 2003).
Three intermediate-duration studies evaluated reproductive hormones in animals exposed to 1-bromo-
propane.  Plasma testosterone levels were significantly decreased by 36% in male rats exposed to
800 ppm for 12 weeks (Ichihara et al. 2000a).  Exposure to 1,000 ppm 1-bromopropane for 6 weeks
resulted in a 56% reduction in serum testosterone in male Wistar rats (Banu et al. 2007).  After a 4-week
recovery period, serum testosterone was reduced 27% relative to controls, and returned to control values
   
 




     
   
      
    
   
 
 
    
   
      
     
   
    
  
   
    
    
     
      
  
     
  
       
 
   
  
     
   
      
       
   




after a 14-week recovery period; no significant changes were reported at 400 ppm 1-bromopropane.  No
changes were observed in testosterone levels at ≤400 ppm or in plasma luteinizing hormone (LH) or FSH
at concentrations up to 800 ppm 1-bromopropane (Ichihara et al. 2000a). No changes were observed in
serum LH or FSH in female rats following intermittent exposure at concentrations up to 800 ppm
1-bromopropane for 12 weeks (Yamada et al. 2003). 
A comprehensive 2-generation reproductive study defined a NOAEL and LOAEL of 100 and 250 ppm
1-bromopropane, respectively, for reproductive effects in rats (BSOC 2001a).  Exposure to 250 ppm
1-bromopropane resulted in a significant reduction (14%) in absolute prostate weight in F0 males and 
increased length of the estrous cycle (9%) in F1 females.  Other reported effects included 48% reduction 
of fertility at 500 ppm and complete infertility at 750 ppm in the F0 generation. The mating index was
also significantly reduced at 750 ppm, and time between paring and coitus was increased in groups
exposed to ≥500 ppm 1-bromopropane.  Males in the F0 generation exposed to ≥500 ppm 1-bromo-
propane had significantly reduced sperm motility and reduced morphologically normal sperm; this was 
also observed in F1 males exposed to 500 ppm. The number of implantation sites was significantly
reduced in F0 dams exposed to 500 ppm 1-bromopropane.  Examination of the ovary of F0 females 
showed significantly decreased corpora lutea at 500 and 750 ppm and increased follicular cysts and
interstitial cell hyperplasia at 750 ppm. Ovaries of 500 ppm-exposed F1 females also showed an 
increased incidence of cysts and interstitial cell hyperplasia. No significant histological alterations were
reported in the testes from male rats in the F0 or F1 generation. It should be noted, however, that
exposure of rats to ≤996 ppm 1-bromopropane (highest concentration tested) during GDs 6–19 did not
significantly affect pregnancy rates (pregnancy at termination), uterus weight, mean number of corpora
lutea, pre- and post-implantation loss, or mean number of early and late resorptions (BSOC 2001b). 
Some of the reproductive effects in rats reported by Albermarle Corporation (2001) were also reported in
a study in which pregnant female rats were exposed to 1-bromopropane from conception to the end of
lactation (Furuhashi et al. 2006). In the latter study, male offspring from rats exposed to 400 ppm
1-bromopropane showed no exposure-related changes in the epididymal sperm count or the percent
motile sperm at postnatal day (PND) 50, but the rate of sperm arrival at cauda epididymides (the tail or
inferior portion leading into the ductus deferens) was significantly lower than in controls.  At 100 ppm
(lowest concentration tested) and 400 ppm, testes showed fewer cells in the seminiferous tubules and
fewer cell layers at PND 21 and a delay in thickening and differentiation of seminiferous tubules at
day 33 (no quantitative data reported).  Evaluation of sexual maturation in female offspring showed no 
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exposure-related changes, as assessed by the timing of the first diestrous.  No changes were observed in
male or female reproductive organ weights at PND 21, 33, or 50.
Overall, the available human data are inadequate to assess the reproductive toxicity of 1-bromopropane.  
However, the available animal data suggest that the reproductive system may be a potential target of
concern for 1-bromopropane toxicity in humans. 
3.2.1.6  Developmental Effects 
No studies were located for developmental effects in humans after inhalation exposure to
1-bromopropane.
Limited information regarding developmental effects in animals indicate that perinatal exposure to 
1-bromopropane can lead to altered growth in rats, but the relevance of this information to exposure of
humans is unclear.  
Reduced fetal weight was reported in a gestational intermittent exposure study in rats (BSOC 2001b).  On
GD 20, fetal body weights (male and female combined) from dams exposed to 100, 498, or 996 ppm
1-bromopropane were reduced 2.5, 4.9, and 7.4% relative to controls, respectively.  Exposure to 
1-bromopropane did not significantly affect the mean number of live fetuses per rat or sex ratio.
Exposure to 1-bromopropane also did not induce external, visceral, or skeletal malformations. There was 
a significant increased dose-related incidence of delayed ossification in fetuses from the mid- and high-
exposure concentration groups, which the investigators suggested was probably associated with maternal
toxicity (reduced food consumption and body weight) and reduced fetal weight. Reduced body weight in 
the offspring was also reported in another study in which rats were exposed intermittently to 700 ppm
1-bromopropane (only exposure concentration tested) on GDs 1–20 (Fueta et al. 2015).  Offspring body
weight on PND 14 (only time measured) was reduced 7.5–9.5% compared to controls; no maternal
toxicity was reported in this study.  Fueta et al. (2015) also reported that maternal exposure to 
1-bromopropane resulted in suppression of a shaking behavior in 14-day-old pups induced by injection of
kainate, but not of a scratching behavior induced by kainate; the relevance of these findings to human 
health is unknown.
In the 2-generation study by BSOC (2001a) summarized above, the number of F1 and F2 pups born and 
litter size from the group exposed to 500 ppm 1-bromopropane were significantly reduced compared to 
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controls; no significant differences were seen at 250 ppm 1-bromopropane.  F1 and F2 viability during
lactation was not significantly affected by exposure to 500 ppm. F1 male pups exposed to 500 ppm had 
significantly reduced weight (13.7%) on PND 28. Male and female F1 pups necropsied on PND 21 or 28 
showed no significant gross alterations in tissues or organs or alterations in selected organ weights (brain, 
spleen, thymus).  A significant delay in F1 preputial separation occurred at 500 ppm; this was attributed 
to reduced body weights. Vaginal patency was not affected in F1 females. F2 male and female pup 
weights on PNDs 14 and 21 were significantly reduced (14–18%) at 500 ppm. Gross necropsy of F2 on 
PND 21 did not show treatment-related gross alterations or alterations in the brain, spleen, or thymus. 
In a study in which rats were exposed to 1-bromopropane from conception to the end of lactation, survival
of offspring during lactation was decreased in a dose-dependent fashion by ~5, 30, and 70% at
100 (lowest concentration tested), 400, and 800 ppm, respectively (Furuhashi et al. 2006). Decreased
survival, however, was only statistically significant at 800 ppm. In order to determine if decreased 
survival and body weight gain in offspring were due to gestational or lactational exposure, a cross-foster 
experiment was also conducted with 0 or 800 ppm 1-bromopropane. The results showed that gestation
and lactation exposure had comparable effects on survival rate, but lactation exposure played a greater
role on growth of the offspring.  Additionally, F1 animals were assessed for their ability to produce F2 
offspring.  Mated offspring from the lactation-only exposure group produced a significantly greater
number of dead F2 offspring, compared with control.  However, no exposure-related effects were 
observed in the F2 litter for gestational-only exposure. This suggested that lactation exposure may have 
played a greater role in sexual maturation of the offspring.
No teratogenic effects were reported by either BSOC (2001a, 2001b) or Furuhashi et al. (2006).
3.2.1.7  Cancer
No studies of cancer in humans exposed to 1-bromopropane by the inhalation route were located in the
literature.
The potential carcinogenicity of 1-bromopropane has been examined in bioassays in rats and mice 
(Morgan et al. 2011; NTP 2011).  In both bioassays, animals were exposed 6 hours/day, 5 days/week for
up to 105 weeks.  Rats were exposed to 0, 125, 250, or 500 ppm 1-bromopropane vapors, while mice 
were exposed to 0, 62.5, 125, 250, or 500 ppm 1-bromopropane vapors.  1-Bromopropane was a multi-
site carcinogen in rats, significantly increasing the incidence of large intestine adenomas in females
   
 






   




     
    
     
 
 




    
   
 
     
    
  
      
  
 
   
 
 
   








(500 ppm), skin keratoacanthoma in males (≥250 ppm), skin keratoacanthoma, basal cell adenoma, or 
squamous cell carcinoma in males (≥125 ppm), malignant mesothelioma in males (500 ppm), and 
pancreatic islet adenoma in males (≥125 ppm).  In mice, exposure to 1-bromopropane significantly 
increased the incidence of combined alveolar/bronchiolar adenoma or carcinoma in females (≥62.5 ppm). 
Based on the information available, the Department of Health and Human Services (DHHS) has classified
1-bromopropane as “reasonably anticipated to be a human carcinogen” (NTP 2016).  Based on the
findings in animals, ACGIH has assigned 1-bromopropane a classification of “A3 – Confirmed animal
carcinogen with unknown relevance to humans” (ACGIH 2104, 2016).  The International Agency for
Research on Cancer (IARC) and the EPA have not evaluated the carcinogenicity of 1-bromopropane
(IARC 2014; IRIS 2014).  
3.2.2 Oral Exposure
3.2.2.1  Death 
No reports of death in humans due to oral exposure to 1-bromopropane were located in the available 
literature.
In male and female rats exposed once to concentrations of 2,000 mg 1-bromopropane/kg via gavage,
0/5 males and 1/5 females died during the 14-day observation period; the LD50 was determined to be
greater than 2,000 mg 1-bromopropane/kg (Elf Atochem S.A. 1993).  Necropsy did not reveal gross
alterations. Although there are no monitoring data for 1-bromopropane in water or soil, it is unlikely that
humans would be orally exposed to these high levels of 1-bromopropane.  
3.2.2.2  Systemic Effects
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, renal, endocrine, dermal, ocular, or metabolic effects in humans or in animals following
oral exposure to 1-bromopropane. In addition, no studies were located regarding hepatic and body weight
effects in humans exposed orally to 1-bromopropane.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
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Key to Species Frequency 
Figure (Strain) (Route) 
ACUTE EXPOSURE 
Systemic 




2 Rat 12 d 
1 x/d(Wistar) 
(GO) 
3 Rat 12 d 
1 x/d(Wistar) 
(GO) 
4 Mouse once 
(BALB/c) (GO) 






















Less Serious Serious 
(mg/kg/day) (mg/kg/day) 
800 M (13% decrease in final 
body weight) 
500 F (centrilobular hepatocyte 
swelling) 
200 F (reduced antibody 




Elf Atochem S.A. 1993 
1-Bromopropane 
Guo et al. 2015 
1-Bromopropane 
Zhong et al. 2013 
1-Bromopropane 
Lee et al. 2007 
1-Bromopropane 
Yu et al. 2008 
1-Bromopropane 
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Table 3-2 Levels of Significant Exposure to 1-Bromopropane - Oral (continued) 
a 


























Chemical Form Comments 
once 
(G) 





100 M 200 M (impaired spatial memory 
and learning ability) 






200 M (impaired spatial learning 
and memory) 





600 M (degeneration of 
pachytene 
spermatocytes) 
Yu et al. 2008 
1-Bromopropane 
a The number corresponds to entries in Figure 3-2. 
b Used to derive an acute-duration (14 days or less) oral minimal risk level (MRL) of 0.2 mg/kg/day for 1-BP. Using benchmark-dose modeling, a BMD1SD and BMDL1SD of 148.37 
and 19.75 mg/kg/day, respectively, were calculated for decreased spatial memory in rats on Day 5 of the Morris water maze task from the selected model (Hill).  The BMDL1SD was 
divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability) to derive the MRL of 0.2 mg/kg/day. 
Bd Wt = body weight; d = day(s); F = Female; (G) = gavage; (GO) = gavage in oil; Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect 
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Figure 3-2 Levels of Significant Exposure to 1-Bromopropane - Oral 
Acute (≤14 days) 
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Hepatic Effects. Data from a single acute-duration oral study in mice suggest that exposure to high 
oral doses of 1-bromopropane may induce severe liver effects, although further studies are needed to 
validate these data.  Gavage administration of a single dose of 500 mg 1-bromopropane/kg to female mice 
induced centrilobular swelling of hepatocytes, and a single dose of 1,000 mg 1-bromopropane/kg induced 
liver congestion, hemorrhage, cellular swelling, and vacuolization assessed 12 hours after dosing and 
increasing in severity at later times (assessed up to 48 hours post-exposure) (Lee et al. 2007); no 
significant effects were reported in mice dosed with 200 mg 1-bromopropane/kg.  These morphological
changes were accompanied by increased serum ALT activity (maximally 380-fold 24 hours after dosing
with 1,000 mg 1-bromopropane/kg).  Biochemically, treatment with 1-bromopropane caused depletion of
GSH and increased the formation of GSH conjugates, possibly leading to increased oxidative stress, as
evidenced by increased levels of malondialdehyde and decreased catalase activity.
Body Weight Effects. Limited data in animals preclude drawing meaningful conclusions regarding
effects from oral 1-bromopropane exposure on body weight.  Body weight was not affected in male or
female rats administered a single dose of 2,000 mg 1-bromopropane/kg and observed for up to 14 days
(Elf Atochem S.A. 1993) or in female mice administered a single dose of 1,000 mg 1-bromopropane/kg
and observed for up to 48 hours (Lee et al. 2007).  In repeated-dose studies, administration of 800 mg
1-bromopropane/kg/day to male rats for 12 consecutive days resulted in a 13% decrease in terminal body
weight; no significant effect was reported at 400 mg 1-bromopropane/kg/day (Zhong et al. 2013). No
data on food consumption were provided in the latter study.  In a similar study, 10 consecutive doses of
up to 600 mg 1-bromopropane/kg/day did not significantly affect body weight in male mice (Yu et al.
2008).  
3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans following oral
exposure to 1-bromopropane.
A single mouse study provides relevant information, although it is insufficient to determine whether the
immunological system might be a target for oral exposure to 1-bromopropane. Female mice dosed once 
by gavage with ≥200 mg 1-bromopropane/kg and immunized intraperitoneally with SRBC 30 minutes
later showed a significant reduction in the antibody response to the T-dependent antigen of up to 60%
4 days later (Lee et al. 2007).  It was also reported that ≥200 mg 1-bromopropane/kg/day significantly 
reduced the number of CD4+IL-2+ cells in response to ConA by up to ~30%. Flow cytometry showed that
   
 




     








    
     
 
  
      
   
  
 
     
  
     
   
     
  
     
   
      
  
  
    
  
   





1-bromopropane reduced the absolute number of all splenocyte subpopulations. The investigators also 
reported that exposure to 1-bromopropane decreased spleen GSH content while increasing a GSH
conjugation product, and suggested that immunotoxicity might be related to increased oxidative stress.
3.2.2.4  Neurological Effects 
No studies were located regarding neurological effects in humans following oral exposure to 
1-bromopropane.
The limited number of studies in animals showed that high oral doses of 1-bromopropane can produce
sedation, and repeated lower doses can affect learning and memory.
Clinical signs of neurotoxicity, including marked decrease in spontaneous activity (sedation),
piloerection, and dyspnea, were observed in male and female rats within 4 hours of receiving a single
gavage dose of 2,000 mg 1-bromopropane/kg (Elf Atochem S.A. 1993).  Surviving animals (9/10) fully
recovered by day 2 of the 14-day post-exposure observation period.
Limited data are available in a study that examined the effects of 1-bromopropane on cognitive function 
in male rats and the possible role of oxidative stress (Zhong et al. 2013).  On days 8–12 of a 12-day 
treatment with 200, 400, or 800 mg 1-bromopropane/kg/day, cognitive function (spatial learning and 
memory) was assessed with the Morris water maze test. Some rats dosed with 400 and 800 mg 1-bromo-
propane/kg/day showed irritability at the start of dosing.  After 1 week of dosing, rats in the 800 mg
1-bromopropane/kg/day group showed slow response and sluggishness.  Dose-related impairments were 
observed in learning and memory measures in the Morris water maze task.  During the 4-day learning
phase, the escape latency was significantly increased in the 800 mg 1-bromopropane/kg/day group and 
the total swimming distance was increased at ≥200 mg 1-bromopropane/kg/day. Time spent in different
swimming "search" patterns (direct finding, approaching target, random searching, and thigmotaxis)
differed significantly in all exposed groups, compared with controls, with exposed animals showing
increased thigmotaxis (time spent in periphery of tank). On day 5, when the escape platform was 
removed to assess memory, all exposure groups showed a significant decrease in the number of times that 
they crossed the former location of the target platform; rats exposed to 800 mg 1-bromopropane/kg/day 
also showed a significant decrease in time spent in the target quadrant. Assessment of biochemical
indices in the brain showed an increase in oxidative stress (increased malondialdehyde and oxidized GSH, 
reduced GSH, and reduced GSH reductase activity) for the most part in the mid- and high-dose groups.  
   
 




    
      
 
   
 
   
   









     
  
  
     
    
   
   
  
    
  
 








Tests with specific monoclonal antibodies also showed increased total levels of reactive aldehyde 
modified proteins in the cerebral cortex. A more recent study by the same groups of investigators (Guo et
al. 2015) confirmed the findings of Zhong et al. (2013) and proposed that 1-bromopropane-induced 
reduction of a novel neuroglobin (Ngb) with antioxidant properties might be involved in the neurotoxicity
induced by 1-bromopropane.  In another similar study, it was reported that melatonin, administered 
simultaneously with 1-bromopropane (600 mg/kg/day for 27 consecutive days) to rats, ameliorated the 
1-bromopropane-induced impairment of learning and memory and loss of hippocampal neurons (Xu et al. 
2016).  The investigators suggested that melatonin acts by scavenging reactive oxygen species and 
reducing oxidative stress.  Data from Zhong et al. (2013) were used to derive an acute-duration oral MRL
for 1-bromopropane. 
3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans following oral exposure to 
1-bromopropane.
Only one animal study with relevant information was identified; the results do not suggest that 1-bromo-
propane is a reproductive toxicant by the oral route.
The available study examined the effect of 1-bromopropane on dominant lethality in male mice (Yu et al.
2008) (see Section 3.3, Genotoxicity).  Administration of 600 mg 1-bromopropane/kg/day (only dose
level tested) for 10 consecutive days did not significantly affect serum testosterone levels, as assessed
5 weeks after treatment.  At that time, microscopic examination of the testes showed degeneration of
pachytene spermatocytes in the treated males.  Evaluation of sperm parameters in cauda epididymides 
showed somewhat reduced motility in the treated group but the difference with controls was not
statistically significant.  All other sperm parameters in treated mice were comparable to controls (path
velocity, straight line velocity, curvilinear velocity, lateral head displacement, and beat cross frequency).
Further studies seem necessary to validate these findings.
No studies were located regarding the following effects in humans or animals following oral exposure to 
1-bromopropane:
3.2.2.6  Developmental Effects 
3.2.2.7  Cancer
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3.2.3 Dermal Exposure 
Only one human study was located with relevant information.  An occupational study reported that
workers exposed to concentrations of 1-bromopropane in the air ≥56.9 ppm experienced symptoms of
nose, eye, and throat irritation (Ichihara et al. 2004a).  It is assumed that this occurred due to direct
contact of vapors of the chemical with the tissues.  It should be noted, however, that the measured
concentrations included 1-bromopropane as well as 2-bromopropane, since the analytical method could
not differentiate between the two compounds.  In addition, no appropriate controls were used.  Finally, 
given the nature of the complaints, it is reasonable to assume that no protective masks were used.
No animal studies were located with information that would support or refute the findings of the
occupational study mentioned above.  However, one animal study was located, in which application of
2,000 mg 1-bromopropane/kg to the skin of male and female rats under a semi-occlusive dressing for
24 hours did not induce mortalities, clinical signs of toxicity, cutaneous reactions, body weight effects, or
gross abnormalities at necropsy during a 14-day post-exposure observation period. (Elf Atochem S.A. 
1995).
3.3  GENOTOXICITY
Only one study was located regarding genotoxic effects in humans exposed to 1-bromopropane.  The
study was conducted in 63 workers at two facilities (facility A: 41 workers; facility B: 22 workers) where
1-bromopropane was used as a solvent for spray adhesives in foam cushions (Toraason et al. 2006).  
1-Bromopropane TWA concentrations assessed from personal breathing zone samples ranged from 0.2 to
271 ppm at facility A and from 4 to 27 ppm at facility B.  In general, exposures at facility A were
estimated to be 4-fold higher than in facility B.  Assessment of DNA damage in peripheral leukocytes
from workers using the comet assay revealed no significant difference in DNA damage between sprayers 
and non-sprayers at either facility.  However, results from multiple linear regression models that
controlled for sex, age, smoking status, facility, and two glutathione S-transferase [GST] polymorphisms
showed increased comet tail moment dispersion coefficients in sprayers at facility A at the end of the 
week.  The covariates that had a significant effect in the models were GSTM1, facility, and sex.  No 
conclusions can be drawn regarding the genotoxicity of 1-bromopropane in humans based on the results
of a single study. 
Results from in vivo and in vitro studies of 1-bromopropane genotoxicity are summarized in Tables 3-3 
and 3-4, respectively. In vivo studies in animals have yielded negative results in tests for induction of
   
 




   
 




    
    
    






Table 3-3.  Genotoxicity of 1-Bromopropane In Vivo
Species (test system) End point Results Reference
Mammalian cells
Human peripheral DNA damage and repair, strand breaks (+) Torasson et al. 2006 
leukocytes
Mouse peripheral blood Micronuclei – NTP 2011
Male rat Dominant lethal – Saito-Suzuki et al. 1982
Male mouse Dominant lethal – Yu et al. 2008
– = negative result; (+) = weak positive
   
 









































    
 
 
    
     








   
 




Table 3-4.  Genotoxicity of 1-Bromopropane In Vitro
Results
With Without







S. typhimurium TA97, TA98,
TA100, TA 1535




Human hepatoma cell-line 
(HepG2)































Barber et al. 1980,
1981




Toraason et al. 2006
Hasspieler et al. 2006
Hasspieler et al. 2006
+ = positive results; – = negative results
   
 




   
     
 





    
     
    
 
    
    
 
     
   
   
  
  
    
 
 
   
 
    
 
 
   
    
  
    





micronuclei and dominant lethality.  Exposure via inhalation to 62.5–500 ppm 1-bromopropane for 
3 months did not increase the frequency of micronucleated normochromatic or polychromatic
erythrocytes in the peripheral blood of male or female mice (NTP 2011).  Gavage administration of
300 or 600 mg 1-bromopropane/kg to male ICR mice for 10 days before mating revealed no dominant
lethal mutations in germ cells (Yu et al. 2008).  In addition, no dominant lethal mutations were observed 
in male rats gavaged with 400 mg 1-bromopropane/kg for 5 days before mating (Saito-Suzuki et al. 
1982). 
Studies of the genotoxic potential of 1-bromopropane in vitro yielded mixed results.  In two studies
conducted by NTP (2011), 1-bromopropane did not induce mutations in Salmonella typhimurium or
Escherichia coli with or without exogenous metabolic activation.  However, when tested in a closed 
system to control for volatility, 1-bromopropane was mutagenic to S. typhimurium strains TA100 and 
TA1535 (Barber et al. 1980, 1981).  In this same study, using a conventional (or open) test system yielded
negative results for all tested Salmonella strains.
An in vitro study in peripheral leukocytes from unexposed volunteers yielded positive results for DNA
damage at the highest concentration tested (1 mM) (Toraason et al. 2006). However, because lower
concentrations (≥0.1 mM) increased the incidence of apoptotic cells, the DNA damage may reflect
general cell toxicity.  In studies using the ethoxyresorufin O-deethylase (EROD) bioassay, 1-bromo-
propane did not induce DNA single-strand breaks or DNA repair in human hepatoma cell-line HepG2 at




The detection of carbon-containing metabolites and elevated bromide ion concentrations in urine samples 
of workers exposed to 1-bromopropane by inhalation and dermal contact provides qualitative evidence
that 1-bromopropane is absorbed by the respiratory tract and the skin in humans (Hanley et al. 2006, 
2009, 2010; Valentine et al. 2007).  In addition, reports of neurological and other effects in occupationally
exposed subjects provide indirect evidence of absorption of 1-bromopropane (Ichihara et al. 2002;
Majersik et al. 2007; MMWR 2008; NIOSH 2003a; Raymond and Ford 2007; Samukawa et al. 2012;
Sclar 1999).
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Dermal absorption characteristics estimated in human epidermal membranes mounted on static diffusion 
cells included steady-state fluxes averaging 625–960 µg cm-2 hour-1 with pure 1-bromopropane and 441– 
722 µg cm-2 hour-1 with a commercial dry cleaning solvent, an average dermal penetration of about 0.2% 
from an applied dose of 13.5 mg/cm2 under non-occluded conditions, and a dermal permeability
coefficient for 1-bromopropane in water of 0.257 cm/hour (Frasch et al. 2011).
Qualitative evidence of absorption by the gastrointestinal and respiratory tracts comes from animal
studies (Garner et al. 2006, 2015; Jones and Walsh 1979).  13C-labeled metabolites were detected in urine 
collected from rats and mice exposed by inhalation to 800 ppm [1,2,3-13C]-1-bromopropane for 6 hours
(Garner et al. 2006). Indicative of rapid and extensive absorption by the respiratory tract, rats placed in 
closed chambers with concentrations ranging from 70 to 2,700 ppm rapidly decreased the chamber
concentrations within 2 hours, followed by a more gradual decrease in 2–8 hours (Garner et al. 2015).  At
the lower end of the initial chamber air concentration range, the decrease was almost complete within 3– 
6 hours (Garner et al. 2015). A number of mercapturic acid derivative metabolites were detected in
pooled urine samples collected from rats given oral doses of 200 mg 1-bromopropane/kg/day in arachis 
oil for 5 days (Jones and Walsh 1979).
No other human or animal studies were located that determined the rate or extent of absorption of
1-bromopropane following inhalation, oral, or dermal exposure. 
3.4.2 Distribution 
Simulations with a preliminary human PBPK model for inhaled 1-bromopropane predicted some
accumulation of the parent material in blood following exposure for 8 hours/day for 5 days (Garner et al. 
2015; see Section 3.4.5 for more discussion of the development and limitations of this model).
Results from metabolic disposition studies with rats and mice exposed to 1-bromopropane by intravenous
injection or inhalation indicate that 1-bromopropane is rapidly and widely distributed by the blood, 
especially to highly perfused tissues like the brain, followed by a rapid clearance mediated by exhalation 
of parent material or metabolically produced CO2 and urinary excretions of oxygenated and conjugated 
metabolites (Garner and Yu 2014; Garner et al. 2006, 2007; Ishidao et al. 2002; Jones and Walsh 1979).
For example, following intravenous injection of [1-14C]-1-bromopropane at nominal doses of 5, 20, or
100 mg/kg, radioactivity remaining in the carcass 48 hours after dose administration accounted for about
6, 6, and 2% of the administered dose in rats, and 4, 2, and 4% in mice (Garner et al. 2006).  In these
   
 




     
   
    
   
 
  
   
      
   
    
 
    
     
   
 
     
 
  
    
  
  
   
     
      




   
  
   




studies, most of the administered radioactivity was exhaled as parent material or metabolized CO2 or
excreted as metabolites in the urine.  Distribution and accumulation of parent material in fatty tissue is 
limited with short-term exposure scenarios, but some accumulation with repeated exposures may occur
(Garner and Yu 2014; Garner et al. 2006, 2015).
A cross-fostering study was conducted in rats to examine the disposition of bromine ion in the brain of
rats and their offspring (Ishidao et al. 2016).  Rats were exposed to 700 ppm 1-bromopropane 6 hours/day
on GDs 1–20.  On GD 20, bromine was significantly more concentrated (approximately 47% higher
concentration) in the brain of exposed virgin rats than in the brain of exposed pregnant rats, which the
investigators suggested could have been due to a dilution effect in the pregnant rats because of increasing
body weight.  On GD 20, brains from fetuses had significantly more bromine (approximately 68% higher
concentration) than brains from the dams, indicating easy transfer of bromine to the fetus via the placenta.
Analyses of the brains from pups from the different exposure groups showed that uptake of bromine via
the milk was higher than through the placenta.
3.4.3 Metabolism
The metabolism of 1-bromopropane in mammals involves:  (1) conjugation, principally with glutathione, 
leading to release of the bromide ion and formation of mercapturic acid derivatives and (2) oxidation 
(catalyzed by cytochrome P-450) of parent material and metabolites leading to metabolites with hydroxyl, 
carbonyl, and sulfoxide groups, and to CO2. These concepts are based on studies of urinary metabolites 
in workers exposed to 1-bromopropane (Hanley et al. 2006, 2009, 2010; Mathias et al. 2012; Valentine et 
al. 2007), in vivo metabolic disposition studies in rats and mice (Barnsley et al. 1966; Garner et al. 2006, 
2007; Ishidao et al. 2002; Jones and Walsh 1979), and in vitro metabolism studies with rat liver
preparations (Jones and Walsh 1979; Kaneko et al. 1997; Tachizawa et al. 1982).  There is evidence that
mice have a higher capacity for oxidative metabolism of 1-bromopropane than rats (Garner and Yu 2014;
Garner et al. 2006, 2007).  
Occupational studies have identified multiple urinary metabolites of 1-bromopropane.  N-Acetyl-
S-(n-propyl)-L-cysteine has been identified in urine samples from workers in a 1-bromopropane
manufacturing plant (Valentine et al. 2007), in foam fabricating plants using spray adhesives containing
1-bromopropane (Hanley et al. 2006, 2009, 2010; Mathias et al. 2012), and in degreasing operations in 
plants using 1-bromopropane as a cleaning solvent in the manufacture of aerospace components,
hydraulic equipment, optical glass, and printed electronic circuit assemblies (Hanley et al. 2010).  Other
   
 




   
    
  
    
  
      
  
   
 
 
    
 
  
   
    
  
 
   
     
 
  
   
 
    
   
  
 
    
     





urinary metabolites identified in 1-bromopropane workers are the bromide ion (Hanley et al. 2010) and 
three oxygenated metabolites present at lower urinary concentrations than N-acetyl-S-(n-propyl)-
L-cysteine:  N-acetyl-S-propylcysteine-S-oxide (also known as N-acetyl-3-(propylsulfinyl) alanine), 
N-acetyl-S-(2-carboxyethyl) cysteine, and N-acetyl-S-(3-hydroxy-propyl) cysteine (Cheever et al. 2009;
Hanley et al. 2009). The correlations between time weighted average workplace air concentrations of
1-bromopropane and urinary levels of bromide and N-acetyl-S-(n-propyl)-L-cysteine (Hanley et al. 2006, 
2009, 2010; Valentine et al. 2007) support the hypothesis that conjugation with glutathione is a
quantitatively important pathway in humans (see Figure 3-3).  The detection of oxygenated metabolites in 
urine samples indicates that oxidation pathways also exist in humans (see Figure 3-4 for structures of
identified oxygenated metabolites).  
Results from metabolic disposition studies in rats and mice illustrate that the metabolism of
1-bromopropane in mammals is complex, involving initial competing conjugation or oxidation steps, 
followed by subsequent conjugation, oxidation, or rearrangement steps.  Figure 3-5 presents proposed 
metabolic pathways based on results from studies of F-344 rats and B6C3F1 mice exposed to
[1-14C]-1-bromopropane by intravenous injection or [1,2,3-13C]-1-bromopropane by inhalation or
intravenous injection (Garner et al. 2006). 
The metabolic scheme shows an oxidation path to CO2 involving cytochrome P450 (CYP) oxidation steps
to 1-bromo-2-propanol and bromoacetone.  This path is proposed based on several findings:
1. Following intravenous injection of 14C-1-bromopropane at nominal doses of 5, 20, or 100 mg/kg, 
radioactivity in CO2 exhaled in 48 hours accounted for approximately 28, 31, and 10% of the
administered dose in rats, and 22, 26, and 19% in mice (Garner et al. 2006).  (These data also 
indicate that oxidative metabolism of 1-bromopropane in rats is more dependent on dose than
oxidative metabolism in mice; the decrease in percentage dose exhaled as CO2 at the highest dose
is greater in rats than mice.)
2. Pretreatment of rats with 1-aminobenzotriazole (ABT) before administration of single intravenous
doses of ~20 mg/kg 14C-1-bromopropane or inhalation exposure to 800 ppm 13C-1-bromopropane
for 6 hours caused decreased exhalation of radioactivity as CO2 and decreased formation of
oxidative urinary metabolites (Garner et al. 2006).  ABT is an inhibitor of a number of CYP
enzymes (Emoto et al. 2003). 
   
 














Figure 3-3.  Formation of N-Acetyl-S-(n-propyl)-L-cysteine from 1-Bromopropane
via Conjugation with Reduced Glutathione (GSH)
HN-Acetyl 








Sources:  Hanley et al. 2009, 2010; Valentine et al. 2007
   
 
















Figure 3-4.  Mercapturic Acid Metabolites with a Sulfoxide Group or a Hydroxyl or
Carbonyl Group on the Propyl Residue Identified in Urine Samples of
1-Bromopropane-Exposed Workers
HN-Acetyl HN-Acetyl 





CH3 C OH H2 
N-Acetyl-S-propylcysteine-S-oxide N-Acetyl-S-(3-hydroxypropyl)cysteine 










Sources:  Cheever et al. 2009; Hanley et al. 2009; Mathias et al. 2012
   
 



















Figure 3-5.  1-Bromopropane Metabolism in Male F-344 Rats and B6C3F1 Mice 
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*Structures in brackets are proposed intermediates and were not isolated in urine.
CYP = cytochrome P450 monooxygenase; FMO = flavin-containing monooxygenease; GSH = glutathione
Sources:  Garner et al. 2006, 2007; NTP 2013
   
 

















   
    
   
  
   
   
   
 
   
    
   
 
 
    
  
 
         





3. Urinary metabolites derived from 1-bromo-2-propanol accounted for over half of all carbon-
containing urinary metabolites identified in rats and mice exposed by inhalation or intravenous
injection of 13C-1-bromopropane.  No 1-bromo-2-propanol-derived metabolites were found in 
urine of ABT-pretreated rats exposed to 13C-1-bromopropane (Garner et al. 2006).  1-Bromo-
2-propanol and bromoacetone themselves were not detected in urine of 1-bromopropane-exposed
rats, but their presence was detected in preparations of rat liver homogenates incubated with
1-bromopropane (Garner et al. 2006).
4. N-Acetyl-S-(2-hydroxypropyl) cysteine was identified in urine of rats given subcutaneous doses of
1-bromopropane (1 mL of a 40% solution of 1-bromopropane in arachis oil per rat) (Barnsley et al.
1966).  
Based on urinary metabolites identified with nuclear magnetic resonance (NMR) spectroscopy, liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), and high-performance liquid chromatography
(HPLC) radiochromatography (Garner et al. 2006), the scheme in Figure 3-5 also shows an initial
conjugation of 1-bromopropane with glutathione leading to N-acetyl-S-(n-propyl)-L-cysteine, an 
oxidation step from 1-bromo-2-propanol to alpha-bromohydrin, a glucuronic acid conjugation step from
1-bromo-2-propanol to 1-bromo-2-hydroxypropane-O-glucuronide, and glutathione conjugation of
1-bromo-2-propanol and bromoacetone followed by oxidation steps leading to metabolites with sulfoxide
groups (e.g., N-acetyl-3-[(2-hydroxypropyl)sulfinyl] alanine).  The steps involving oxidation of sulfur in
the glutathione conjugate derivatives were proposed to be catalyzed by CYP oxygenases or flavin-
containing monooxygenases (FMO) as suggested by Krause et al. (2002).  
Catalysis of the oxidation steps by a number of CYP isozymes is supported by results from metabolic
disposition studies in wild-type and Cyp2e1-/- knock-out mice (F1 hybrids of 129/Sv and C57BL/6N
strains) exposed by inhalation to 800 ppm 13C-1-bromopropane for 6 hours (Garner et al. 2007).  Three
major metabolites were identified in urine collected from wild-type mice during exposure:  N-acetyl-
S-(2-hydroxypropyl) cysteine (34 µmoles in collected urine), 1-bromo-hydroxypropane-O-glucuronide
(5 µmoles), and N-acetyl-S-(n-propyl)-L-cysteine (8 µmoles).  In Cyp2e1-/- mice, the amounts of these 
metabolites in collected urine were changed to 21, 2, and 24 µmoles, respectively.  The ratio of
2-hydroxylated metabolites to N-acetyl-S-(n-propyl)-L-cysteine was approximately 5:1 in wild-type and 
1:1 Cyp2e1-/- mice.  The results indicate that the deletion of CYP2E1 increased the relative importance of
the glutathione conjugation pathway but did not eliminate the formation of oxygenated metabolites, 
suggesting the involvement of other CYP enzymes, in addition to CYP2E1, in oxidation steps as
illustrated in Figure 3-5. 
   
 





    
   
   
 




   
   
    
     
 




   
  











   
    
     
  
   
    
      
    
   
   
    
961-BROMOPROPANE
3. HEALTH EFFECTS
Evidence for the initial conjugation of 1-bromopropane with glutathione leading to the formation of
N-acetyl-S-(n-propyl)-L-cysteine comes from a number of studies in rats and mice (Garner et al. 2006, 
2007; Jones and Walsh 1979; Khan and O’Brien 1991).  
1. N-Acetyl-S-(n-propyl)-L-cysteine was detected in the urine of wild-type and Cyp2e1-/- mice 
exposed to 800 ppm 1-bromopropane for 6 hours, at molar ratios to hydroxylated metabolites of
5:1 and 1:1, respectively (Garner et al. 2007).  
2. N-Acetyl-S-(n-propyl)-L-cysteine and N-acetyl-3-(propylsulfinyl) alanine (i.e., N-acetyl-
S-propylcysteine-S-oxide) accounted for approximately 39 and 5% of excreted urinary
metabolites, respectively, in urine collected for 24 hours after inhalation exposure of rats to 
800 ppm 1-bromopropane for 6 hours (Garner et al. 2006).  
3. N-Acetyl-S-(n-propyl)-L-cysteine was a relatively minor urinary metabolite in rats given single
5-mg 1-bromopropane/kg intravenous doses, but accounted for >80% of urinary metabolites
following administration of 100 mg 1-bromopropane/kg (Garner et al. 2006).
4. N-Acetyl-S-(n-propyl)-L-cysteine and N-acetyl-S-propylcysteine-S-oxide were among the six 
mercapturic acid derivatives identified in urine from rats given 200 mg 1-bromopropane/kg by
gavage (in arachis oil) for 5 days (Jones and Walsh 1979). The structures of the other four
mercapturic acid derivatives identified were consistent with glutathione conjugation of
oxygenated metabolites of 1-bromopropane, rather than 1-bromopropane itself.  These included 
N-acetyl-S-(2-hydroxypropyl) cysteine, N-acetyl-S-(3-hydroxypropyl) cysteine, and N-acetyl-
S-(2-carboxyethyl) cysteine (Jones and Walsh 1979).  The techniques used in this study did not
determine the relative amounts of the urinary mercapturic acid derivatives.
5. Isolated hepatocytes incubated for 60 minutes with 1-bromopropane showed a decrease in 
glutathione content (from 58.4 to 40.8 nmol/106 cells), consistent with the importance of
glutathione conjugation in metabolic disposition of 1-bromopropane in mammals (Khan and 
O’Brien 1991).  
Other studies have identified other metabolites, not included in Figure 3-5, in urine from rats and mice
exposed to 1-bromopropane (Ishidao et al. 2002; Jones and Walsh 1979) and in in vitro systems (Jones
and Walsh 1979; Kaneko et al. 1997; Tachizawa et al. 1982).  Jones and Walsh (1979) reported detecting
metabolites in urine from rats orally exposed to 1-bromopropane that are consistent with the initial 
oxidation of the 3-C of 1-bromopropane:  N-acetyl-S-(3-hydroxypropyl) cysteine, 3-bromopropionic acid,
and N-acetyl-S-(2-carboxyethyl) cysteine.  Garner et al. (2006) were not able to detect these metabolites 
in urine following administration of single intravenous doses up to 100 mg 1-bromopropane/kg in rats or
exposure to 800 ppm for 6 hours in rats or mice.  Garner et al. (2006) proposed that the apparent
discrepancy may have been due to an amplification of minor metabolites from the pooling, concentration,
and acid hydrolysis processes used in the earlier study. Glycidol (1,2-epoxy-3-propanol) was detected in 
urine of Wistar rats exposed by inhalation 6 hours/day to 700 ppm for 3 or 4 weeks or 1,500 ppm for 4 or
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12 weeks; however, no determination of the amount of this compound was made, and the report did not
mention the detection of any other carbon-containing metabolites (Ishidao et al. 2002).  Kaneko et al. 
(1997) monitored the formation of n-propanol during incubation of rat liver microsomes with 
1-bromopropane.  3-Bromopropanol and 3-bromopropionic acid were detected when 1-bromopropane
was incubated in an in vitro oxidizing system, but 1-bromopropane metabolism with rat liver
homogenates was not examined due to the low water solubility of 1-bromopropane (Jones and Walsh
1979).  Propene, 1,2-epoxypropane, 1,2-propanediol, and proprionic acid were detected when liver
microsomes from phenobarbital-treated rats were incubated with 1-bromopropane, and the addition of
glutathione to the reaction mixture led to formation of S-(1' propyl)glutathione and S-(2' hydroxyl-
1'-propyl) glutathione (Tachizawa et al. 1982).  Garner et al. (2006) reported that propene, propylene
oxide, propanediol, and propionic acid were not detected in liver homogenate incubations with 
1-bromopropane; they suggested that the use of phenobarbital as a CYP inducer may have resulted (in the 
Tachizawa et al. [1982] studies) in the formation of metabolites not generated by constitutive CYP
enzymes.
3.4.4 Elimination and Excretion 
Results from animal metabolic disposition studies indicate that 1-bromopropane is eliminated from the
body by exhalation of the parent material and metabolically derived CO2 and by urinary excretion of
metabolites (Garner et al. 2006; Jones and Walsh 1979).  There is evidence that differences of relative 
importance of different excretion pathways between mice and rats may reflect higher capacity for
oxidative metabolism of 1-bromopropane in mice than in rats (Garner and Yu 2014; Garner et al. 2006, 
2007).  
Following single intraperitoneal injections of 200 mg/kg doses of [1-14C]-1-bromopropane in rats, about
60% of the administered radioactivity was eliminated as unchanged 1-bromopropane in the expired air 
within 4–6 hours, about 1.4% of the administered radioactivity was exhaled as 14CO2 over 48 hours, and 
about 15% of the administered radioactivity was excreted in the urine within 48 hours.  Following
intravenous injection of [1-14C]-1-bromopropane at nominal doses of 5, 20, or 100 mg/kg, radioactivity in 
CO2 exhaled in 48 hours accounted for about 28, 31, and 10% of the administered dose in rats, and 22, 26, 
and 19% in mice (Garner et al. 2006).  Radioactivity in exhaled parent material accounted for about 25, 
32, and 71% of the administered dose in rats, and 45, 39, and 48% in mice (Garner et al. 2006).  
Radioactivity in urine collected for 48 hours accounted for about 17, 19, and 13% of the administered 
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dose in rats, and 23, 19, and 14% in mice (Garner et al. 2006).  Radioactivity in feces accounted for <2%
of administered doses, regardless of dose level, in both species (Garner et al. 2006).
Animal studies show that the elimination of 1-bromopropane from the body is rapid and only limited 
accumulation in the body is expected (Garner and Yu 2014; Garner et al. 2006; Ishidao et al. 2002). 
Following intravenous injection of [1-14C]-1-bromopropane at nominal doses of 5, 20, or 100 mg/kg, 
radioactivity remaining in the carcass 48 hours after dose administration accounted for about 6, 6, and 2%
of the administered dose in rats, and 4, 2, and 4% in mice (Garner et al. 2006).  Garner et al. (2006)
proposed that radioactivity remaining in the carcass could represent covalently bound residues from
reactive metabolites or incorporation of 14C into cellular macromolecules from intermediate metabolic 
pathways.  Following intravenous injection of 5 or 20 mg 1-bromopropane/kg doses into rats, the mean 
half-times of elimination of 1-bromopropane from the blood were 0.39 and 0.85 hours, respectively
(Garner and Yu 2014).  In gas uptake studies with male and female rats, calculated half-times of
elimination for 1-bromopropane were rapid and increased with increasing air concentrations of 1-bromo-
propane (Garner and Yu 2014).  Terminal elimination half-times were 0.5, 0.6, 1.1, and 2.4 hours for
males, and 1.0, 1.0, 2.0, and 6.1 hours for females, exposed to initial air concentrations of 70, 240, 800, 
and 2,700 ppm, respectively.  Pretreatment of female rats with ABT to inhibit CYP metabolism
(intraperitoneal injection of 50 mg 1-bromopropane/kg 4 hours prior to gas uptake measurements) or
buthionine sulfoxime, an inhibitor of glutathione synthesis (1,000 mg 1-bromopropane/kg/day orally for
3 days before gas uptake), resulted in longer elimination half-times: 9.6 hours with ABT and 4.1 hours
with D,L-butionine(S,R)-sulfoximine (BSO), compared with 2.0 hours in untreated females at 800 ppm
1-bromopropane in the gas uptake chamber (Garner and Yu 2014). The results with the inhibitors show
that both CYP mediated oxidative metabolism and glutathione conjugation play important roles in the
elimination of 1-bromopropane.  Levels of 1-bromopropane in blood decreased rapidly to detection limits
within 0.7 hours after exposure stopped in Wistar rats exposed to 700 or 1,500 ppm 1-bromopropane
6 hours/day for ≥3 weeks (Ishidao et al. 2002).  Clearance of the bromide ion from blood and urine,
however, showed slower elimination kinetics: elimination half-times for bromide were 4.7–15.0 days in 
blood and 5.0–7.5 days in urine (Ishidao et al. 2002).
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
   
 




   
   
 
  
     
 
   
    
   
  
     
  
   
   
 
       
  









    
  
      





models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  However, if the uptake and disposition of the chemical substance(s)
are adequately described, this simplification is desirable because data are often unavailable for many
biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
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PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-6 shows a conceptualized representation of a PBPK model.
If PBPK models for 1-bromopropane exist, the overall results and individual models are discussed in this
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
Garner et al. (2015) developed male and female PBPK models for 1-bromopropane in F-344 rats, using
data from gas uptake experiments at initial closed chamber concentrations of 70, 240, 800, and 2,700 ppm
1-bromopropane (Garner and Yu 2014).  The models consisted of seven compartments:  blood, lung, fat, 
rapidly perfused tissues, slowly perfused tissues, kidneys, and liver. The models assumed flow-limited
distribution and metabolism in the liver via two competing initial steps: saturable CYP2E1-mediated
oxidation (described by Vmax and Km kinetic constants) and GSH conjugation (described by a Kgst kinetic
constant).  Values for blood flow and tissue volume parameters were based on those used by Brown et al.
(1997) and tissue partition coefficients were based on those reported by Gargas et al. (1989).  Metabolic
kinetic constants for the male and female rat models were estimated through optimization procedures
involving visual assessment of fits to time-course data for closed chamber concentrations of 1-bromo-
propane, while holding other model parameters constant.  Further validations or calibrations of the rat
models were not conducted (e.g., comparing simulated blood concentrations versus observed blood 
concentration time-course data).  Model simulations of blood concentrations indicated rapid attainment of
maximal concentration after the start of 8-hour exposure periods, and rapid decline (within 30 minutes)
after cessation of exposure.  Simulations for a repeated exposure scenario (8 hours/day for 5 days)
indicated no accumulative increase in blood concentrations at exposure levels of 20 and 800 ppm
1-bromopropane.  A human PBPK model was developed from a general human model for volatile
chemicals developed by Anderson et al. (2008) and body weight scaling of the rat metabolic parameters.  
Simulations with the human model for the repeated exposure scenario at 200 ppm indicated that the blood 
concentration at the end of the fifth day of exposure was increased by about 25% above the concentration 
at the end of the first day.  Garner et al. (2015) speculated that simulated results showing that humans (but
not rats) have accumulative increases in blood concentrations after a 5-day exposure scenario might be
due to species differences in fat tissue volume (rat 7% and human 21.4%).  Further development of the rat
   
 

















Figure 3-6.  Conceptual Representation of a Physiologically Based
Pharmacokinetic (PBPK) Model for a
Hypothetical Chemical Substance













































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  Krishnan and Andersen 1994
   
 




   
      
   
 
 
   
 
     
 
      
    
     
   
   
    
     
   
 
 
     
     
  
   
     
    
     
 
 
     
    
   
   





and the human models are necessary before they can be used to reliably extrapolate doses between rats 
and humans in the development of MRLs.  Garner et al. (2015) noted that further development of the
model to include metabolite concentrations in the model would be particularly useful for cross-species 
dosimetry purposes.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption. As discussed in Section 3.1, 1-bromopropane is expected to be well absorbed by the
gastrointestinal tract and the respiratory tract, but quantitative data on the extent of absorption are not
available. In vitro studies with human epidermal explants have determined a dermal permeability
coefficient of 0.25 cm/hour in water, dermal fluxes with pure compound and a commercial dry cleaning
solvent ranging from 441 to 960 µg cm-2 hour-1, and a low dermal penetration of about 0.2% under non-
occluded conditions (Frasch et al. 2011). Results from gas uptake studies with rats in closed chambers 
indicated rapid and extensive absorption by the respiratory tract (Garner 2015). Like other volatile,
lipophilic, noncharged gases, absorption of 1-bromopropane from the alveoli to the blood is thought to be
mediated by passive diffusion (Lehman-McKeeman 2013).
Distribution. As discussed in Section 3.4.2, results from metabolic disposition studies with rats and 
mice exposed to 1-bromopropane by intravenous injection or inhalation indicate that 1-bromopropane is
rapidly and widely distributed by the blood, especially to highly perfused tissues like the brain, followed 
by a rapid clearance mediated by exhalation of parent material or metabolically produced CO2 and urinary
excretion of oxygenated and conjugated metabolites (Garner and Yu 2014; Garner et al. 2006, 2007; 
Ishidao et al. 2002; Jones and Walsh 1979). Distribution and accumulation of parent material in blood or
fatty tissue is limited with short-term exposure scenarios, but some accumulation with repeated exposures 
may occur (Garner et al. 2006; 2015; Garner and Yu 2014). 
Metabolism. As discussed in Section 3.4.3, and illustrated in Figures 3-3, 3-4, and 3-5, the
metabolism of 1-bromopropane in mammals is complex, involving initial competing conjugation or
oxidation steps, followed by subsequent conjugation, oxidation, or rearrangement steps. The balance
between oxidative and glutathione-mediated metabolic pathways will determine whether 1-bromopropane
is activated to reactive metabolites or degradation products are conjugated and eliminated in the urine
(Garner and Yu 2014; Garner et al. 2015; Lee et al. 2010; Liu et al. 2009; Zong et al. 2016). Most urinary 
and exhaled metabolic products are debrominated leading to elevated levels of bromide ion in blood and 
   
 








     
   
    





        
   
     
     
   





   
  
   
 
     
 
    
      
     
    
     
1031-BROMOPROPANE
3. HEALTH EFFECTS
urine (Hanley et al. 2006, 2009, 2010; Garner and Yu 2014; Garner et al. 2006, 2007; Ishidao et al. 2002;
Valentine et al. 2007).  Oxidation steps are mediated by CYP2E1 and other, as yet unspecified CYP
monooxygenases.  Reduced glutathione is the principal conjugating molecule for the parent compound, as
well as for proposed oxygenated brominated intermediate metabolites (Garner et al. 2006, 2007; Jones 
and Walsh 1979). The most recent metabolic disposition studies in rats and mice indicate that oxidation 
at the 2-C of 1-bromopropane is the principal oxygenation site (Garner et al. 2006, 2007), but
oxygenation at the 3-C of 1-bromopropane may be possible based on the identification of urinary
metabolites, N-acetyl-S-(2-carboxyethyl) cysteine and N-acetyl-S-(3-hydroxypropyl) cysteine, in an 
earlier rat study (Jones and Walsh 1979) and in human workers (Cheever et al. 2009; Hanley et al. 2006).  
Proposed reactive intermediate metabolites include bromoacetone and alpha-bromohydrin (Garner et al. 
2006, 2007), glycidol (Ishidao et al. 2002), and propene and 1,2-epoxypropane (Tachizawa et al. 1982).
Excretion. Results from animal studies indicate that 1-bromopropane is rapidly eliminated from the
body by exhalation of the parent material and metabolically derived CO2 and by urinary excretion of
bromide ion and carbon-containing metabolites (Garner and Yu 2014; Garner et al. 2006, 2007; Ishidao et
al. 2002; Jones and Walsh 1979). Forty-eight hours after single intravenous injections of doses of
radiolabeled 1-bromopropane to rats and mice, residual radioactivity in the body accounted for <7% of
administered doses (Garner et al. 2006).  Gas uptake studies indicated that whole-body elimination half-
times in rats increased with increasing air concentration, and were 2.4 and 6.2 hours at the highest tested
concentration of 2,700 ppm (Garner and Yu 2014).  Pretreatment of rats with inhibitors of CYP
monoxygenases or glutathione synthesis prolonged whole-body elimination half-times indicating the
importance of metabolism to the clearance of 1-bromopropane (Garner and Yu 2014).  Elimination half-
times for the bromide ion from the blood (~5–15 days) and urine (~5–8 days) were considerably longer
than clearance of 1-bromopropane from the blood of rats repeatedly exposed by inhalation to 700 or
15,000 ppm; blood levels of 1-bromopropane were below levels of detection within 0.7 hours of the end 
of exposure (Ishidao et al. 2002).
3.5.2 Mechanisms of Toxicity
Overview. As summarized in Section 2.2 (Summary of Health Effects) and detailed in Section 3.2.1.4,
Neurological Effects, the main target of concern following 1-bromopropane exposure in humans is the
nervous system. The mechanisms for neurotoxicity have not been elucidated; however, proposed 
mechanisms include changes in neurotransmitter systems, electrophysiological alterations, decreased
neurogenesis, glial activation, alteration of hippocampal proteins, and oxidative stress. Other potential 
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targets for 1-bromopropane toxicity include the respiratory, hepatic, renal, reproductive, immune, and 
hematological systems; however, evidence for these end points is limited.  Likewise, mechanistic data for
effects outside the nervous system are extremely limited. Available mechanistic data are summarized
below.
Mechanisms of Neurotoxicity. Neurotoxic effects observed in humans range from subtle neurological
deficits, such as decreased vibration sense and paresthesia, to frank neurotoxic effects, including ataxia, 
spastic paraparesis, and symmetric demyelinating polyneuropathy (Ichihara et al. 2002; Li et al. 2010;
Majersik et al. 2007; NIOSH 2002; Raymond and Ford 2007; Samukawa et al. 2012; Sclar 1999).  
Evidence from animal studies supports that exposure to 1-bromopropane can result in neurotoxicity
(Fueta et al. 2002; Honma et al. 2003; Ichihara et al. 2000b; Kim et al. 1999; Mohideen et al. 2011, 2013;
Subramanian et al. 2012; Wang et al. 2002, 2003; Yu et al. 2001; Zhong et al. 2013).  
Observed neurological effects may result from alterations in the gabanergic system following exposure to
1-bromopropane.  A series of studies reported a decrease in paired pulse inhibition (PPI) of pyramidal
cells of CA1 and granule cells of the dentate gyrus (DG) in hippocampal slices harvested from rats
exposed to 1-bromopropane at ≥700 ppm intermittently for 4–12 weeks (Fueta et al. 2002, 2004).  
Granule cells, but not pyramidal cells, also showed decreased PPI at 400 ppm for 8–12 weeks; no effect
was observed in either cell type at 200 ppm (Fueta et al. 2007; Ueno et al. 2007).  Since no changes were
observed in excitatory field potentials, changes in the PPI are likely caused by a reduction of recurrent
inhibition (disinhibition) rather than changes in excitatory drives of principal neurons.  In support, 
application of a γ-aminobutyric acid (GABA) receptor agonist (pentobarbital), a selective inhibitor of
GABA transporter GAT 1 (Tiagabine), or a NMDA receptor antagonist (DL-2-amino-5-phosphono-
pentanoic acid) led to an increase in PPI in the DG, indicating that 1-bromopropane exposure may lead to
reduced GABA inhibition of N-methyl-D-aspartate (NMDA) receptors; the disinhibition in the
hippocampal CA1 region appeared to have been caused by a different (unknown) mechanism (Fueta et al. 
2002, 2004). Ueno et al. (2007) also showed that exposure to 1-bromopropane decreased the expression
of the GABAA receptor β3 and δ subunit mRNA in the hippocampus from rats intermittently exposed to 
400 ppm 1-bromopropane for 12 weeks.  A significant reduction of mRNA expression of GABAal was
also observed in the hippocampus of rats exposed to ≥800 ppm for 4 weeks; in the cortex, mRNA
expression was significantly reduced after exposure to 800 ppm but not 1,000 ppm (Mohideen et al. 
2009).  In another study, a significant reduction in GABA neurotransmitter levels was reported in the 
hippocampus and cortex of rats intermittently exposed to 1,000 ppm 1-bromopropane for 3 weeks,
compared with controls; no changes were observed at ≤200 ppm (Suda et al. 2008).  
   
 





    
 
     
       
      
 
      
     
  
      
    
      
     
    
    
   
   
   
      
      
    
      
  
     
   
 
   
     
   
  




Other neurotransmitter systems have also been evaluated in rats following inhalation exposure to
1-bromopropane. Changes in levels of neurotransmitters or their metabolites or precursors from the 
serotonergic (5HT), dopaminergic (DA), noradrenergic (NE), and glutamatergic systems have been
reported in various brain regions in rat intermittently exposed to 50–1,000 ppm 1-bromopropane for 
3 weeks, compared with controls, when examined 2 and 19 hours after the final exposure (Suda et al.
2008).  At 2 hours, significant observations in the 1,000 ppm group included decreased 5-hydroxy-
indoleacetic acid (5HIAA; 5HT metabolite) in the striatum, decreased 3,4-dihydroxyphenylacetic acid
(DOPAC; DA metabolite) in the hippocampus, and increased glutamine (glutamate precursor) in the
hippocampus, midbrain, and cerebellum.  5HIAA was also significantly decreased at 200 ppm; no 
changes were observed at 2 hours in the 50 ppm group except for a significant decrease in DA in the 
striatum and in 5HIAA in the frontal cortex. At 19 hours, significant changes included decreased
homovanillic acid (HVA; DA metabolite) and HVA/DA ratio in the striatum; decreased 3-methoxy-
4-hydroxyphenylglycol (MHPG, NE metabolite), decreased MHPG/NE ratio, and increased 5HT in the
occipital cortex; increased 5HIAA in the medulla; and increased glutamine in the frontal cortex, occipital 
cortex, hippocampus, striatum, midbrain, hypothalamus, and cerebellum. Alterations in the NE, DA, and 
5HT neurotransmitter and/or metabolite levels were also reported in rats exposed to ≥200 ppm for 1– 
4 weeks (Zhang et al. 2013).  At 1 week, observed effects included decreased NE and DOPAC/DA ratio 
in the striatum and a decreased HVA/DA ratio in the prefrontal cortex.  At 4 weeks, observed effects
included decreased NE and DA and increased HVA, HVA/DA, DOPAC/DA and (DOPAC + HVA)/DA
ratio in the hippocampus; decreased NE, 5HIAA, HVA, and HVA/DA in the prefrontal cortex; and
decreased NE in the striatum.  In another study, several changes in the expression of serotonergic and 
dopaminergic receptor mRNA were reported in various brain regions of rats intermittently exposed to
≥400 ppm for 4 weeks (Mohideen et al. 2009). Significant changes included decreased 5HTr1a (cortex at
800 and 1,000 ppm, medulla at 400, 800, and 1,000 ppm), decreased 5HTr2a (cortex at 800 ppm, 
hippocampus at 1,000 ppm), increased 5HTr2c (cortex at 1,000 ppm), increased 5HTr3a (amygdala at
400 and 1,000 ppm), decreased D1R (cerebellum and cortex at 800 ppm), decreased D2R (hippocampus
at 400, 800, and 1,000 ppm), and decreased 5HTr3a (pons/medulla at 400, 800, and 1,000 ppm).  
However, protein levels of D2 and 5HTr2a were not significantly altered in the cortex or hippocampus at
up to 1,000 ppm; other receptor protein levels were not measured (Mohideen et al. 2009). Although the
above studies show that exposure to 1-bromopropane can affect numerous neurotransmitter systems in
various brain areas, these changes have not been associated with specific functional alterations; therefore,
the biological significance of the changes is yet unknown.
   
 







   
   
    
   
    
  
     
    
 
   
   
     
  
    
  
    
  
   
  
    
 
   
   
  
  
   





1-Bromopropane may also cause neurotoxicity by interfering with neurogenesis, as a decrease in the 
number of BrdU-positive cells in the dentate gyrus of the hippocampus was observed in rats exposed to 
≥800 ppm for 4 weeks (Zhang et al. 2013).  Observed downregulation of hippocampal brain-derived 
neurotrophic factor (BDNF) and glucocorticoid receptor (GR) mRNA levels and low hippocampal NE
levels may contribute to the reduced neurogenesis.  Significant reductions in BDNF mRNA expression 
have also been observed in the U251 human astrocytoma cell line and mouse primary astrocytes (Yoshida 
et al. 2009).  Yoshida et al. (2009) also show that DNA-binding and specific reporter activity of cAMP
response element-binding transcription factor (CREB) and protein kinase A (PKA) activity were reduced 
in U251 cells, suggesting that BDNF downregulation may result from suppression of PKA activity (and 
subsequent decreased phosphorylation of CREB).  Results of experiments by Huang et al. (2015) showed 
that exposure of rats to 1-bromopropane induced up- and down-regulation of proteins in the hippocampus
involved in response to stimuli, metabolic processes, and apoptosis signaling.
1-Bromopropane has also been shown to cause glial activation (Mohideen et al. 2013; Subramanian et al. 
2012), which suggests that neuroinflammation may contribute to observed neurotoxic effects.  Immuno-
staining showed that exposure to ≥400 ppm 1-bromopropane significantly increased the number of
astrocytes in the middle cerebellar peduncle and induced significant elongation of processes in astrocytes 
in the cerebellum (Mohideen et al. 2013).  In another study, cerebellar microglia cells appeared larger and 
had longer ramified processes in rats exposed to 1,000 ppm 1-bromopropane for 4 weeks, compared with 
controls; this effect was not observed at 800 ppm (Subramanian et al. 2012). Increased markers of
oxidative stress (TBARs), as well as reactive oxygen species and nitric oxide (NO) content, were also
observed in the cerebellum of rats exposed to 1,000 ppm, suggesting that oxidative stress may contribute
to glial activation (and potential neuroinflammation) associated with 1-bromopropane exposure 
(Subramanian et al. 2012). Alterations in markers of oxidative stress (total and oxidized glutathione, 
glutathione reductase, thiol content, malondialdehyde, glutathione peroxidase) have also been reported in 
the brain and spinal cord of rats exposed to 200–1,000 ppm 1-bromopropane for 1–4 weeks (Guo et al. 
2015; Huang et al. 2012; Wang et al. 2002, 2003; Zhong et al. 2013).  Guo et al. proposed that 
1-bromopropane-induced reduction of a neuroglobin with antioxidant properties might be involved in the
neurotoxicity of 1-bromopropane.  Additionally, studies in murine macrophages suggest that
1-bromopropane can cause dose-dependent induction of NO and proinflammatory proteins/genes, such as 
IL-1β, IL-6, TNF-α, COX-2, prostaglandin E2, through nuclear factor-kappaB (NF-kB) transactivation via
the Akt/ERK and p38 MAP kinase pathways (Han et al. 2008, 2012).  
   
 





    
   
  
   
      
   
  
 
     
    
  
   
     
  
    
   
    








    








Human and animal studies have reported decreased nerve conduction velocities following 1-bromo-
propane exposure (Ichihara et al. 2000b; Li et al. 2010; Sclar 1999; Yu et al. 2001).  Decreased nerve
conduction velocity could be due to morphological changes such as swelling of the axons and alteration 
of the myelin sheath, which have been observed in rats exposed to ≥800 ppm for several weeks (Ichihara
et al. 2000b; Wang et al. 2002; Yu et al. 2001).  Mohideen et al. (2013) reported adverse effects on 
myelination in the cerebellum in rats exposed to 1,000 ppm 1-bromopropane for 4 weeks, including
decreased levels of myelin basic protein (MBP) and decreased numbers of oligodendrocytes; however, the
mechanisms underlying these changes have not been determined.
Protein expression studies have identified multiple systems/pathways in the brain that can be altered
following 1-bromopropane exposure; however, strong conclusions regarding mechanisms of neurotoxicity
from these studies cannot be made at this point.  Decreased CK and isoenzyme (CK-B, CK-M) activity
and increased heat-shock protein 27 levels were observed in the brain and/or spinal cord from rats
exposed to ≥200 ppm 1-bromopropane for 1 or 12 weeks (Wang et al. 2002, 2003).  These studies also 
indicated that modification of functional proteins containing a sulfhydryl base as a critical site might
underlie mechanisms of neurotoxicity because 1-bromopropane exposure decreased levels of sulfhydryl
bases of protein and nonprotein fractions in the cerebrum, cerebellum, and brain stem (Wang et al. 2002, 
2003).  Suda et al. (2008) reported a significant decrease in the level of the free amino acid taurine in
several brain regions in rats exposed to ≥50 ppm 1-bromopropane for 3 weeks.  Taurine is involved in 
many functions such as detoxification, cholesterol metabolism, neuromodulation, and transamination. 
Other amino acids involved in transamination were also altered, including cystathionine, serine, 
threonine, and β-alanine.  In a proteomic analysis of hippocampal tissue obtained from rats intermittently
exposed to 0, 400, or 1,000 ppm, 19 proteins were significantly altered after 1 and 4 weeks of exposure 
and 8 were altered in a dose-dependent fashion (Huang et al. 2011).  Identified proteins were categorized 
into functional classes, including nucleocytoplasmic transport, immunity and defense, energy metabolism, 
ubiquitination-proteasome pathway, neurotransmitter, and purine metabolism, suggesting that
hippocampal damage associated with 1-bromopropane exposure may involve oxidative stress, loss of
ATP production, neurotransmitter dysfunction, and inhibition of the ubiquitination-proteasome system.
Due to evidence of oxidative stress, another study by the same group of investigators specifically looked
for proteins with increased carbonyl modification using the same protocol (Huang et al. 2012).  Ten 
proteins with increased carbonyl modification were identified, including proteins involved in glycolysis, 
ATP production, tyrosine catabolism, GTP binding, guanine degradation, and neuronal metabolism of
dopamine. 
   
 




   
  
 
    
 
   
    




    
    
 
  




     
   
  
   
    
    
   
 
    
     
    
    
   




As summarized above, 1-bromopropane can induce neurological alterations by acting at multiple levels in
the nervous system.  The identity of the neurotoxic moiety(s), however, remains unknown.
Mechanisms of Hepatotoxicity. Hepatic effects have been observed in animal studies following
inhalation exposure to 1-bromopropane, including histopathological changes (liver congestion,
hemorrhage, cellular swelling, vacuolization of hepatocyte and/or degeneration) and increased liver
weight (Albemarle Corporation 1997; Kim et al. 1999; Lee et al. 2007; Liu et al. 2010; NTP 2011;
Yamada et al. 2003; Zong et al. 2016). Following exposure to ≥100 ppm for 28 days, Nrf2-null mice
(lacking nuclear factor erythroid 2-related factor 2) showed significantly larger areas of hepatic necrosis 
relative to wild-type mice at the same exposure level (Liu et al. 2010).  Since Nrf2 is a transcription factor
that upregulates a battery of cytoprotective genes in response to oxidative stress and/or chemical
exposure, these findings suggest that oxidative stress may play a role in hepatotoxic effects of 1-bromo-
propane.  In wild-type mice, 1-bromopropane exposure at 300 ppm increased the mRNA levels of several
cytoprotective genes regulated by Nrf2, including heme oxygenase-1 (HO-1), glutamate-cysteine ligase 
modifier subunit (GcLM), glutamate-cysteine synthetase (GcLc), glutathione reductase, and
NAD(P)H:quinone oxidoreductase 1 (NQO1); these genes were not upregulated in Nrf2-null mice.  
Additionally, Nrf2-null mice have constitutively low mRNA expression levels of antioxidant enzymes 
and high malondialdehyde levels (Lui et al. 2010).  Khan and O’Brien (1991) also suggested that 
oxidative stress plays a role in hepatotoxic effects of 1-bromopropane, reporting time-dependent
glutathione depletion in isolated rat hepatocytes exposed to 100 µM 1-bromopropane. The role of
oxidative stress in 1-bromopropane-induced liver toxicity is also suggested by the results of a study in
three mouse strains with different capacities to metabolize 1-bromopropane (C57Bl/6J, DBA/2J, and 
BALB/cA) (Liu et al. 2009).  Intermittent exposure of the mice induced concentration-related increases in
hepatocellular degeneration and liver necrosis; the strain with the highest CYP2E1 protein level and 
lowest total GSH content and GST activity in the liver (BALB/cA) was the most susceptible to hepatic 
damage (Liu et al. 2009). 
Mechanisms of Testicular Toxicity. Testicular effects have been observed in animal studies following
inhalation or oral exposure to 1-bromopropane, including alterations in sperm parameters and 
degeneration of spermatocytes (Banu et al. 2007; Ichihara et al. 2000a; Liu et al. 2009; NTP 2011; Yu et
al. 2008).  While oral exposure to 400 ppm 1-bromopropane caused failure of spermiation in male Wistar
rats, exposure to 1,000 ppm caused spermatogenic cell depletion (Banu et al. 2007), suggesting that
different mechanisms operate depending on the exposure levels. Similarly, decreased epididymal sperm
count was observed in rats injected with intraperitoneal doses of 1,000 mg 1-bromopropane/kg/day for 
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14 days (Xin et al. 2010).  This finding was accompanied by a significant increase in the number of
TUNEL-positive cells, indicating that increased apoptosis may be a mechanism of testicular toxicity.
However, the apoptotic pathway is unclear because 1-bromopropane did not lead to significant changes in 
the expression of apoptosis-related genes and proteins (caspase-3, p53, Bax, Bcl-2, Fas, FasL). As with
hepatotoxicity (see above), sperm toxicity appears to be, at least in part, caused by oxidative stress, based 
on findings of Garner et al. (2007) and Liu et al. (2009).  The former showed that 1-bromopropane
reduced sperm motility in CYP2E1-null mice to a much lesser extent than in wild type mice.  Liu et al.
(2009) exposed three mouse strains with different capacities to metabolize 1-bromopropane (C57Bl/6J, 
DBA/2J, and BALB/cA) and reported that the strain with the highest CYP2E1 protein level and lowest
total GSH content and GST activity in the liver (BALB/cA) was the most susceptible to 1-bromoprapane-
induced alterations in sperm parameters.
Mechanisms of Respiratory Toxicity. Limited human data from case reports suggest that exposure to 
1-bromopropane can cause respiratory tract irritation at concentrations >100 ppm (Ichihara et al. 2002;
Raymond and Ford 2007), and lesions of both the upper and lower respiratory tracts have been observed
in rats and mice exposed to 1-bromopropane for intermediate and chronic durations (Morgan et al. 2011;
NTP 2011).  While studies specifically evaluating mechanisms of toxicity in the respiratory system have 
not been identified, Morgan et al. (2011) suggested that these lesions likely reflect the local irritant
activity of 1-bromopropane, consistent with observations of other inhaled hydrocarbons.
Mechanisms of Carcinogenicity. 1-Bromopropane is a multisite carcinogen in rats and mice (Morgan et
al. 2011; NTP 2011, 2013).  While mechanisms of carcinogenicity for 1-bromopropane are unknown, 
Morgan et al. (2011) suggested possible mechanisms may include formation of reactive metabolites that
can alkylate proteins or nucleic acids and/or oxidative stress due to glutathione depletion. In vitro
incubation of 1-bromopropane with calf thymus DNA resulted in the formation of a N7-guanine adduct
(Thapa et al. 2016). Available data are insufficient to determine if 1-bromopropane can act by a 
genotoxic mode-of-action; see Section 3.3, Genotoxicity, for more details.
3.5.3 Animal-to-Human Extrapolations 
Studies in rodents have shown species, strain, and sex differences in sensitivity to some 1-bromopropane-
induced effects that are related to differences in the metabolic disposition of the chemical (Garner and Yu 
2014; Garner et al. 2007; Liu et al. 2009). Differences in some toxicities of 1-bromopropane, such as
hepatotoxicity and sperm toxicity, between rats and mice and between mice strains are related to
   
 





       
    
    
   
 
    
 
   
  
   
    
   
 
    
 
  
   
      
    
   
 
   
    
  
   
  









differences in oxidative capacity, specifically CYP2E1 protein levels, and differences in glutathione
levels and GST activity in the liver.  How the activities of the oxidative and conjugation pathways in
humans compare to those in rats and mice in disposing of 1-bromopropane has not been determined.
Therefore, the rodent model that is most appropriate to assess potential liver and sperm toxicity of
1-bromopropane in humans is unknown.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
   
 





     
  
     
   
    
  
   
       
   
   
    




     




      
    
   
     
   
 
     
 
   
 
   




Limited human data do not suggest that 1-bromopropane is an endocrine disruptor.  In the study of
workers exposed to 1-bromopropane conducted by Li et al. (2010) discussed in Section 3.2.1, Inhalation 
Exposure, a significant trend for increased serum TSH was reported in females.  Regression analyses that
included exposure level and duration showed significant trends for increased serum TSH and FSH in
female workers. However, neither serum estradiol in females nor serum testosterone levels in males were 
significantly associated with exposure to 1-bromopropane.  A critical review of this study noted that
because several of the measures in females experience temporal fluctuations related to the menstrual
cycle, lack of appropriate control for these variables could have led to misleading results (Smith et al.
2011).  Raymond and Ford (2007) reported that a 41-year-old woman who experienced adverse 
neurological effects after 2 weeks of working with a glue formulation containing 1-bromopropane had 
normal thyroid function tests results; the tests were performed about 2 months after she became ill.  No 
further relevant information is available for humans.
In general, acute-, intermediate-, and chronic-duration inhalation studies in animals did not report
significant gross or microscopic alterations in endocrine glands with the exception of moderate to marked 
necrosis of the adrenal cortex of female mice exposed intermittently to 500 ppm 1-bromopropane for
14 weeks (NTP 2011); the NOAEL was 250 ppm.
Two intermediate-duration studies evaluated reproductive hormones in animals exposed to 
1-bromopropane.  Plasma testosterone levels were significantly decreased by 36% in male Wistar rats 
exposed to 800 ppm 1-bromopropane for 12 weeks (Ichihara et al. 2000a).  No significant changes were
observed in testosterone levels at ≤400 ppm or in plasma LH or FSH at concentrations up to 800 ppm
1-bromopropane (Ichihara et al. 2000a).  No changes were observed in serum LH or FSH in female 
Wistar rats following intermittent exposure at concentrations up to 800 ppm 1-bromopropane for 
12 weeks (Yamada et al. 2003).
No in vitro studies were located regarding endocrine disruption of 1-bromopropane.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to
maturity at 18 years of age in humans, when most biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
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effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to adverse health effects from exposure to 
hazardous chemicals, but whether there is a difference depends on the chemical(s) (Guzelian et al. 1992;
NRC 1993).  Children may be more or less susceptible than adults to exposure-related health effects, and
the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993).  Vulnerability
often depends on developmental stage.  There are critical periods of structural and functional
development during both prenatal and postnatal life that are most sensitive to disruption from exposure to 
hazardous substances.  Damage from exposure in one stage may not be evident until a later stage of
development. There are often differences in pharmacokinetics and metabolism between children and
adults.  For example, absorption may be different in neonates because of the immaturity of their
gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980;
NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al.
1978).  Distribution of xenobiotics may be different; for example, infants have a larger proportion of their
bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer
1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964).  Past
literature has often described the fetus/infant as having an immature (developing) blood-brain barrier that 
is leaky and poorly intact (Costa et al. 2004).  However, current evidence suggests that the blood-brain 
barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular
junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective 
(Saunders et al. 2008, 2012).
However, during development of the brain, there are differences between fetuses/infants and adults that
are toxicologically important. These differences mainly involve variations in physiological transport
systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and efflux)
play an important role in the movement of amino acids and other vital substances across the blood-brain 
barrier in the developing brain; these transport mechanisms are far more active in the developing brain 
than in the adult.  Because many drugs or potential toxins may be transported into the brain using these
same transport mechanisms—the developing brain may be rendered more vulnerable than the adult.  
   
 





     
    
 
 
        
  
    
   
 
 
   
  
   
      
   
  
    
   
     














Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of
the developing brain to toxins is valid.  It is important to note however, that this potential selective
vulnerability of the developing brain is associated with essential normal physiological mechanisms; and
not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing;
whether these mechanisms provide protection for the developing brain or render it more vulnerable to 
toxic injury is an important toxicological question.  Chemical exposure should be assessed on a case-by-
case basis.  Research continues into the function and structure of the blood-brain barrier in early life
(Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns given their low glomerular filtration rate and not having developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
No information was located regarding health effects in children following exposure to 1-bromopropane.  
Since exposure to 1-bromopropane occurs mainly in occupational settings, children are not expected to
experience exposures to 1-bromopropane.  
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No studies were located that exposed animals of different ages to 1-bromopropane to determine whether
age might be a factor in the toxicity of 1-bromopropane.  Therefore, it is not known whether younger
animals are more susceptible to 1-bromopropane than older animals.  However, because the nervous 
system is the main target for 1-bromopropane toxicity in humans and animals, it seems reasonable to 
suggest that younger organisms, in which the nervous system is still developing, might be more
susceptible to 1-bromopropane toxicity than mature individuals, if such an exposure were to occur.
1-Bromopropane was a developmental toxicant in rats.  Studies of rats exposed to ≥400 ppm 1-bromo-
propane during gestation and lactation reported decreased survival of offspring during lactation
(Furuhashi et al. 2006).  A cross-foster experiment actually showed that gestation and lactation exposure
had comparable effects on survival rate of the neonates, but lactation exposure played a greater role on
growth of the offspring.  Additional experiments showed that mated F1 offspring from the lactation-only
exposure group produced a significantly greater number of dead F2 offspring, compared with controls.  
However, no exposure-related effects were observed in the F2 litter for gestational exposure only.  This
suggested that lactation exposure played a greater role in growth and sexual maturation of the offspring.
1-Bromopropane has not shown teratogenicity in studies in animals (BSOC 2001a, 2001b).
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g.,
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
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(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 1-
bromopropane are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by 1-bromopropane are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to 1-Bromopropane
Proposed biomarkers of exposure to 1-bromopropane include urinary levels of N-acetyl-S-(n-propyl)-
L-cysteine (AcPrCys), bromide, and 1-bromopropane itself.  Field studies indicated that urinary levels of
N-acetyl-S-(n-propyl)-L-cysteine and bromide were significantly correlated with time-weighted-average 
breathing zone air concentrations of 1-bromopropane in several groups of workers (Hanley et al. 2006, 
2009, 2010).  Use of N-acetyl-S-(n-propyl)-L-cysteine is expected to be more specific to 1-bromopropane
than bromide due to the presence of the bromide ion in foods. Mathias et al. (2012) also reported a 
significant increase in urinary N-acetyl-S-(n-propyl)-L-cysteine and bromide ion levels in workers 
exposed to 1-bromopropane in a foam cushion manufacturing plant, compared with controls.  The
suitability of urinary levels of the metabolites 3-bromopropionic acid, N-acetyl-S-(n-propyl)-L-cysteine-
S-oxide, N-acetyl-S-2-hydroxypropylcysteine, and N-acetyl-S-2-carboxyethylcysteine was also
investigated by Mathias et al. (2012).  There was no significant difference between urinary
3-bromopropionic acid levels between exposed and control workers, indicating that it is a poor biomarker.  
The analysis of the mercapturic acid metabolites N-acetyl-S-(n-propyl)-L-cysteine-S-oxide, N-acetyl-
S-2-hydroxypropylcysteine, and N-acetyl-S-2-carboxyethylcysteine was discontinued due to low levels of
   
 








   
     
      
     
   
 
     
  




   
   
 
 
   
  
   
  
   
     
 
     
 
    
   
 




detection in urine samples (Mathias et al. 2012).  In another study of workers involved in 1-bromopropane
manufacturing, urinary 1-bromopropane concentrations were significantly correlated with TWA
concentrations of 1-bromopropane in workplace air (Ichihara et al. 2004a).  Valentine et al. (2007) studied
blood and urine samples from workers and ambient air samples in a Chinese 1-bromopropane production 
plant in order to support the potential of urinary AcPrCys and globin S-propylcysteine (PrCys) adducts as 
biomarkers of exposure in humans.  It was found that there was a significant increase in globulin PrCys
adducts in exposed workers (1.52 pmol/mg globin) compared with that of control factory workers (0.11 
pmol/mg globin).  Also, an increase in urinary AcPrCys levels was directly related to an increase in
ambient air exposure levels, which ranged from 0 to 170.54 ppm.  In a study of Japanese workers exposed 
to 1-bromopropane in cleaning and painting workshops, urinary 1-bromopropane at the end of an 8-hour
shift correlated closely with the exposure concentration (geometric mean 1.4 ppm) (Kawai et al. 2001).
The investigators noted that an exposure concentration of 2 ppm could be readily biomonitored.  Urinary
bromide also correlated with 1-bromopropane in air, but the correlation was not as good as with urinary
1-bromopropane.
The distribution of the proposed biomarker N-acetyl-S-(n-propyl)-L-cysteine was evaluated in the general
population in the National Health and Nutrition Examination Survey (NHANES) 2011–2012 (Jain 
2015a).  The study examined the distribution of urinary metabolites of volatile compounds by age, 
gender, race/ethnicity, and smoking status among 2,328 NHANES participants ≥20 years of age.  
Adjusted urinary geometric means of N-acetyl-S-(n-propyl)-L-cysteine were the same in males and
females (5.3 ng/mL).  Nonsmokers did not have statistically significantly different urinary levels of
N-acetyl-S-(n-propyl)-L-cysteine than smokers. Non-Hispanic white subjects (3.9 ng/mL) had
significantly lower levels of N-acetyl-S-(n-propyl)-L-cysteine than non-Hispanic black subjects 
(4.1 ng/mL) and non-Hispanic Asians (7.7 ng/mL).  Non-Hispanic black subjects (4.1 ng/mL) had 
significantly lower levels of urinary N-acetyl-S-(n-propyl)-L-cysteine than Hispanics (6.2 ng/mL) and 
non-Hispanic Asians (7.7 ng/mL).  Evaluation of 417 children, 6–11 years of age, also participants in
NHANES 2011–2012 showed no significant differences between genders (2.6 ng/mL in males and
3.3 ng/mL in females) (Jain 2015b).  Non-Hispanic Asian children had the highest urinary levels of
N-acetyl-S-(n-propyl)-L-cysteine (5.0 ng/mL) followed by non-Hispanic black children (3.4 ng/mL), non-
Hispanic white children (2.4 ng/mL), and Hispanic children (2.1 ng/mL).  Children had significantly
lower levels of urinary N-acetyl-S-(n-propyl)-L-cysteine than nonsmoking adults (3.4 versus 5.7 ng/mL).
Values similar to those reported by Jain (2015a, 2015b) were reported in pregnant women participants in 
the National Children’s Vanguard Study (Boyle et al. 2016).  The study included 488 women enrolled
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from 2009 to 2010 from seven locations in the United States.  N-Acetyl-S-(n-propyl)-L-cysteine was 
detected in urinary samples collected during the third trimester of pregnancy with a frequency of 99%; the
median was 2.61 ng/mL and the 75th percentile value was 9.44 ng/mL.
The ubiquitous nature of N-acetyl-S-(n-propyl)-L-cysteine in the urine of the general population suggests
that it may not be a specific biomarker for 1-bromopropane, as exposure to 1-bromopropane is expected 
to be primarily occupational with limited exposure in the general population (NTP 2011, 2016); see
Section 6.5 for more details.  It is unknown if other chemicals and/or endogenous metabolism contributed 
to the observed urinary levels of N-acetyl-S-(n-propyl)-L-cysteine in the studies by Jain (2015a) and 
Boyle et al. (2016).  However, occupational studies indicate that N-acetyl-S-(n-propyl)-L-cysteine is 
likely to be the most predictive biomarker of exposure available at this time (Hanley et al. 2006, 2009, 
2010; Mathias et al. 2012; Valentine et al. 2007).
3.8.2 Biomarkers Used to Characterize Effects Caused by 1-Bromopropane
There are no specific biomarkers to characterize effects caused by 1-bromopropane in humans. As
summarized in Section 3.2.1, Inhalation Exposure, the main target of 1-bromopropane toxicity in humans
is the nervous system, as demonstrated in several cases of occupational exposure to 1-bromopropane.  
Symptoms commonly reported include, but are not limited to, headache, dizziness, numbness, pain, 
paresthesias and weakness of the lower extremities, and difficulty walking/poor balance (Majersik et al.
2007).  Signs reported include spasticity and weakness of the lower extremities, difficulty with tandem
gait, lower extremity hyperreflexia, decreased lower extremity sensation to vibration, proprioception, 
temperature, and light touch.  Sclar (1999) noted that results from nerve conduction velocity studies were
consistent with primary, symmetric demyelinating polyneuropathy.  Symptoms suggesting involvement
of mainly the central nervous system include anxiety, irritation, forgetfulness, difficulty in concentrating, 
and listlessness (Ichihara et al. 2002). Many of these signs and symptoms can occur in subjects 
overexposed to solvents in general, not even structurally-related to 1-bromopropane.  
3.9  INTERACTIONS WITH OTHER CHEMICALS
The only information regarding interaction of 1-bromopropane with other chemicals is that pretreatment 
of rats with 1-aminobenzotriazole (an inhibitor of a number of CYP enzymes) before administration of
single intravenous doses of ~20 mg/kg 14C-1-bromopropane or inhalation exposure to 800 ppm
13C-1-bromopropane for 6 hours caused decreased exhalation of radioactivity as CO2 and decreased
formation of oxidative urinary metabolites (Garner et al. 2006). In general, chemicals that interfere with
   
 




   
 
 
   
 
 
   
   
 
  
   
 
  




   
   
  
    
     
   
 
   
      
  
 
       
  
   




CYP enzymes or glutathione are likely to affect the metabolism of 1-bromopropane and increase or
decrease toxicity.
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to 1-bromopropane than will most
persons exposed to the same level of 1-bromopropane in the environment.  Factors involved with 
increased susceptibility may include genetic makeup, age, health and nutritional status, and exposure to 
other toxic substances (e.g., cigarette smoke).  These parameters result in reduced detoxification or
excretion of 1-bromopropane, or compromised function of organs affected by 1-bromopropane.  
Populations who are at greater risk due to their unusually high exposure to 1-bromopropane are discussed 
in Section 6.7, Populations with Potentially High Exposures.
No information was located in the available literature regarding human populations that may be unusually
susceptible to toxic effects from 1-bromopropane.  As discussed in Section 3.7 (Children’s
Susceptibility), children are not expected to experience exposures to 1-bromopropane since exposure
occurs mainly in occupational settings.
Genetic differences in the ability to metabolize 1-bromopropane may confer differential susceptibility to
toxic effects of 1-bromopropane.  Following intermittent exposure to 50–250 ppm 1-bromopropane for 
4 weeks, three mouse strains with different capacities to metabolize 1-bromopropane (C57Bl/6J, DBA/2J, 
and BALB/cA) showed dose-related increases in hepatocellular degeneration and liver necrosis; however,
the strain with the highest CYP2E1 protein level and lowest total GSH content and GST activity in the
liver (BALB/cA) was the most susceptible to hepatic damage (Liu et al. 2009).  Mice are considerably
more susceptible to 1-bromopropane-induced hepatotoxicity and spermatoxicity than rats (Liu et al. 2009, 
2010; NTP 2011). The greater susceptibility of mice is likely due to higher CYP2E1-catalyzed
production of cytotoxic metabolites. Lower reduced GSH levels in mice may also play a role in increased
sensitivity to cellular injury.
Studies that evaluated more than one rat strain have not been identified; however, available single-strain
studies suggest that Sprague-Dawley rats are less susceptible to neurotoxic effects of inhaled 1-bromo-
propane, compared with Wistar and F-344 rats (Albemarle Corporation 1997; Fueta et al. 2002; Honma et
al. 2003; Ichihara et al. 2000b; Sohn et al. 2002; Yu et al. 2001). The mechanism(s) underlying the
apparent strain differences are unknown.  
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3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to 1-bromopropane.  Because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to 1-bromopropane.  
When specific exposures have occurred, poison control centers, board certified medical toxicologists,
board-certified occupational medicine physicians and/or other medical specialists with expertise and
experience treating patients overexposed to 1-bromopropane can be consulted for medical advice. No
texts were located that provide specific information about treatment following exposure to 
1-bromopropane; however, the following texts provide information about treatment following exposures
to halogenated aliphatic hydrocarbons (or hydrocarbons in general):
Currance PL, Clements B, Bronstein, AC. 2007.  Halogenated aliphatic hydrocarbons and related 
compounds.  In: Currance PL, Clements B, Bronstein, AC, eds. Emergency care for hazardous materials 
exposure. 3rd edition.  St. Louis, MO: Mosby, Inc., 216-223.
Gummin DD.  2015. Hydrocarbons.  In: Hoffman RS, Lewin NA, Goldfrank LR, et al., eds.  Goldfrank's
toxicologic emergencies. 7th ed.  New York, NY:  McGraw-Hill Education, 1334-1345. 
Thompson TM.  2014.  Chapter 126:  Hydrocarbons.  In: Schafermeyer R, Tenenbein M, Macias CG,
eds.  Strange and Schafermeyer's pediatric emergency medicine. New York, NY:  McGraw-Hill.
Additional relevant information can be found in the front section of this profile under QUICK
REFERENCE FOR HEALTH CARE PROVIDERS.
3.11.1 Reducing Peak Absorption Following Exposure 
1-Bromopropane is expected to be absorbed by the skin, gastrointestinal tract, and respiratory tract, but
quantitative data on the extent of absorption are not available (Frasch et al. 2011; Garner et al. 2006;
Hanley et al. 2006, 2009, 2010; Jones and Walsh 1979; Valentine et al. 2007).  There are no known 
methods for reducing peak absorption following inhalation exposure.  In cases of ingestion, the use of
Activated charcoal has limited ability to reduce gastrointestinal absorption of hydrocarbons in general
(Gummin 2015; Thompson 2014).  Because it may also distend the stomach and predispose patients to
vomiting and aspiration, the use of activated charcoal may be justified only in patients with mixed 
overdoses (Gummin 2015). Rapid rinsing of the skin with water or washing with soap and water will
reduce the opportunity for dermal absorption.  If the eyes are affected, proper rinsing procedures should 
be followed (Currance et al. 2007; HSBD 2013).
   
 





     
 
     
  
    
  
   
      
  
 
       
 
      
    
 
  
       
   
    
       
   
  
 
   
 
   
   
    
 
  






3.11.2 Reducing Body Burden
Results from animal studies indicate that 1-bromopropane is rapidly eliminated from the body by
exhalation of the parent material and metabolically derived CO2 and by urinary excretion of bromide ion 
and carbon-containing metabolites (Garner and Yu 2014; Garner et al. 2006, 2007; Ishidao et al. 2002;
Jones and Walsh 1979).  Following inhalation exposure, oxygen therapy and positive-pressure ventilation
may be useful following inhalation exposure to 1-bromopropane to promote the loss of unmetabolized 
1-bromopropane from the lungs (Currance et al. 2007; HSBD 2013).  There are no known methods for
reducing body burdens following oral or dermal exposure. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
Since the mechanism(s) of toxicity for 1-bromopropane in humans is/are not yet elucidated, there are no
known methods for interfering with the mechanism of action.
However, there is evidence that CYP2E1-catalyzed oxidation contributes to 1-bromopropane-induced 
spermatoxicity and hepatotoxicity in mice (Garner et al. 2006, 2007; Liu et al. 2009; Zong et al. 2016). 
The putative cytotoxic oxidative metabolites have not been identified, but CYP2E1 inhibition should be
protective. An alternative therapeutic approach would be to administer antioxidants to inhibit
lipoperoxidation. N-Acetylcysteine or another agent that will significantly enhance levels of reduced
glutathione may also be beneficial. Whether these treatments would be beneficial in humans exposed to 
1-bromopropane is unknown. 
3.12  ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of 1-bromopropane is available. Where adequate information
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the adverse health effects (and
techniques for developing methods to determine such health effects) of 1-bromopropane.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
   
 





     
 
 
     
 
 
     
     
     





   
     
 
   
 
   
    





reduce the uncertainties of human health risk assessment.  This definition should not be interpreted to 
mean that all data needs discussed in this section must be filled.  In the future, the identified data needs
will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of 1-Bromopropane
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
1-bromopropane are summarized in Figure 3-7.  The purpose of this figure is to illustrate the existing
information concerning the health effects of 1-bromopropane.  Each dot in the figure indicates that one or
more studies provide information associated with that particular effect. The dot does not necessarily
imply anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
As shown in Figure 3-7, there is a limited amount of data on the health effects of 1-bromopropane in 
humans following inhalation exposures.  There are no oral or dermal data available for humans; however,
these are not primary routes by which humans are exposed to 1-bromopropane.  It should be noted that
while exposure to 1-bromopropane occurred primarily via the inhalation route in the available human 
studies, dermal exposure may have also occurred.  In most cases, it was not known whether or not the 
workers were using protective clothing and/or respirators, so the specific contribution of each route of
exposure is not possible to determine.  Figure 3-7 also shows that information on health effects of
1-bromopropane in animals is available for all effect categories, but is mainly limited to inhalation
exposure studies in animals.
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3.12.2 Identification of Data Needs 
Acute-Duration Exposure. The only acute-duration inhalation studies in humans were a few case 
studies reporting subjective symptoms in workers within 2 weeks of 1-bromopropane introduction into 
the workplace.  Adverse effects included respiratory irritation, headache, nausea, and lower extremity
numbness, pain, and weakness. The geometric mean air concentration was 107 ppm for glue sprayers 
(range 58–254 ppm) (Raymond and Ford 2007).  Acute animal inhalation studies are limited to two 
single-exposure studies evaluating lethality (Elf AtoChem S.A. 1997; Kim et al. 1999) and one evaluating
sperm motility (Garner et al. 2007), a 1-week study evaluating neurogenesis and endocrine end points
(Zhang et al. 2013), and a 1-week study evaluating morphological and biochemical changes in the brain 
(Wang et al. 2002); all of these studies were conducted in rats.
The lowest LOAEL identified in these studies may have been lower than 800 ppm because in the Garner
et al. (2007) study, sperm motility was significantly decreased in mice following a single 6-hour exposure
to an initial concentration of 800 ppm 1-bromopropane, which decreased steadily during the exposure 
period.  Wang et al. (2002) reported for morphological changes in the medulla oblongata and posterior
tibial nerve in rats exposed to 800 ppm 1-bromopropane, but not ≤400 ppm, for 1 week (Wang et al.
2002).  However, it should be noted that only 1 rat/group was assessed for morphological alterations.  
Wang et al. (2002) also reported several biochemical changes in the central nervous system following
exposure to 1-bromopropane at ≥200 ppm. The adversity of these changes is unclear because there were 
no clear associations between biochemical and morphological changes.  Other reported neurological
effects included decreased activity and ataxia after single exposures to ≥1,800 ppm, but not 300 ppm
(Kim et al. 1999).  No exposure-related changes in hippocampal neurogenesis, adrenal weight, or plasma 
corticosterone levels were reported in male rats intermittently exposed to 1,000 ppm 1-bromopropane for
1 week (Zhang et al. 2013). A study that reported decreased grip strength in male rats exposed for
8 hours/day to 1,000 ppm 1-bromopropane for 14 days was used to derive an acute-duration inhalation
MRL for 1-bromopropane (Honma et al. 2003). Yet, the acute database would benefit from studies 
examining a comprehensive set of neurotoxicological end points as well as developmental studies to
adequately characterize the most sensitive adverse effects following acute exposure.  Additionally, a
morphological study with larger animal groups and/or a comprehensive neurological battery in animals 
would be useful.
Acute oral studies are limited to a single-dose lethality study in rats (Elf Atochem S.A. 1993), a single-
exposure study evaluating hepatotoxicity and immunotoxicity in mice (Lee et al. 2007), a 10-day study
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evaluating male reproductive end points in rats (Yu et al. 2008), and two 12-day studies evaluating
neurobehavioral end points (learning and memory) in rats (Guo et al. 2015; Zhong et al. 2013).  The
lowest LOAELs identified in these studies were 200 mg 1-bromopropane/kg/day for impaired spatial 
learning and memory during the Morris water maze test in rats (Guo et al. 2015; Zhong et al. 2013) and 
200 mg/kg/day for reduced antibody responses to the T-dependent SRBC antigen (Lee et al. 2007).  A 
NOAEL of 100 mg 1-bromopropane/kg/day was identified in the Guo et al. (2015) study. Other effects 
reported at higher doses in other studies include congestion, hemorrhage, cellular swelling, and 
vacuolization of hepatocytes in mouse liver at ≥500 mg 1-bromopropane/kg/day, but not 200 mg
1-bromopropane/kg/day (Lee et al. 2007); degeneration of spermatocytes in mouse testes at 600 mg
1-bromopropane/kg/day (only dose tested) (Yu et al. 2008); and a 13% decrease in body weight at 800 mg
1-bromopropane/kg/day, but not ≤400 mg 1-bromopropane/kg/day (Zhong et al. 2013).  While the acute
oral database is limited, observed neurological effects are consistent with neurological effects observed in
the more comprehensive inhalation database.  Therefore, the LOAEL of 200 mg 1-bromopropane/kg/day 
for impaired spatial learning and memory was selected as the basis for the acute-duration oral MRL
(Zhong et al. 2013); the results of Guo et al. (2015) support the oral MRL. Additional studies examining
a comprehensive set of systemic and neurological end points, as well as developmental studies, would be
useful to reduce uncertainty in the identification of the most sensitive outcome following acute oral
exposure.
The available data for dermal exposure are limited to a single dermal study that reported a lack of
cutaneous effects and lethality at 2,000 mg 1-bromopropane/kg (Elf Atochem S.A. 1995); however, this is 
not a primary route by which humans are exposed to 1-bromopropane.  
Intermediate-Duration Exposure. The only intermediate-duration inhalation studies in humans are
case studies, most of them reporting neurological signs and symptoms in workers following exposure to 
>100 ppm 1-bromopropane for a few weeks or months, including marked ataxia, impaired balance and 
coordination, sensory deficits, inability to walk, and damage to peripheral nerves (Ichihara et al. 2002;
Majersick et al. 2007; MMWR 2008; Raymond and Ford 2007; Sclar 1999).  Several intermediate-
duration inhalation studies in animals are available. Similar to the human case studies, animal studies
reported neurological effects following intermediate-duration inhalation exposure at concentrations
ranging from 50 to 1,500 ppm (Banu et al. 2007; Fueta et al. 2002, 2004, 2007; Honma et al. 2003;
Ichihara et al. 2000b; Mohideen et al. 2011, 2013; Subramanian et al. 2012; Ueno et al. 2007; Wang et al. 
2003; Yu et al. 1998, 2001; Zhang et al. 2013); all these studies were conducted in rats.  Other effects 
observed at similar exposure levels include altered sperm parameters and liver effects at ≥50 ppm in rats 
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and mice (Kim et al. 1999; Liu et al. 2009).  The study by Honma et al. (2003) identified a NOAEL and 
LOAEL of 10 ppm and 50 ppm, respectively, for neurological effects in rats and was used to derive an
intermediate-duration inhalation MRL for 1-bromopropane.  
No intermediate-duration oral or dermal studies were located for 1-bromopropane; however, these are not
primary routes by which humans are exposed to 1-bromopropane.
Chronic-Duration Exposure and Cancer. An epidemiological study of 1-bromopropane
production workers from three plants in China reported neurological effects in females exposed to
median 1-bromopropane concentrations ≥1.28 ppm for ~40 months, including decreased vibration 
sense, electrophysiological changes, and impaired visual perception and memory (Li et al. 2010).  
Limitations of the study acknowledged by the investigators include:  (1) lack of control of the
temperature of the skin of the legs may have impacted measurements of nerve conduction velocity;
(2) clinical assessment of vibration threshold using a tuning fork is inherently inaccurate due to
examiner bias and subject characteristics (age, weight, height); and (3) uncertainty in the assessment of
cumulative exposure (1–3-day measurements, presumed to be the same level for entire duration of
employment).  Criticisms from others (Smith et al. 2011) include lack of monitoring data for the
controls and possible underestimation of exposure since masks were not used.  However, findings from
this study were determined to be adequate as the basis for a chronic inhalation MRL, although 
confidence in this MRL is low due to the acknowledged limitations.  Further discussion regarding the
rationale for selecting the human study to derive the chronic inhalation MRL of 0.02 ppm, as well as
data from a supporting animal study that yielded a virtually identical MRL of 0.03 ppm, can be found in
Appendix A.  Additional epidemiological studies of neurological end points in workers with better
study designs (preferably prospective, longitudinal studies), longer durations of employment, more
diligent measurement and reporting of exposure levels, and standardized measurement methods
(particularly a quantitative measure of vibration sense) would be useful to better characterize the 
neurotoxicity of 1-bromopropane and increase the confidence in the MRL.  
A limited number of studies have assessed carcinogenic effects of 1-bromopropane in rodents.  In rats 
exposed by inhalation to 1-bromopropane for 2 years, significantly increased incidences of tumors were 
found in multiple sites: large intestine adenomas in females and skin keratoacanthoma, basal cell
adenoma or squamous cell carcinoma, malignant mesothelioma, and pancreatic islet adenoma in males 
(Morgan et al. 2011; NTP 2011).  In mice, exposure to 1-bromopropane significantly increased the 
incidence of combined alveolar/bronchiolar adenoma or carcinoma in females (Morgan et al. 2011; NTP
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2011).  No studies have evaluated cancer mortality or morbidity in groups of 1-bromopropane-exposed
humans. The chronic or carcinogenic effects of 1-bromopropane have not been investigated in humans or
animals following oral or dermal exposures; however, these are not considered major routes of 1-bromo-
propane exposure. Studies of cancer mortality or morbidity in cohorts of 1-bromopropane-exposed 
workers and mechanistic studies of interspecies differences in 1-bromopropane carcinogenicity may help 
to better determine the potential carcinogenicity of 1-bromopropane in humans.
Genotoxicity. Available studies do not clearly identify 1-bromopropane as a genotoxic agent, and 
only a limited number of end points have been evaluated.  The only study located regarding genotoxic
effects in humans exposed to 1-bromopropane reported a weak association between 1-bromopropane
exposure and DNA damage in peripheral lymphocytes (Toraason et al. 2006).  In vivo animal studies did 
not show micronuclei induction or dominant lethality (Chung et al. 2006; NTP 2011; Saito-Zuzuki et al.
1982; Yu et al. 2008). In vitro studies have reported mixed findings for reverse mutation and DNA
damage (Barber et al. 1980, 1981; Hasspieler et al. 2006; NTP 2011; Torasson et al. 2006).  Additional
studies for various genotoxic end points, including clastogenicity, could be useful to determine the
genotoxicity of 1-bromopropane.  Due to the volatility of 1-bromopropane, in vitro studies utilizing
closed test systems would be preferential.
Reproductive Toxicity. Limited information regarding reproductive effects of 1-bromopropane in 
humans is available from two NIOSH Health Hazard Evaluation reports and two preliminary health
surveys in workers exposed to 1-bromopropane (Ichihara et al. 2004a, 2004b; NIOSH 2002, 2003a).  In 
these studies, no self-reported effects on fertility or menstrual cycles were observed in 1-bromopropane
exposed workers and there was no evidence of exposure-related changes in sperm count, motility, or
morphology in a limited number of individuals (three exposed males, nine unexposed males).  However,
several studies in rats and mice suggest that repeated inhalation exposure to 1-bromopropane may
adversely affect both the male (sperm effects, decreased testosterone) and female reproductive systems
(altered estrous cycles) at concentrations as low as 50 and 250 ppm, respectively (Banu et al. 2007;
Ichihara et al. 2000a; Liu et al. 2009; NTP 2011; Yamada et al. 2003).  Results from a comprehensive 
2-generation study in rats showed that exposure of males and females to 750 ppm 1-bromopropane for at
least 70 days before mating resulted in complete infertility and exposure to 500 ppm reduced fertility by
48% (BSOC 2001a).  Exposure to lower concentrations (250 ppm) reduced prostate weight in F0 males
and increased estrous cycle length in F1 females.  Alterations in sperm parameters were reported in rats at
≥500 ppm and in mice at ≥250 ppm in the 14-week NTP (2011) study.  Because Liu et al. (2009) reported 
significant sperm alterations in three strains of mice exposed to 50 ppm 1-bromopropane for 4 weeks,
   
 




   
      
    
    
  
       
   
 
       
   
      
      
   
   
  
    




       
  
        
 
   
  
     
 
   
    




studies trying to replicate the findings of Liu et al. (2009) may be warranted.  In addition, measurements 
of hepatic levels of CYP2E1 and GST activities in the B6C3F1 strain of mice used in the NTP (2011)
study would be useful to possibly explain the significantly lower sensitivity of that strain for sperm
effects compared to the mice strains studied by Liu et al. (2009). Epidemiology studies with fewer
limitations (greater number of subjects, longer exposure durations, and better control for confounding
factors) would help characterize the reproductive toxicity of 1-bromopropane in humans. Additional
studies in animals do not seem necessary at this time.
Developmental Toxicity. No studies were located for developmental effects in humans after
exposure to 1-bromopropane, and available studies in animals are inadequate to determine if
developmental toxicity is a concern following 1-bromopropane exposure in humans.  Two studies in rats
showed that maternal exposure to 1-bromopropane during gestation can induce reductions in fetal or
neonate body weight (BSOC 2001b; Fueta et al. 2015).  Data from a 2-generation reproductive study in 
rats showed that exposure to 500 ppm 1-bromopropane can affect growth in rat pups (Albemarle
Corporation 2002).  An additional study in rats showed that perinatal exposure to 800 ppm can drastically
reduce viability during the first weeks of life (Furuhashi et al. 2006).  No teratogenic effects were 
reported in developmental studies. Based on the fact that 1-bromopropane did not have significant effects
on endocrine organs in animals, and the chemical structure of 1-bromopropane, it seems unlikely that
1-bromopropane could affect development by disrupting endocrine processes.  Therefore, studies focused
on this issue do not seem warranted at this time.
Immunotoxicity. No studies were located that evaluated immunological effects in humans after
inhalation exposure to 1-bromopropane, and available studies in animals are insufficient to assess the 
immunotoxic potential of 1-bromopropane exposure in humans. In animals exposed to 1-bromopropane
via inhalation for 4–10 weeks, suppression of the IgM plaque forming response to immunization with 
SRBCs was observed in splenocytes harvested from female rats and mice exposed to 1,000 and 
≥125 ppm, respectively (Anderson et al. 2010).  Other exposure-related changes observed included
reduced spleen weight and cellularity and significant changes in spleen cell subpopulations. Immune
responses to SRBC and ConA were also reduced in mice dosed once by gavage with ≥200 mg 1-bromo-
propane/kg (Lee et al. 2007).  No other animal studies examining immune function were located.  
Epidemiology studies evaluating immune end points and immunotoxicity batteries in animals would be
useful to better characterize the immunotoxicity of 1-bromopropane.
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Neurotoxicity.   The main target of concern following 1-bromopropane exposure in humans is the
nervous system because the available data clearly indicate that the nervous system is a target for 1-bromo-
propane toxicity in humans and animals.  Observed effects in humans range from subtle neurological
deficits at exposure levels as low as 1.28 ppm 1-bromopropane, such as decreased vibration sense and
paresthesia, to frank neurotoxic effects at exposures to concentrations ≥100 ppm, including ataxia, spastic
paraparesis, and symmetric demyelinating polyneuropathy (Ichihara et al. 2002, 2004b; Li et al. 2010;
Majersik et al. 2007; NIOSH 2002; Raymond and Ford 2007; Samukawa et al. 2012; Sclar 1999; Wang et
al. 2015).  Evidence from animal studies supports the 1-bromopropane neurotoxicity findings in humans.  
Observed effects in acute and intermediate-duration inhalation studies in rats showed that concentrations 
as low as 50 ppm can induce changes in neurobehavior, muscle strength, electrophysiology, and 
morphology and biochemistry of neural tissues (Banu et al. 2007; Fueta et al. 2002; Guo et al. 2015;
Honma et al. 2003; Ichihara et al. 2000b; Kim et al. 1999; Mohideen et al. 2011, 2013; Subramanian et al. 
2012; Ueno et al. 2007; Wang et al. 2002, 2003; Yu et al. 1998, 2001).  Impaired learning and memory, 
sedation, and biochemical changes were also reported at doses as low as 200 mg 1-bromopropane/kg/day 
in the only available oral studies in rats examining neurological end points (Elf Atochem S.A. 1993;
Zhong et al. 2013).  Additional studies may be conducted to try to identify an acute-duration oral NOAEL
for neurotoxicity, but consideration should be given to the fact that the oral route of exposure is not a
route of concern for the general public or for occupational exposure. Research aimed at identifying the 
moiety(s) responsible for 1-bromopropane-induced neurotoxicity would be valuable.  Studies could be
conducted to examine the influence of CYP or GSH inducers or inhibitors or null strains of rodents on 
neurotoxic potency.  Additional epidemiological studies in workers, particularly prospective, longitudinal
studies, would be useful to lend support to the findings reported in the cross-sectional study by Li et al.
(2010), which included minor neurological impairments in female workers exposed to median 1-bromo-
propane concentrations reported to be as low as 1.28 ppm.  The critical effect identified in this study was 
increased vibration sense threshold; however, the methods employed relied heavily on the neurologist
administering the test. Therefore, studies including quantitative measures of vibration sense as well as
other neurophysiological and neurobehavioral parameters would be of particular interest.  Improved 
procedures for more reliable exposure assessment are also necessary.
Epidemiological and Human Dosimetry Studies. Epidemiological studies are limited to a cross-
sectional study in Chinese 1-bromopropane production workers from three factories (Li et al. 2010), two
preliminary health surveys in Chinese 1-bromopropane production workers from a single factory
(Ichihara et al. 2004a, 2004b), and two NIOSH health surveys in 1-bromopropane glue sprayers (NIOSH
2002, 2003a).  As discussed above in the Chronic Studies section, the Li et al. (2010) study was selected
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as the basis of the chronic-duration inhalation MRL.  Additional epidemiological studies in 1-bromo-
propane-exposed workers, particularly prospective, longitudinal studies, may help to better characterize 
the potential neurotoxicity and carcinogenicity of 1-bromopropane in humans.
Biomarkers of Exposure and Effect.
Exposure.  Proposed biomarkers of exposure to 1-bromopropane include urinary levels of N-acetyl-
S-(n-propyl)-L-cysteine, bromide, and 1-bromopropane itself (Hanley et al. 2006, 2009, 2010; Ichihara et
al. 2004a; Kawai et al. 2001; Mathias et al. 2012; Valentine et al. 2007), as well as globin 
S-propylcysteine adducts in blood (Valentine et al. 2007).  Use of N-acetyl-S-(n-propyl)-L-cysteine is 
expected to be more specific to 1-bromopropane than bromide due to the presence of the bromide ion in 
foods, although in a study of workers involved in 1-bromopropane manufacture, urinary 1-bromopropane
concentrations were significantly correlated with TWA concentrations of 1-bromopropane in workplace 
air (Ichihara et al. 2004a).  Other compounds considered as potential biomarkers were determined to be
uncorrelated with exposure (3-bromopropionic acid) or were excluded from analysis due to low
concentrations in urine (N-acetyl-S-(n-propyl)-L-cysteine-S-oxide, N-acetyl-S-2-hydroxypropylcysteine, 
and N-acetyl-S-2-carboxyethylcysteine) (Mathias et al. 2012). Additional occupational studies may better
determine the reliability of proposed biomarkers of exposure.
N-Acetyl-S-(n-propyl)-L-cysteine has been measured in the urine of children and adult members of the 
U.S. general population participants in NHANES 2011–2012 (Jain 2015a, 2015b).  The results showed no 
significant differences between geometric means in males and females and significantly lower levels in
children (3.4 ng/mL) than in adults (5.7 ng/mL).  Differences between race/ethnicities were reported. 
N-Acetyl-S-(n-propyl)-L-cysteine also was measured in urine collected from pregnant women during the 
third trimester of pregnancy (median, 2.61 ng/mL) (Boyle et al. 2016). These studies suggest that urinary
N-acetyl-S-(n-propyl)-L-cysteine is found ubiquitously in the general population.  However, it is unclear
how the general public was exposed to 1-bromopropane, as most exposure is expected to be occupational
(NTP 2011; see Section 6.5 for more details).  This suggests that exposure to other chemicals and/or
endogenous metabolism may be additional sources of urinary N-acetyl-S-(n-propyl)-L-cysteine.  Studies 
designed to identify other environmental or endogenous sources of N-acetyl-S-(n-propyl)-L-cysteine 
would help to clarify the specificity of N-acetyl-S-(n-propyl)-L-cysteine as a biomarker of
1-bromopropane exposure in non-occupational settings.  If the specificity of N-acetyl-S-(n-propyl)-
L-cysteine is quantified (or another more specific biomarker is identified), research could potentially be 
aimed at estimating biomonitoring equivalents for 1-bromopropane would be useful.  Biomonitoring
   
 








   
 
 




      
 
     
     
     
     
  
     
      
    
   
 
   
  
   
  
 
    
 
      
     




equivalents are defined as the concentration or range of concentrations of a chemical or its metabolites in
a biological matrix (i.e., urine for N-acetyl-S-(n-propyl)-L-cysteine) that is consistent with an existing
noncancer health-based exposure guidance value (i.e., reference dose [RfD] or reference concentration 
[RfC]) (Aylward et al. 2013).  Comparing biomonitoring equivalents with guidance values helps
determine whether exposure to a chemical is excessive.  Biomonitoring equivalents have been derived for
a number of chemicals (Aylward et al. 2013).
Effect. There are no specific biomarkers to characterize effects caused by 1-bromopropane.  Additional
information on the mechanism of neurotoxicity may suggest a useful biomarker of either exposure or
effect.  However, at this time, there is little to suggest that such biomarkers exist.
Absorption, Distribution, Metabolism, and Excretion. The detection of urinary metabolites in 
humans and animal exposed to 1-bromopropane provides qualitative evidence for absorption by the 
gastrointestinal tract and the respiratory tract, but quantitative data on the extent of absorption are not
available (Garner and Yu 2014; Garner et al. 2006, 2007; Hanley et al. 2006, 2009, 2010; Ishidao et al. 
2002; Jones and Walsh 1979; Valentine et al. 2007). In vitro dermal absorption characteristics have been
measured in studies with human skin samples (Frasch et al. 2011). 1-Bromopropane is not expected to
accumulate in tissues due to efficient processes leading to exhalation of parent material or metabolically
produced CO2 and urinary excretion of oxygenated and conjugated metabolites (Garner and Yu 2014;
Garner et al. 2006, 2007; Ishidao et al. 2002; Jones and Walsh 1979).  Metabolism of 1-bromopropane in
mammals is complex, involving initial competing conjugation or oxidation steps, followed by subsequent
conjugation, oxidation, or rearrangement steps.  Most urinary and exhaled metabolic products are
debrominated leading to elevated levels of bromide ion in blood and urine (Hanley et al. 2006, 2009, 
2010; Garner and Yu 2014; Garner et al. 2006, 2007; Ishidao et al. 2002; Valentine et al. 2007).  
Oxidation steps are mediated by CYP2E1 and other, as yet unspecified, CYP oxygenases; reduced 
glutathione is the principal conjugating molecule for the parent compound, as well as for proposed 
oxygenated brominated intermediate metabolites (Garner et al. 2006, 2007; Jones and Walsh 1979).
Comparative Toxicokinetics. Metabolic disposition and toxicokinetic studies have found 
differences between mice and rats that reflect higher capacity for oxidative metabolism of 1-bromo-
propane in mice than rats (Garner and Yu 2014; Garner et al. 2006, 2007).  In rats given nominal single
intravenous doses of 5, 20, or 100 mg 1-bromopropane/kg, the percentage dose exhaled as metabolized
CO2 or excreted as oxygenated metabolites in urine decreased with increasing dose, whereas the 
percentage dose excreted in urine as metabolites from the glutathione conjugation pathway and the
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percentage dose exhaled as parent material increased with increasing dose (Garner et al. 2006).  In mice, 
the percentage dose exhaled as metabolized CO2 did not decrease with increasing dose to the same degree 
as in rats, and the percentage dose exhaled as parent material did not significantly change with increasing
dose (Garner et al. 2006, 2007).  Additional research may increase understanding of how these species 
differences in metabolism and toxicokinetics may be related to species differences in the sensitivity to
1-bromopropane-induced toxicity. A PBPK model for 1-bromopropane in F-344 rats was developed 
(Garner et al. 2015).  The model examined two metabolic assumptions for gas uptake in inhalation 
studies. Experiments are being conducted to further develop the model by including the compartments of
the metabolites of 1-bromopropane in order to help with quantitative extrapolation of animal studies to 
humans (Garner et al. 2015).
Methods for Reducing Toxic Effects. Oxygen therapy and positive-pressure ventilation may be 
useful following inhalation exposure to 1-bromopropane to promote the loss of unmetabolized 1-bromo-
propane from the lungs (Currance et al. 2007; HSBD 2014).  Washing of 1-bromopropane from exposed 
body surfaces is beneficial.  In cases of ingestion of isolated hydrocarbons, the use of activated charcoal
to reduce gastrointestinal absorption is generally not recommended (Gummin 2015; Thompson 2014); 
however, its use may be justified in patients with mixed overdoses (Gummin 2015).  Other than these 
general guidelines, there is very little information available on methods of mitigating the toxic effects of
1-bromopropane.  Additional data on the outcome of emergency response procedures would be beneficial.
Further research assessing the efficacy of antioxidants and compounds that increase glutathione levels, 
thus preventing the formation of hepatotoxic intermediates or metabolites that affect sperm parameters,
would be valuable.  Studies of the benefit of diet, ethanol absence, and controlled exposure to prescription 
or nonprescription drugs on blood levels of 1-bromopropane and its metabolites could provide
information that would be helpful in understanding the impact of these factors on the risks from
occupational exposure.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
The health effects of 1-bromopropane exposure in children are unknown; however, the nervous system is 
expected to be a target based on findings in adults.  Because the nervous system is still developing in
children, they might be more susceptible to 1-bromopropane toxicity than adults if exposure to 1-bromo-
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propane were to occur. However, since exposure to 1-bromopropane occurs mainly in occupational
settings, children are not expected to experience exposures to 1-bromopropane.  
Fetuses and infants may potentially be exposed to 1-bromopropane through their mothers; however, there
are no human studies that evaluated effects in offspring of mothers exposed to 1-bromopropane during
pregnancy and/or lactation.  Studies evaluating placental or lactation transfer of 1-bromopropane would 
be useful for determining the potential risk to developing offspring. Limited information from a
1-generation study in rats indicates that there is a potential for alterations in growth and maturity of
offspring following gestational and lactation exposure to 1-bromopropane vapors (Furuhashi et al. 2006).  
Guideline developmental toxicity studies would be useful to better characterize the potential
developmental toxicity of 1-bromopropane.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No ongoing studies pertaining to 1-bromopropane have been identified (RePORTER 2014).
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Information regarding the chemical identity of 1-bromopropane is provided in Table 4-1.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of 1-bromopropane is provided in Table 4-2.
Commercial 1-bromopropane has been reported to be 99% pure (ACGIH 2014).  1-Bromopropane used 
as a commercial solvent blend is formulated to improve performance and inhibit decomposition, including
stabilization to prevent hydrolysis (NTP 2011) and is between 85 and 99% pure (UNEP 2001).  
2-Bromopropane is present as a contaminant at 0.1–0.2% (OSHA 1999).










    





   
   
    
   
   
   
   
 









4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of 1-Bromopropanea 
Characteristic Information
Chemical name 1-Bromopropane
Synonym(s) Propane, 1-bromo-; propyl bromide; n-propyl bromide; 1-BP
Registered trade name(s) Abzol; Ensolv; Solvon; Ensolv-NDI; Whisper Spray; Soft Seamb 
Chemical formula C3H7Br




NIOSH RTECS TX4110000c 
EPA Hazardous Waste No data
OHM/TADS No data
DOT/UN/NA/IMDG UN 2344; IMO 3
HSDB 1068
NCI No data
aAll information obtained from HSDB (2013), unless otherwise noted.
bEPA 2007c.
cRTECS 2009.
CAS = Chemical Abstracts Services; CIS = Chemical Information System; DOT/UN/NA/IMDG = Department of
Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EPA = Environmental
Protection Agency; HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National
Institute for Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data 
System; RTECS = Registry of Toxic Effects of Chemical Substances















       
  
 
   
   
  
 
    
      
 
   
   
  
    













4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of 1-Bromopropanea 
Property












Water at 20°C 2.45x103 mg/L 




Log Koc 40 (estimated)
Vapor pressure at 20°C 110.8 mm Hg
OH radical rate constant at 25°C 1.18×10-12 cm3/molecules-secondb 
Henry's law constant at 20°C 7.3×10-3 atm-m3/mol (estimated)
Autoignition temperature 490°C
Flashpoint 21°Cc 
Flammability limits at 25°C No data
Incompatibilities Strong oxidants; strong bases
Conversion factors (25°C and 1 atm) 1 mg/L=198.8 ppm; 1 ppm=5.03 mg/m3 
Explosive limits LEL=4.6%
aAll information obtained from HSDB (2013), unless otherwise noted.
bDonaghy et al. (1993)
cAlfa Aesar (2014)
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
1-Bromopropane is primarily produced by reacting propanol with an excess of hydrogen bromide gas.  
Small amounts of 2-bromopropane are produced as a byproduct. There are various modifications to the
production method that increase the purity of the 1-bromopropane product, as well as distillation 
procedures to remove byproducts (NTP 2011).
Another production method is dehydration of propanol with bromine or hydrogen bromide in the presence
of a sulfur catalyst (NTP 2003).
In 2012, 1-bromopropane was reported to be manufactured by at least 21 companies globally, including at
least 1 in the United States (NTP 2013).
Worldwide annual production capacity of 1-bromopropane was estimated to be >20,000 metric tons (mt)
in 2006.  The same year, U.S. production was estimated to be about 5,000 mt and growing by 15–20% per
year (NTP 2011).  The non-confidential 2012 Chemical Data Reporting (CDR) database listed the U.S.
national production volume as 15,348,727 lb/year (6,962 mt/year) (HSDB 2013).
It was estimated that in 2000, 2001, and 2002, the global sales and emissions of 1-bromopropane for
solvent and adhesive applications were 4,839, 3,152, and 3,736 mt, respectively.  In 2003, the estimation 
of use and emissions was 5,000–10,000 mt (NTP 2003).
As of November 23, 2015, the EPA published a final rule adding 1-bromopropane to the TRI list of
reportable chemicals (EPA 2015).  Under this rule, facilities that manufacture or process 1-bromopropane
are required to report release and waste management data under Section 313 of the Emergency Planning
and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of
1986) (EPA 2005). This rule applies to the reporting year beginning January 1, 2016, and facility reports
are due on July 1, 2017 (EPA 2015).  It is estimated that 140 facilities will be required to report release 
and waste management data (EPA 2015).
Available data on the release and environmental fate of 1-bromopropane can be found in Sections 6.2 and 
6.3.
   
 




   
 
   










   
  
   
       
  
 
   








   
     
   
   
1381-BROMOPROPANE
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.2  IMPORT/EXPORT
It was reported that the U.S. imported 2.8 million pounds (1,270 mt) of 1-bromopropane in 2000 (NTP
2003).  In 2007 and 2011, U.S. imports were reported as 10.9 and 10.3 million pounds (4,944 and 
4,672 mt), respectively; however, this amount was for brominated derivatives of acyclic hydrocarbons 
and included other chemicals in addition to 1-bromopropane.
5.3  USE 
1-Bromopropane was originally used as an intermediate in the early to mid-1990s, primarily in the
production of pesticides, flavors and fragrances, pharmaceuticals, and other chemicals.  In the mid to late-
1990s, methylene chloride, used in emissive applications such as degreasing operations and cleaning of
electronics and metals, was determined to be toxic to workers, so 1-bromopropane was introduced as a
less toxic replacement for these applications. 1-Bromopropane is often used as a vapor due to its
relatively high vapor pressure.  Aerosol-applied adhesives containing 1-bromopropane have been used 
extensively in the foam fabricating industry (NTP 2011).
In 2007 and 2011, U.S. exports were reported as 8.8 and 15.1 million pounds (3,992 and 6,849 mt), 
respectively; however, this amount was for brominated derivatives of acyclic hydrocarbons and included 
other chemicals in addition to 1-bromopropane (NTP 2013).
In the last decade, the use of 1-bromopropane in industry has increased due to new applications as an 
alternative to ozone-depleting substances (ODS) and possible carcinogens.  For example, the dry cleaning 
industry started using 1-bromopropane as a substitute for tetrachloroethylene, in response to states
pursuing to ban the suspected carcinogen (NTP 2013).  Also, 1-bromopropane was reviewed through the
U.S. EPA’s Significant New Alternatives Policy (SNAP) program that identifies substitutes for ODSs, 
such as hydrochlorofluorocarbons (EPA 2007c).  Due to increased application of 1-bromopropane, 
exposure to workers has been increasing, which has caused some human health concern, such as
neurological alterations and reproductive toxicity.  Therefore, its use in certain industries is being
reevaluated (NTP 2013).  In 2007, the U.S. EPA proposed to allow the use of 1-bromopropane as an 
alternative to CFC-113, HCFC-141b, and methyl chloroform in some, but not all, end uses.  The decision 
found 1-bromopropane to be an acceptable substitute in metals, electronics, and precision cleaning and 
acceptable subject to use conditions as a coating, but not as an aerosol solvent or adhesive carrier solvent
due to the exposure potential and health risks to workers (EPA 2007c).  It has also been reported that at
least three manufacturers are limiting or eliminating use of 1-bromopropane for solvent applications (NTP
   
 




    
    
  
      
  
    
     
  
   
 
   




   
 
    
      
 




5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
2003).  In 2013, OSHA issued a hazard alert for 1-bromopropane suggesting that the most effective way
to reduce worker exposure is by eliminating or substituting 1-bromopropane (OSHA 2014). In addition, 
in 2014, ACGIH significantly lowered the TLV-TWA for 1-bromopropane, from 10 to 0.1 ppm and also 
reclassified it as a confirmed animal carcinogen (USAPHC 2014). In 2016, EPA developed a Toxic
Substances Control Act (TSCA) Work Plan Chemical risk assessment for 1-bromopropane in order to 
assess the uses with significant potential for exposure, and based on the findings, may bring about risk
reduction actions (EPA 2016). Due to these new threshold values and hazard alerts, 1-bromopropane may
no longer be a viable option for use in some industry applications, such as vapor degreasing, and 
therefore, the occupational use of 1-bromopropane may decrease in the future.
The EPA (2014e) indicated that some consumer products may contain 1-bromopropane, including aerosol
cleaning products, spot cleaners, and arts and craft spray glues.  However, no consumer products were
identified as containing 1-bromopropane in the U.S. Department of Health and Human Services (DHHS)
household database (DHHS 2016).  
5.4  DISPOSAL
Disposal of the chemical must take into consideration the material’s impact on air quality, its potential
migration to groundwater, its effect on biological species, and must follow disposal regulations (HSDB
2013).  Because of its propensity to volatilize, most disposal is by release to the atmosphere.  Disposal of
liquid or solid wastes that contain 1-bromopropane is regulated by federal restrictions that apply to
hazardous substances (see Chapter 8).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
1-Bromopropane has not been identified in any of the 1,832 hazardous waste sites that have been
proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2015).
6.2  RELEASES TO THE ENVIRONMENT
As of November 23, 2015, the EPA published a final rule adding 1-bromopropane to the TRI list of
reportable chemicals (EPA 2015).  Under this rule, facilities that manufacture or process 1-bromopropane
are required to report release and waste management data under Section 313 of the Emergency Planning
and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of
1986) (EPA 2005). This rule applies to the reporting year beginning January 1, 2016, and facility reports
are due on July 1, 2017 (EPA 2015). 
1-Bromopropane is a solvent widely used in commercial applications, such as adhesive sprays, degreasing
operations for cleaning metals, plastics, and electronic components, dry cleaning, asphalt production, 
aircraft maintenance, and synthetic fiber manufacturing (Chalupka 2014).  Almost all of the potential
exposure to 1-bromopropane is associated with its production and use.  Individuals living in close
proximity to facilities that use aerosol products containing 1-bromopropane may be exposed via
inhalation of ambient air (Blando et al. 2010; NTP 2011, 2016).
The dominant process affecting the overall environmental fate and transport of 1-bromopropane is
volatilization.  In water, estimated volatilization half-lives for a model river and a model lake were 
reported as 1.2 hours and 4.4 days, respectively (EPIWIN 2012).  1-Bromopropane in air will be degraded 
by photochemically produced hydroxyl radicals, with a half-life of 14 days (Donaghy et al. 1993).  
Hydrolysis and biodegradation by microorganisms have also been shown to break down 1-bromopropane
in aquatic and terrestrial environments (Janssen et al. 1987; Mabey and Mill 1978; NITE 2010).  
1-Bromopropane is not expected to bioaccumulate in aquatic organisms (EPIWIN 2012).
The use of 1-bromopropane in commercial and industrial applications, such as vapor and immersion 
degreasing, adhesive sprays, dry cleaning, and solvent sprays, may result in its release to the environment
(Chalupka 2014).












   
    
 
     
 
 




    
 
 
   
 
 
    
      
 
    
 
     
 
 
   
      
 
1421-BROMOPROPANE
6.  POTENTIAL FOR HUMAN EXPOSURE
6.2.1 Air
Since 1-bromopropane is volatile and is used as a vapor in emissive applications (NTP 2011), most
environmental releases are into the air.  No data regarding the amount of 1-bromopropane released to air
could be located in the available literature.
There is no information on releases of 1-bromopropane to the atmosphere from manufacturing and 
processing facilities at this time; however, facility reports are due July 1, 2017 (EPA 2015).
6.2.2 Water
Schwarzenbach et al. (1985) reported on the investigation of groundwater contamination caused by a
leaking waste water tank at an alkyl halides chemical plant in Switzerland where 1-bromopropane was
manufactured at >5 tons/year.  No 1-bromopropane could be detected in groundwater 7 years after the
termination of plant operations and an extensive area cleanup, most likely due to hydrolysis.
It was reported that 1-bromopropane may be transported from macroalgae that produce 1-bromopropane
as a product of fatty acid hydrolysis to the marine environment (Gschwend et al. 1985).
No other data regarding the amount of 1-bromopropane released to water could be located in the available 
literature.
There is no information on releases of 1-bromopropane to the water from manufacturing and processing
facilities at this time; however, facility reports are due July 1, 2017 (EPA 2015).
6.2.3 Soil 
No data regarding the amount of 1-bromopropane released to soil could be located in the available
literature.
There is no information on releases of 1-bromopropane to the soil from manufacturing and processing
facilities at this time; however, facility reports are due July 1, 2017 (EPA 2015).






   
 




   
 
   
    
 








     
     
   
 
     
 
     
  
 
   
 
    
  
   
    
   
1431-BROMOPROPANE
6.  POTENTIAL FOR HUMAN EXPOSURE
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Due to its volatility, 1-bromopropane released to the environment is expected to partition mostly to air.  
Based on the vapor pressure of 1-bromopropane (see Table 4-2), when released to the atmosphere, it
would be expected to exist in the vapor phase (Bidleman 1988).  
1-Bromopropane released to water will primarily volatilize based on its estimated Henry’s Law constant
(see Table 4-2). Estimated volatilization half-lives for a model river and a model lake were reported as 
1.2 hours and 4.4 days, respectively (EPIWIN 2012).  It is not expected to adsorb to suspended soils or
sediments based on its estimated organic carbon partition coefficient (Koc) of 40, and therefore, leaching
to groundwater may occur (EPIWIN 2012).
1-Bromopropane is not expected to bioaccumulate in aquatic organisms.  This is based on its estimated 
bioconcentration factor (BCF) of 11 (EPIWIN 2012).  No experimental data on the bioaccumulation of
1-bromopropane in fish could be located in the available literature.
If released to soil, 1-bromopropane is expected to partition primarily to the atmosphere through 
volatilization based on its vapor pressure (see Table 4-2).  It may also be transported to surface water via
runoff and to groundwater as a result of leaching.  1-Bromopropane is expected to have very high 
mobility in soil based on its estimated Koc (Swann et al. 1983).
6.3.2 Transformation and Degradation
1-Bromopropane is subject to a variety of abiotic and biotic degradation processes in all environmental
compartments (Belkin 2002; Donaghy et al. 1993; ECHA 2014; Mabey and Mill 1978).
6.3.2.1  Air
1-Bromopropane in the atmosphere will be degraded by photochemically produced hydroxyl radicals at a
rate that has been measured as 1.18x10-12 cm3/molecule-second at 25°C (Donaghy et al. 1993).  This
corresponds to a half-life of 14 days, assuming an atmosphere containing 5x105 hydroxyl radicals/m3 at
25°C (Meylan and Howard 1993).  The atmospheric lifetime of 1-bromopropane is not largely affected by
photolysis (Wuebbles et al. 1998).












    
  




   
  








    
  
     
  
   
    
   




6.  POTENTIAL FOR HUMAN EXPOSURE
6.3.2.2  Water
1-Bromopropane released to water may be subject to both abiotic and biotic degradation by
microorganisms (Belkin 2001; ECHA 2014; Mabey and Mill 1978).  
1-Bromopropane will slowly hydrolyze in water.  A neutral first-order hydrolysis rate constant of
3.01x10-7/second was measured at 55°C, corresponding to an aqueous hydrolysis half-life of
approximately 26 days (Mabey and Mill 1978).  It should be noted that this hydrolysis half-life is longer
than the estimated volatilization half-lives from a model river and a model pond (see Section 6.3.1), 
suggesting that most 1-bromopropane will volatilize before extensive hydrolysis can occur.
1-Bromopropane has been shown to degrade in activated sludge during ready biodegradation tests.  At a
concentration of 100 mg/L, it degraded 70% after 4 weeks using an activated sludge inoculum at
30 mg/L.  However, it was noted that 1-bromopropane was hydrolyzed in the test solution to 1-propanol
and bromide ion, and degradation of 1-propanol is what was measured (NITE 2010).  In a closed bottle
test, 5.6 mg/L of 1-bromopropane biodegraded 19.2% after 28 days using an activated sludge inoculum
(ECHA 2014).
Pure culture microorganisms have also been shown to have the potential to biodegrade 1-bromopropane.  
Degradation of haloalkanes, such as 1-bromopropane, by microorganisms takes place primarily via 
hydrolytic dehalogenation by enzymes (Belkin 2002).  1-Bromopropane was hydrolytically
dehalogenated by Arthrobacter HA1 with a specific growth rate of 0.12/hour, a growth yield of 4.0 g
protein/molC, and producing 1-propanol as a product (Scholtz et al. 1987).  Acinetobacter strain GJ70 had
a generation time of 7.4 hours when utilizing 1-bromopropane as a carbon source (Janssen et al. 1987).
1-Bromopropane was completely dehalogenated within 6 days when added to a 32 mM culture medium, 
producing 2.2 mM of the halide.  A crude cell extract of strain GJ70 degraded 1-bromopropane to 
reaction products, 1-propanol and bromide ion.  The mechanism for this reaction was reported to be
hydrolytic dehalogenation, considering that no aldehydes were produced and no oxygen was consumed 
(Janssen et al. 1987). Pseudomonas strain ES-2, isolated from organobromide-rich industrial wastewater,
was shown to organically debrominate 1-bromopropane, but was unable to use it as a carbon source for
growth (Shochat et al. 1993).










     
 
 
   
 
    
 
 
   
 
   
    
      
 
     











     
 
    
 
1451-BROMOPROPANE
6.  POTENTIAL FOR HUMAN EXPOSURE
6.3.2.3  Sediment and Soil
Volatilization from moist and dry soil surfaces will be the predominant removal mechanism from these 
environmental compartments (Lyman et al. 1990).  Ready biodegradation tests and pure culture studies
(see Section 6.3.2.2) have shown that biodegradation may also be an important fate process for
1-bromopropane.
6.3.2.4  Other Media
Information on the transformation or degradation of 1-bromopropane in other media was not found in the
available literature.
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to 1-bromopropane depends in part on the
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of 1-bromopropane in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits of current analytical methods.  In reviewing data on 1-bromopropane levels
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods 
available for monitoring 1-bromopropane in a variety of environmental media are detailed in Chapter 7.
There are very limited data on the detection of 1-bromopropane in the environment in the available 
literature.
6.4.1 Air
The Air Quality System (AQS) database is EPA's repository of criteria air pollutant and hazardous air
pollutants monitoring data.  In 2014, the AQS reported only positive detections of 1-bromopropane at one
monitoring location.  1-Bromopropane was detected in ambient air of Philadelphia, Pennsylvania at levels 
of 0.14–0.16 ppb (0.047–0.053 ppbv) (EPA 2014b).
6.4.2 Water
No data on monitored levels of 1-bromopropane in water were found in the available literature.  






     
 
    
 
    
 
  
    
   
  
   
 




   
       
    
     




   
   
 
 
    
   





6.  POTENTIAL FOR HUMAN EXPOSURE
6.4.3 Sediment and Soil
No data on monitored levels of 1-bromopropane in soil or sediment were found in the available literature.  
6.4.4 Other Environmental Media 
The EPA (2014e) indicated that some consumer products may contain 1-bromopropane, including aerosol
cleaning products, spot cleaners, and arts and craft spray glues, which could result in exposure to the
general population; however, no consumer products were identified as containing 1-bromopropane in the
U.S. Department of Health and Human Services household database (DHHS 2016).  NTP (2016)
indicated that no data are available on levels of 1-bromopropane in consumer products.
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Exposure of 1-bromopropane to the general population may occur via inhalation of ambient air at
locations in close proximity to the emissive use of 1-bromopropane due to potential vapor migration, such 
as degreasing operations or dry cleaners (Blando et al. 2010; NTP 2011, 2016).  Vapor intrusion may also 
be a potential source of 1-bromopropane exposure, as vapor intrusion has been observed for several
volatile organic chemicals (VOCs) with similar properties and overlapping usage (e.g.,
tetrachloroethylene and dry cleaning) (Blando et al. 2010). However, no information was located
specifically evaluating vapor intrusion potential of 1-bromopropane. 1-Bromopropane has not been 
identified in consumer products (DHHS 2016; NTP 2016). 
In NHANES 2011–2012, the distribution of the urinary metabolite of 1-bromopropane, N-acetyl-
S-(n-propyl)-L-cysteine, by age, gender, race/ethnicity, and smoking status among 2,328 participants was
examined; participants were ≥20 years of age.  Adjusted urinary geometric means of N-acetyl-
S-(n-propyl)-L-cysteine were the same in males and females (5.3 ng/mL).  Nonsmokers did not have
statistically significantly different urinary levels of N-acetyl-S-(n-propyl)-L-cysteine than smokers.  Non-
Hispanic white subjects (3.9 ng/mL) had significantly lower levels of N-acetyl-S-(n-propyl)-L-cysteine 
than non-Hispanic black subjects (4.1 ng/mL) and non-Hispanic Asians (7.7 ng/mL).  Non-Hispanic black
subjects (4.1 ng/mL) had significantly lower levels of urinary N-acetyl-S-(n-propyl)-L-cysteine than
Hispanics (6.2 ng/mL) and non-Hispanic Asians (7.7 ng/mL).
In the National Children’s Vanguard Study from 2009 to 2010 (Boyle et al. 2016), urinary samples
collected from 488 pregnant women during the third trimester from seven locations in the United States









   
  
  
    
 
     
   
 
   
 
    







   
  
     
  
    
     








6.  POTENTIAL FOR HUMAN EXPOSURE
contained N-acetyl-S-(n-propyl)-L-cysteine at a detection frequency of 99%; the median measured 
concentration was 2.61 ng/mL and the 75th percentile value was 9.44 ng/mL.
Biological exposure to the general population and workers can be assessed by measurement of bromide 
ion, 1-bromopropane, and its metabolite, N-acetyl-S-(n-propyl)-L-cysteine (AcPrCys) in urine or blood
(NTP 2013). N-Acetyl-S-(n-propyl)-L-cysteine is expected to be more specific to 1-bromopropane than 
bromide due to the presence of the bromide ion in foods; however, there have also been concerns
regarding the specificity of N-acetyl-S-(n-propyl)-L-cysteine.  The ubiquitous nature of N-acetyl-
S-(n-propyl)-L-cysteine in the urine of the general population suggests that it may not be a specific 
biomarker for 1-bromopropane, as general population exposure is expected to be limited.  It is unknown if
other chemicals and/or endogenous metabolism contributed to the observed urinary levels of N-acetyl-
S-(n-propyl)-L-cysteine in biomonitoring studies.
Use of 1-bromopropane in emissive applications can lead to dermal and inhalation exposure of workers
(NTP 2011).  No data on the contribution of dermal exposure to body burdens could be located, but many
studies have assessed personal breathing zone and indoor air concentrations.
Exposure to 24 female and 13 male workers in a 1-bromopropane factory in China was assessed through 
air, urine, and blood samples (Ichihara et al. 2004a).  Mean ambient air concentrations of 1-bromopropane
within the factory ranged from 2.1 to 79.7 ppm.  Twelve-hour TWA 1-bromopropane breathing zone
concentrations for workers ranged from 0.9 to 170.5 ppm.  The study found that urinary 1-bromopropane
levels directly correlated with individual exposure levels, but serum levels did not, suggesting urine
samples may be a better biomarker for exposure.  Valentine et al. (2007) studied blood and urine samples
from workers and ambient air samples in a Chinese 1-bromopropane production plant in order to support
the potential of urinary AcPrCys and globin S-propylcysteine (PrCys) adducts as biomarkers of exposure 
in humans.  It was found that there was a significant increase in globin PrCys adducts on workers’ globin
(1.52 pmol/mg globin) compared with that of control factory workers (0.11 pmol/mg globin).  Also, an 
increase in urinary AcPrCys levels was directly related to an increase in ambient air exposure levels,
which ranged from 0 to 170.54 ppm (Valentine et al. 2007).
Air samples taken at the workplace where furniture foam cushions were manufactured during gluing
operations had a mean 1-bromopropane concentration of 130 parts per million by volume (ppmv) (range, 
91–176 ppmv) with a 7-hour TWA of 108 ppm (range, 92–127 ppm) (Majersik et al. 2007).  Workers
who complained of neurological symptoms had serum bromide levels of 44–170 mg/dL.  Hanley et al. 







     
  
   
   
   
   
   
 
  
    
  
    
 
    
    
 
    
   




   
   
   




6.  POTENTIAL FOR HUMAN EXPOSURE
(2006) measured urinary bromide and personal breathing zone concentrations of 1-bromopropane during
two full-shift days for 30 workers exposed to flexible foam spray adhesives used to construct foam seat
cushions.  Mean personal breathing zone concentrations were 92 ppm for adhesive sprayers and 11 ppm
for other non-sprayer jobs, including glue line leads, sewing machine operators, wrappers, pillow stuffers, 
and foam and cloth cutters.  Complete 48-hour urine samples for adhesive sprayers contained urinary
bromide concentrations of 77–542 mg/g creatinine at work, 58–308 mg/g creatinine after work, and 46– 
672 mg/g creatinine in wake-up samples.  Urinary bromide concentrations taken at the beginning of the
week for sprayers were significantly higher than for non-spraying workers and unexposed controls, with 
measured means of 102, 31, and 3.8 mg/g creatinine, respectively (Hanley et al. 2006).  In another study
assessing the exposure of workers to 1-bromopropane in foam cushion spray adhesives used to construct
foam seat cushions, personal breathing zone concentrations, as well as the metabolite, AcPrCys, in
48-hour urine samples from 30 workers and 21 unexposed controls were measured at two factories 
(Hanley et al. 2009).  Full-shift geometric mean TWA personal breathing zone concentrations were 
reported as 92.4 and 10.5 ppm for sprayers and non-sprayers, respectively.  Complete 48-hour urine
samples for adhesive sprayers contained AcPrCys concentrations of 9.9–100 mg/g creatinine at work, 
17.5–186 mg/g creatinine after work, and 15–184 mg/g creatinine in wake-up samples.  Urinary AcPrCys 
concentrations taken at the beginning of the week for sprayers were significantly higher than for non-
spraying workers and unexposed controls, with measured means of 3.2, 0.58, and 0.02 mg/g creatinine, 
respectively (Hanley et al. 2009).
In 1999 and 2001, NIOSH (2003a) evaluated exposure to 1-bromopropane at a facility that used a spray
adhesive containing 1-bromopropane by measuring air and blood samples. The mean full shift personal
breathing zone concentration for 16 samples collected in 1999 was 81.2 ppm (range, 18–254 ppm) and for
13 samples collected in 2001 was 45.7 ppm (range, 7–281 ppm).  Unexposed workers full-shift personal
breathing zone samples collected in 2001 had a mean 1-bromopropane concentration of 1.1 ppm (range, 
0.1–4.9 ppm), which shows that 1-bromopropane vapors may migrate from spraying operations to other
areas.  Blood samples from all workers taken at the end of the week had a mean bromide concentration of
4.8 mg/dL (range, 1.7–43.5 mg/dL), of which exposed workers had a mean concentration of 14.9 mg/dL
and unexposed workers had a mean concentration of 2.7 mg/dL.  End of the week urine samples for all
workers had a mean bromide concentration of 46.5 mg/dL (range, 15–595 mg/dL, of which exposed 
workers had a mean concentration of 151.8 mg/dL, and unexposed workers had a mean concentration of
28.5 mg/dL.
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Breathing zone samples taken at five facilities using 1-bromopropane solvents for vapor degreasing
operations had mean full shift (8–10 hours) TWA 1-bromopropane concentrations of 2.6 and 0.31 ppm
for workers near degreasers and those remote from degreasers, respectively (Hanley et al. 2010).  Urinary
metabolites for workers near degreasers were reported at mean bromide and AcPrCys concentrations of
8.9 and 1.3 mg/g creatinine, respectively, while workers remote from degreasers had mean bromide and
AcPrCys concentrations of 3.7 and 0.12 mg/g creatinine, respectively (Hanley et al. 2010). In an 
assessment of a facility using 1-bromopropane in a cold vapor degreaser, the full shift time weighted 
average 1-bromopropane personal breathing zone concentrations for 20 remote workers ranged from
0.01 to 0.63 ppm, while two short-term task-based measurements from employees using the degreaser
were 2.3 and 8.4 ppm (NIOSH 2001).  The highest ambient air concentration in the facility collected 
during one area air sampling event was found in the degreaser room, which had 1-bromopropane
concentrations of 4.42 ppm at the degreaser and 1.7 ppm at an area 5 feet from the degreaser. 
In an investigation of potential exposure to 1-bromopropane among dry cleaners in New Jersey by
measuring personal breathing zone and indoor air samples, the highest exposure measured for a dry
cleaning machine operator was 54.55 ppmv as an 8-hour TWA, and the highest exposure for a clerk was
21.85 ppmv as an 8-hour TWA.  Indoor air samples taken continuously for the time period dry cleaning
work was being performed had measured average 1-bromopropane air concentrations ranging from not
detected to 35.12 ppmv.  This study found that the highest exposures to dry cleaning workers may occur
during the addition of 1-bromopropane to the machines, during machine maintenance, unloading and 
sorting the cleaned clothes, when interrupting the wash cycle, and possible leaks from the machine 
(Blando et al. 2010).  In 2008, NIOSH conducted an evaluation of the use of 1-bromopropane in four dry
cleaning facilities in New Jersey (NIOSH 2010). Personal breathing zone air concentrations of 40 ppm
for the machine operator and 17 ppm for the cashier during full shift sampling conducted at one of the
facilities were reported.  At the other three facilities, personal breathing zone concentrations in partial
shift samples ranged from 1.5 to 160 ppm.
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a






     
  
  
      
    
   
 
 
   
   
    
 
 
     
 
 
    
 
  





    
   
   






   
     
1501-BROMOPROPANE
6.  POTENTIAL FOR HUMAN EXPOSURE
larger skin surface in proportion to their body volume than adults.  A child’s diet often differs from that of
adults.  The developing human’s source of nutrition changes with age: from placental nourishment to 
breast milk or formula to the diet of older children who eat more of certain types of foods than adults.  A
child’s behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their
mouths, sometimes eat inappropriate things (such as dirt or paint chips), and may spend more time
outdoors.  Children also are generally closer to the ground and have not yet developed the adult capacity
to judge and take actions to avoid hazards (NRC 1993).
The general population may be exposed to 1-bromopropane in air when it is used during aerosol
applications due to potential vapor migration, particularly at locations in close proximity to the emissive
use of 1-bromopropane (NTP 2011).  No studies on exposures specific to children could be located in the
available literature.
Evaluation of 417 children, 6–11 years of age, also participants in the NHANES 2011–2012 study
examining the distribution of the urinary metabolite of 1-bromopropane, N-acetyl-S-(n-propyl)-L-
cysteine, among the general population, showed measured mean concentrations of 2.6 ng/mL in males 
and 3.3 ng/mL in females (Jain 2015b).  Non-Hispanic Asian children had the highest urinary levels of
N-acetyl-S-(n-propyl)-L-cysteine (5.0 ng/mL) followed by non-Hispanic black children (3.4 ng/mL), 
non-Hispanic white children (2.4 ng/mL), and Hispanic children (2.1 ng/mL).  Children had significantly
lower levels of urinary N-acetyl-S-(n-propyl)-L-cysteine than nonsmoking adults (3.4 versus 5.7 ng/mL).
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Exposure to 1-bromopropane occurs mainly in occupational settings.  Workers may be exposed by
inhalation of vapors or spray mists or by dermal absorption.  Workers involved in the production of
1-bromopropane, as well as those using it in commercial applications, such as adhesive sprays, degreasing
operations for cleaning metals, plastics, and electronic components, dry cleaning, asphalt production, 
aircraft maintenance, and synthetic fiber manufacturing, have potential for high dose exposures (Chalupka
2014).
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of 1-bromopropane is available. Where adequate information















    
 
      
    
 
         
   
  
   
       
      




    
    
   
 





6.  POTENTIAL FOR HUMAN EXPOSURE
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of 1-bromopropane.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical-chemical properties of 1-bromopropane are
provided in Chapter 4.  Important properties such as melting point, boiling point, vapor pressure, water 
solubility, and octanol/water partition coefficient are available.  No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. No information is available in the
TRI database on facilities that manufacture or process 1-bromopropane because this chemical is not
required to be reported under Section 313 of the Emergency Planning and Community Right-to-Know
Act (Title III of the Superfund Amendments and Reauthorization Act of 1986) (EPA 2005). However, as 
of November 23, 2015, the EPA published a final rule adding 1-bromopropane to the TRI list of
reportable chemicals (EPA 2015). This rule applies to the reporting year beginning January 1, 2016, and 
facility reports are due on July 1, 2017 (EPA 2015).  It is estimated that 140 facilities will be required to
report release and waste management data (EPA 2015).
Production, use, and import/export data are available (NTP 2003, 2011, 2013).  Continuously updated 
information regarding these quantities is necessary. Information regarding use in consumer products, if
any, would be useful. The identification of stabilizers and additives used in commercial grades of
1-bromopropane would be useful in determining potential health effects.
Environmental Fate. The environmental fate and transport of 1-bromopropane is well understood.
Volatilization is the dominant process affecting the overall fate and transport.  Additional studies on the
rate of volatilization, rate of hydrolysis, and bioaccumulation potential would be useful.
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Bioavailability from Environmental Media. 1-Bromopropane is expected to volatilize and 
hydrolyze in water and is not frequently detected in ambient air, so bioavailability from environmental
media is expected to be low.  No data needs are identified.
Food Chain Bioaccumulation. Due to the low bioavailability of 1-bromopropane, it is not expected 
to bioaccumulate.  Measured BCF data would be useful in determining the actual bioaccumulation 
potential in the food chain.
Exposure Levels in Environmental Media.  Reliable monitoring data for the levels of
1-bromopropane in contaminated media at hazardous waste sites are needed so that the information
obtained on levels of 1-bromopropane in the environment can be used in combination with the known 
body burden of 1-bromopropane to assess the potential risk of adverse health effects in populations living
in the vicinity of hazardous waste sites.
Exposure Levels in Humans. Additional studies on levels of 1-bromopropane in the general
environment would be useful in determining the exposure to the general public (NTP 2003).
Environmental levels in indoor air due to use of consumer products containing 1-bromopropane would be
particularly useful (EPA 2016). No measured data were located on levels of 1-bromopropane found in 
food, consumer products, or non-occupational exposures (NTP 2016). As there is potential for exposure 
to the general population through the use of at home consumer products, monitoring data on these
products would be useful in determining exposure levels to the general public (EPA 2016).
Studies assessing the contribution of dermal contact to exposure of workers would be useful (NTP 2003).  
Additional research to better understand the potential exposure of the general public living or working in 
close proximity to dry cleaners that may vent 1-bromopropane vapors would be useful in assessing risk to 
these populations (Blando et al. 2010).
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Studies assessing the exposure of children due to their proximity to 
commercial uses of 1-bromopropane would be helpful in assessing their overall exposure risk.
Specifically, monitoring data determining the exposure to children through the use of at home consumer
products containing 1-bromopropane would be useful.






   
 
 
      
  
    
    
    
  
 




6.  POTENTIAL FOR HUMAN EXPOSURE
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for 1-bromopropane were located.  This substance is
not currently one of the compounds for which a sub-registry has been established in the National
Exposure Registry.  The substance will be considered in the future when chemical selection is made for
sub-registries to be established. The information that is amassed in the National Exposure Registry
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to
exposure to this substance.
6.8.2 Ongoing Studies 
No ongoing studies were located for 1-bromopropane.
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1551-BROMOPROPANE
7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring 1-bromopropane, its metabolites, and other biomarkers of exposure and 
effect to 1-bromopropane. The intent is not to provide an exhaustive list of analytical methods.  Rather, 
the intention is to identify well-established methods that are used as the standard methods of analysis.
Many of the analytical methods used for environmental samples are the methods approved by federal
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health
(NIOSH).  Other methods presented in this chapter are those that are approved by groups such as the 
Association of Official Analytical Chemists (AOAC) and the American Public Health Association
(APHA).  Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Table 7-1 lists the methods used for determining 1-bromopropane in biological materials.  Biological
exposure to the general population and workers can be assessed by measurement of bromide ion, 
1-bromopropane, and its metabolite, N-acetyl-S-(n-propyl)-L-cysteine (AcPrCys), in urine or blood (NTP
2013).  Direct analysis of 1-bromopropane in urine samples by gas chromatography (GC) equipped with 
an electron capture detector (ECD) was accomplished at a detection limit of 2 ng/mL (B’hymer and
Cheever 2005).  
The longer physiological half-lives of the metabolites of volatile organic compounds, such as those of
1-bromopropane, in urine compared to blood give monitoring urinary metabolites an advantage over
blood sampling (Alwis et al. 2012).  One method to measure the urinary metabolite of 1-bromopropane, 
AcPrCys, involves ultra-high performance liquid chromatography (UPLC) with electrospray ionization 
tandem mass spectrometry (ESI/MS/MS).  Sample preparation involved collection of urine, where a 
1.8 mL aliquot was stored at -70°C until the time of the assay.  When assayed, the samples were diluted
1:10 with 425 µL of 15 mM ammonium acetate (pH 6.8), followed by washing with acetonitrile to obtain 
a mobile phase for detection.  The limit of detection was reported to be 1.2 ng/mL (Alwis et al. 2012).  
Another method to measure the urinary metabolite, AcPrCys, involves solid-phase extraction (SPE) from
urine samples by washing with a 40:60 solution of methanol and water followed by elution with acetone
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Urine 50 µL urine diluted with 
425 µL 15 mM ammonium
acetate pH 6.8; washed with 





95 (mean) Alwis et al.
2012
mobile phase; analysis for
AcPrCys
Urine Urine samples diluted with 
water (1:4) and fortification 
with 1-bromobutane, which 
GC/ECD 2 ng/mL 104–121 B’hymer and 
Cheever 2005
was used as an internal
standard; each sample then 
sealed in a headspace vial
and placed in the analyzer
Urine Urine sample was extracted 
4 times with 4.0 mL of ethyl
acetate using a vortex mixer
for 1 minute for each 
GC/MSD 0.01 µg/mL 
(3-BPA)




Urine Urine sample extracted by
SPE; washed with 40%
methanol/60% water
followed by elution with
acetone; analysis for
AcPrCys
HPLC/MS 0.01 µg/mL 
(AcPrCys)
96–103 Cheever et al.
2009
Urine SPE of urine samples with 
addition of 1 mL ammonium
LC/MS 2.0 µg/mL (PrMA) 99.5 Eckert and 
Goen 2014
formate buffer (50 mmol/L,
pH 2.5) and 40 µL formic
acid; sample vortex-mixed 
and centrifuged
Blood Blood collected from
laboratory animals by 
cardiac puncture using a 
heparinized syringe; plasma 
separated by centrifugation
at 4°C and stored at -80°C
GC/MS No data No data Ishidao et al.
2002
until analysis
3-BPA = 3-bromopropionic acid; AcPrCys = N-acetyl-S-(n-propyl)L-cysteine; ECD = electron capture detector; ESI =
electrospray ionization; GC = gas chromatography; HPLC = high-performance liquid chromatography; LC = liquid 
chromatography; MS = mass spectrometry; MSD = mass selective detector; PrMA = n-propyl mercapturic acid;
SPE = solid phase extraction; UPLC = ultra high performance liquid chromatography
   
 




   
 
    







   





    
       
  
 





   
    









and analysis using high performance liquid chromatography (HPLC) and mass spectrometry (MS)
(Cheever et al. 2009).  3-Bromopropionic acid (3-BPA) is also a metabolic product of 1-bromopropane in 
human urine.  B’hymer and Cheever (2004) discuss a GC method to quantify this metabolite in human 
urine.  A method for the simultaneous determination of four short-chain alkyl mercapturic acids,
including 1-bromopropane metabolite n-propyl mercapturic acid (PrMA), in human urine by SPE and 
detection by column-switching liquid chromatography and MS/MS has been discussed (Eckert and Goen
2014).
7.2  ENVIRONMENTAL SAMPLES 
Table 7-2 lists the methods used for determining 1-bromopropane in environmental samples.  Due to its
volatility, 1-bromopropane released to the environment is expected to partition mostly to air (HSDB
2013).  
The principal separation and detection methods for 1-bromopropane in air samples include GC in 
conjunction with flame ionization detection (FID).  NIOSH Method 1025 and OSHA Method PV2061 
have both been fully validated for use in occupational settings where regulatory exposure limits are of
concern (NIOSH 2003b; OSHA 1999).  Both of these methods draw air samples through a solid coconut
shell charcoal (CSC) sorbent tube. The sample is then desorbed with carbon disulfide or a 99/1 (v/v)
carbon disulfide/dimethylformamide mixture followed by GS/FID analysis.  The limit of detection for
NIOSH Method 1025 is 1.0 µg/sample, while the detection limit for OSHA Method PV2061 is reported 
as 0.007 ppm (0.037 mg/m3) at a 12-L air volume using a sampling rate of 0.1 L per minute.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of 1-bromopropane is available. Where adequate information
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of 1-bromopropane. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
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Table 7-2. Analytical Methods for Determining 1-Bromopropane in Environmental
Samples
Sample 
Sample Analytical detection Percent
matrix Preparation method method limit recovery Reference
Air Air drawn through a solid sorbent tube GC/FID 1.0 µg/sample 96.8 NIOSH 
lined with Anasorb CSC; desorbed with (Method (RSD= 2003b
addition of 1.0 mL of carbon disulfide for 1025) 0.015)
30 minutes
Air Air drawn through CSC tube; desorbed GC/FID 0.007 ppm 97.5 OSHA 1999
with a mixture of 99/1 (v/v) carbon (Method (0.037 mg/m3)
disulfide/dimethylformamide PV2061)
Air Air sampled at 530 mL/minute to lithium SCF/MS 52 pptv No data Fujii 1992
ionization chamber
CSC = coconut shell charcoal; FID = flame ionization detector; GC = gas chromatography; MS = mass spectrometry;
RSD = relative standard deviation; SCF = super critical fluid chromatography
   
 





   
 
    
 




    
     
      
 
 
    
 
  
   
 
  
      
  
 
     
  
     
   
 





that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Exposure to 1-bromopropane is typically assessed by measuring its metabolites such as 
AcPrCys, 1-bromopropionic acid, or released bromine in urine or blood (NTP 2013).  Field studies 
indicated that urinary levels of N-acetyl-S-(n-propyl)-L-cysteine and bromide were significantly
correlated with 8–12-hour TWA breathing zone air concentrations of 1-bromopropane in several groups
of workers (Hanley et al. 2006, 2009, 2010).  Methods of determining biomarkers of exposure are well
characterized by urine analysis. Additional studies on the direct detection of 1-bromopropane biomarkers
in human blood would be useful in determining exposure.
Effect. There are no specific biomarkers to characterize effects caused by 1-bromopropane.  Nervous
system effects caused by inhalation of 1-bromopropane can be caused by many other substances as well.  
See Section 3.8.2 for more details.  Identification and additional studies of specific biomarkers would be
useful in characterizing the effects caused by 1-bromopropane.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Human exposure to 1-bromopropane may occur through inhalation of ambient air and dermal
uptake through occupational contact and consumer products containing 1-bromopropane.  Methods have
been reported for the detection of 1-bromopropane in air.  The methods of NIOSH (2003b) (LOD
1.0 µg/sample) and OSHA (1999) (LOD 0.007 ppm [0.037 mg/m3]) are adequate for the determination of
1-bromopropane in air.  Methods for detection of 1-bromopropane in other environmental media are not
needed, as it is rarely found in environmental compartments other than air.  Additional studies do not
seem necessary at this time.
7.3.2 Ongoing Studies 
No ongoing studies were located for 1-bromopropane.
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates that are intended to serve as screening levels. They are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
ATSDR has derived an acute-duration inhalation MRL of 1 ppm for 1-bromopropane based on a
BMCL1SD of 97.4 ppm for reduced forelimb strength in male rats exposed for 14 days (Honma et al. 
2003).  The BMCL1SD was duration adjusted (8/24 hours) to a BMCL(HEC) of 32.3 ppm and an uncertainty
factor of 30 was used (3 for dosimetric adjustment and 10 for human variability).
ATSDR has derived an intermediate-duration inhalation MRL of 0.1 ppm for 1-bromopropane based on a
NOAEL of 10 ppm for increased spontaneous locomotor activity in rats (Honma et al. 2003).  The 
NOAEL was duration adjusted (8/24 hours) to a NOAEL(HEC) of 3.33 ppm and an uncertainty factor of
30 was used (3 for extrapolation from animals to humans with dosimetric adjustment and 10 for human 
variability).
ATSDR has derived a chronic-duration inhalation MRL of 0.02 ppm for 1-bromopropane based on a
minimal LOAEL of 1.28 ppm for a mild neurological impairment (decreased vibration sense as measured
by increased vibration sense threshold) in female 1-bromopropane production workers (Li et al. 2010).
The LOAEL was adjusted for continuous exposure (5/7 days x 12/24 hours) to a LOAEL of 0.46 ppm and 
an uncertainty factor of 30 was used (3 for use of a minimal LOAEL and 10 for human variability).
ATSDR has derived an acute oral MRL of 0.2 mg/kg/day for 1-bromopropane based on a BMDL1SD of
19.75 mg 1-bromopropane/kg/day for impaired learning and memory in rats exposed via gavage for
12 days (Zhong et al. 2013). An uncertainty factor of 100 was used (10 for extrapolation from animals to 
humans and 10 for human variability).
IARC and the EPA have not evaluated the carcinogenicity of 1-bromopropane (IARC 2014; IRIS 2014).  
However, ACGIH has assigned 1-bromopropane a classification of “A3 – Confirmed animal carcinogen 
with unknown relevance to humans” (ACGIH 2014, 2016) and the Department of Health and Human 
Services has classified 1-bromopropane as “reasonably anticipated to be a human carcinogen” (NTP
2016).








      




      
  
   
 
  
   
     
  
 
   
  





8.  REGULATIONS, ADVISORIES, AND GUIDELINES
OSHA has not set permissible exposure limits (PELs) to protect workers against adverse health effects 
resulting from exposure to 1-bromopropane (OSHA 2013a, 2013b).  ACGIH has recommended a 
TLV-TWA of 0.1 ppm 1-bromopropane for workers (ACGIH 2014, 2016).  No guidelines for worker
exposure limits have been recommended by NIOSH (2014). The EPA has not derived RfDs or RfCs for
1-bromopropane.
The World Health Organization (WHO) has not established any air quality guidelines for 1-bromo-
propane (WHO 2010). 1-Bromopropane is not designated as a hazardous air pollutant, and no acute
exposure guidelines (AEGLs) have been derived (EPA 2013a, 2014a).  The Department of Energy (DOE) 
has established values for responding to potential releases of airborne 1-bromopropane for use in 
community emergency planning.  The values established by the DOE (2012) are the Protective Active 
Criteria (PAC-1, -2, and -3).  The PAC-1, -2, and -3 values are 18, 18, and 700 ppm, respectively,
represent increasing severity of effects (mild, irreversible, and life threatening, respectively) for a 1-hour
exposure (DOE 2012). The American Industrial Hygiene Association (AIHA) has not established
Emergency Response Planning Guidelines (ERPGs-1, -2, -3) for 1-bromopropane (AIHA 2014).
WHO has not established any drinking water guidelines for 1-bromopropane (WHO 2011) and the EPA
has not set drinking water standards for 1-bromopropane (EPA 2009a, 2009b, 2012, 2013c, 2013d, 
2014c).  The FDA has not set allowable levels for 1-bromopropane in bottled water (FDA 2013).
The international and national regulations, advisories, and guidelines regarding 1-bromopropane in air, 
water, and other media are summarized in Table 8-1.  






     
 
 
    
    
    
     
     
     
    
 
   
    
     
     






















     























     
     
     
  
 




8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to 
1-Bromopropane
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2014
WHO Air quality guidelines No data WHO 2010





ACGIH TLV-TWA 0.1 ppm ACGIH 2014, 2016
AIHA ERPGs No data AIHA 2014




EPA AEGLs No data EPA 2013a
Regulated toxic and flammable No data EPA 2013b
substances under Section 112(r) of the 40 CFR 68.130
Clean Air Act
Hazardous Air Pollutants No data EPA 2014a
NAAQS No data EPA 2014b
Protection of stratospheric ozone –
listing of substitutes for ozone-depleting 
substances
In solvent cleaning Acceptable (final rule) EPA 2007a
72 FR 30142
In adhesives and aerosols Unacceptable EPA 2007b
(proposed rule) 72 FR 30168
In coatings Acceptable subject to 
use conditions
(proposed rule)
NIOSH REL No data NIOSH 2014
IDLH No data
OSHA PEL (8-hour TWA) for general industry No data OSHA 2013a
29 CFR 1910.1000,
Table Z-1
Highly hazardous chemicals No data OSHA 2013b
29 CFR 1910.119,
Appendix A






     
 
 
    
    
    












   
 
  
   
 
  
   
  
  











     
    
      
     
     




    
 









     










   
 
  





8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to 
1-Bromopropane
Agency Description Information Reference
NATIONAL (cont.)
b. Water
EPA Designated as hazardous substances
in accordance with Section 311(b)(2)(A) 
of the Clean Water Act
No data
Drinking water contaminant candidate 
list
No data
Drinking water standards and health 
advisories
No data
National primary drinking water
standards
No data
National recommended water quality
criteria
No data
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
No data
c. Food




ACGIH Carcinogenicity classification A3b 
EPA Carcinogenicity classification No data
RfC No data
RfD No data
Chemical substances subject to 
proposed or final TSCA rules or orders
No data
TSCA Work Plan Chemical Risk No data
Assessment
Chemicals subject to EPCRA and 
Section 112(r) of the Clean Air Act
No data
Identification and listing of hazardous
waste
No data
Master Testing List No data
RCRA waste minimization PBT priority
chemical list
No data
Standards for owners and operators of
hazardous waste TSD facilities;
groundwater monitoring list
No data
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to 
1-Bromopropane
Agency Description Information Reference
NATIONAL (cont.)
Effective date of toxic chemical July 1, 2017 EPA 2013h
release reporting 40 CFR 372.65; EPA 
2015
Extremely hazardous substances No data EPA 2013i
and its threshold planning quantity 40 CFR 355,
Appendix A
DHHS Carcinogenicity classification Reasonably NTP 2016
anticipated to be a 
human carcinogen
aThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS.
bA3: Confirmed animal carcinogen with unknown relevance to humans.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
AEL = acceptable exposure limit; AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive 
Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations;
DHHS = Department of Health and Human Services; DOE = Department of Energy; EAFUS = Everything Added to 
Food in the United States; EPA = Environmental Protection Agency; EPCRA = Emergency Planning and Community
Right-To-Know Act; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration;
FR = Federal Register; GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer;
IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; NAAQS = National
Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National
Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria;
PBT = persistent, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation 
and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral
reference dose; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TSD = treatment, storage, and 
disposal; TWA = time-weighted average; USC = United States Code; WHO = World Health Organization
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1831-BROMOPROPANE
10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study— A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.












      




   





   












   
    
     
 
   
 
 
    
   
   
 
   
  
 
        
    
 
 





Ceiling Value—A concentration that must not be exceeded. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of
human health risk assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health.  
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.








    
     
  
 
   
 
 




      
 
 
    
    
 
    
  
 
     
 
 
















   
   









Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.








   
 
   
  
 
   
 
 
   
   








      






   
     
 
   
     
 
    




   
 
  
    
 
 
     
   





Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air 
averaged over any 8-hour work shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 






   
    
      
   
    
 
 
    
 
 
     
 
    
  
       
  
 





   
  




       
 
     
    
    
 
 
   
  





    
  




   
   
    
1871-BROMOPROPANE
10.  GLOSSARY
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as blood:air partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the
integrity of this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.















     
 
 









    
 
 
   
    





   
     
 
   
 
   
    
     
   
  
   
    
    
 
 
    
1881-BROMOPROPANE
10.  GLOSSARY
Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of
disease or other health-related event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be
exceeded at any time during a workday.  
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly
exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a 
Time Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling
limit (TLV-C).
Time-Weighted Average (TWA)—An average exposure within a given time period.  
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any substance that is foreign to the biological system.










    
  
 
      
   
 
  
    
    
   
    
    






   
     
   
   
 
    
 
   
   
 
     
  
A-11-BROMOPROPANE
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure. MRLs are based on noncancer health effects only and are not based on a
consideration of cancer effects. These substance-specific estimates, which are intended to serve as 
screening levels, are used by ATSDR health assessors to identify contaminants and potential health 
effects that may be of concern at hazardous waste sites.  It is important to note that MRLs are not
intended to define clean-up or action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive substance-induced
endpoint considered to be of relevance to humans.  Serious health effects (such as irreparable damage to 
the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that






     
  
    
   
   





   
   
    
  






are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
F-57, Atlanta, Georgia 30329-4027.
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APPENDIX A





Route: [X] Inhalation   [ ] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 10
Species: Rat
Minimal Risk Level:  1 [ ] mg/kg/day   [X] ppm
Reference:  Honma T, Suda M, Miyagawa M.  2003.  Inhalation of 1-bromopropane causes excitation in 
the central nervous system of male F344 rats.  Neurotoxicology 24(4-5):563-575.
Experimental design:  The study examined the effects of 1-bromopropane on several neurobehavioral
tests conducted in male F-344 rats.  Groups of rats were exposed whole-body to 0, 10, 50, 200, or
1,000 ppm 1-bromopropane vapors 8 hours/day, 7 days/week for 3 weeks.  All tests were conducted at
various times after the 3-week exposure period except for a traction test that was also conducted on 
exposure days 1, 7, and 14. In the traction test, rats are forced to hang from a horizontal bar with the
forelimbs and the time until the rat falls from the bar is recorded. The traction test is used to measure 
forelimb grip strength. Five rats per group were used in this test.
Effect noted in study and corresponding doses: No statistically significant differences in grip strength
were observed between exposed rats and controls on days 1 or 7.  On day 14, however, rats exposed to 
1,000 ppm 1-bromopropane showed a statistically significant decrease in grip strength compared to lower
exposure groups and controls, thus defining NOAEL and LOAEL values of 200 and 1,000 ppm, 
respectively, for neurological effects in an acute-duration inhalation study.  Because all data were
presented graphically, the means and standard error (SDs were subsequently calculated) for traction time
(assessed on day 14) were extracted digitally using GrabIt! Software (version XP2) (see Table A-1).
Table A-1. Digitized Dataset for Traction Time in Male F-344 Rats Exposed to
Vaporized 1-Bromopropane for 14 Daysa
Exposure concentration (ppm) Number of rats Traction time (seconds) Standard deviation
0 5 15.158 9.644
10 5 13.433 6.339
50 5 11.338 3.582
200 5 8.627 5.787
1,000 5 3.204b 2.480
aData extracted from Figure 11 in Honma et al. (2003).
bp<0.05.
Dose and end point used for MRL derivation: BMCL1SD of 97.50 ppm for neurological effects in male
rats.
[  ] NOAEL   [ ] LOAEL  [X]  BMCL1SD 








    
  
  
    
  
    
       
  
 
   
 
    
  
    
    





     






The traction time data were fit to all available continuous models in EPA’s Benchmark Dose Software
(BMDS, version 2.4.0) using a benchmark response of 1 SD change from control.  The following
procedure for fitting continuous data was used.  The simplest model (linear) was first applied to the data
while assuming constant variance.  If the data were consistent with the assumption of constant variance
(p≥0.1), then the fit of the linear model to the means was evaluated and the polynomial, power, 
exponential, and Hill models were fit to the data while assuming constant variance.  Adequate model fit
was judged by three criteria: goodness-of-fit p-value (p>0.1), visual inspection of the dose-response 
curve, and scaled residual at the data point (except the control) closest to the predefined benchmark
response.  Among all of the models providing adequate fit to the data, the lowest BMDL (95% lower
confidence limit on the BMD) was selected as the POD when the difference between the BMCLs 
estimated from these models were >3-fold; otherwise, the BMDL from the model with the lowest
Akaike’s Information Criterion (AIC) was chosen.  If the test for constant variance was negative, the 
linear model was run again while applying the power model integrated into the BMDS to account for
nonhomogenous variance.  If the nonhomogenous variance model provided an adequate fit (p≥0.1) to the
variance data, then the fit of the linear model to the means was evaluated and the polynomial, power, 
exponential, and Hill models were fit to the data and evaluated while the variance model was applied.
Model fit and POD selection proceeded as described earlier.  If the test for constant variance was negative 
and the nonhomogenous variance model did not provide an adequate fit to the variance data, then the data
set was considered unsuitable for modeling.
All but two BMD models provided adequate and nearly equivalent fits (see Table A-2) by the various
statistical criteria. Because the BMCL estimates are not sufficiently close, the model with the lowest
BMCL (Exponential model 4) was selected. The Exponential model calculates BMC1SD and BMCL1SD
values of 259.23 and 97.40 ppm, respectively, for decreased traction time (reduced grip strength) on
day 14 (see Figure A-1). 


























   
 
          
 
 
         
 
 
         
 
 
         
 
 
         
          
          
 
 
         
 
 
         
 
 
         




    
 
  
   
  
  





   





Table A-2. Model Predictions for Traction Time in Male F-344 Rats Exposed to
Vaporized 1-Bromopropane for 14 Days (Honma et al. 2003)


























0.01 0.46 0.51 -0.54 0.17 0.64 112.84 452.29 211.80
Exponential
(model 3)e 
0.01 0.46 0.51 -0.54 0.17 0.64 112.84 452.29 211.80
Exponential
(model 4)e,f 
0.01 0.46 0.45 0.08 0.01 0.36 114.10 259.23 97.40
Exponential
(model 5)e 





0.01 0.46 0.34 -0.86 0.06 -0.86 113.85 673.69 461.93
Polynomial
(3-degree)d 
0.01 0.46 0.34 -0.86 0.06 -0.86 113.85 673.69 461.93
Polynomial
(4-degree)d 
0.01 0.46 0.34 -0.86 0.06 -0.86 113.85 673.69 461.93
Powere 0.01 0.46 0.34 -0.86 0.06 -0.86 113.85 673.69 461.93
aValues >0.05 fail to meet conventional goodness-of-fit criteria.
bValues <0.10 fail to meet conventional goodness-of-fit criteria.
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.
dCoefficients restricted to be negative.
ePower restricted to ≥1.
fSelected model.  Constant variance model did not fit variance data, but non-constant variance model did. With non-
constant variance model applied all models, except for the Hill and the Linear (BMCL computation failed), provided 
adequate fit to the variance data.  BMCLs for models providing adequate fit were not sufficiently close (differed by 
>2–3-fold), so the model with the lowest BMCL was selected (Exponential 4 model; the Exponential 5 converged 
onto the Exponential 4).
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL1SD = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 1SD = exposure concentration associated to a change in the mean response equal to one
control standard deviation from the control mean); ND = not determined (BMCL computation failed or the BMC was
higher than the highest dose tested)















   
      
   
  
    
  
 








Figure A-1.  Selected Model (Exponential Model 4) for Decreased Grip Strength
Following Exposure to 1-Bromopropane (Honma et al. 2003)
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustment
[X]  10 for human variability
MRL = BMCL[HEC] / 30 (UF)
MRL = 32.3 ppm / 30 = 1 ppm
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
BMCL1SD[HEC] =  BMCL1SD[ADJ] x (Hb/gA / Hb/gH)

















    
 
   
   
 
   
  
   
   
 
      







BMCL1SD[ADJ] = 97.40 ppm x 8 hours/24 hours = 32.3 ppm
Hb/gA = animal blood:air partition coefficient = 11.7 (NTP-CERHR 2004)
Hb/gH = human blood:air partition coefficient = 7.08 (NTP-CERHR 2004)
(Hb/gA / Hb/gH) = 11.7/7.08 = 1.653
Because the ratio of the partition coefficients is >1, a default value of 1 was used.
BMCL[HEC] = 32.3 ppm x 1 = 32.3 ppm
Was a conversion used from intermittent to continuous exposure? Yes, see above.
Other additional studies or pertinent information that lend support to this MRL: Limited information 
from a few case studies showed that workers exposed to 1-bromopropane for a few weeks reported
subjective symptoms including respiratory irritation, headache, nausea, and lower extremity numbness, 
pain, and weakness; the geometric mean air concentration was 107 ppm for glue sprayers (range 58– 
254 ppm) (Raymond and Ford 2007).  An acute-inhalation study in rats reported decreased activity and 
ataxia after single exposures to ≥1,800 ppm, but not 300 ppm; however, only qualitative data were
provided (Kim et al. 1999). Intermediate-duration inhalation studies have shown that concentrations as
low as 50 ppm can induce changes in neurobehavior, muscle strength, electrophysiology, morphology, 
and biochemistry (Fueta et al. 2002; Honma et al. 2003; Ichihara et al. 2000b; Kim et al. 1999; Mohideen 
et al. 2011, 2013; Subramanian et al. 2012; Ueno et al. 2007; Wang et al. 2002, 2003; Yu et al. 2001).
Agency Contact (Chemical Manager): Nickolette Roney










   
  
  









     
  
   
    
   
   
 
 
     
  
      
    
     
  
     
  
     
    
     
   
    
   
   
 
     
 
      
 
 
     
      
   
   
     
A-81-BROMOPROPANE
APPENDIX A





Route: [X] Inhalation   [ ] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 55
Species: Rat
Minimal Risk Level:  0.1   [ ] mg/kg/day   [X] ppm
Reference:  Honma T, Suda M, Miyagawa M.  2003.  Inhalation of 1-bromopropane causes excitation in 
the central nervous system of male F344 rats.  Neurotoxicology 24(4-5):563-575. 
Experimental design:  The study examined the effects of 1-bromopropane on several neurobehavioral
tests conducted in rats. Tests included locomotor activity, open field behavior, passive avoidance test, 
water maze test, traction test and rota-rod tests.  Body weight and temperature were also monitored.  
Groups of male F-344 rats (4 per group) were exposed whole-body to 0, 10, 50, 200, or 1,000 ppm
1-bromopropane vapors 8 hours/day, 7 days/week for 3 weeks.  All tests were conducted at various times
after a 3-week exposure period except for a traction test that was also conducted on exposure days 1, 7, 
and 14.  
Effect noted in study and corresponding doses: Rats in the 1,000 ppm lost weight during the 3-week
exposure period.  At termination of exposure, body weight in the 1,000 ppm group was about 12% lower
than in controls.  However, it recovered over the next 25 days.  Body temperature also was significantly
reduced in 1,000 ppm group, especially during exposure days 1–7, but recovered when exposure ceased.
Spontaneous locomotor activity was significantly increased in rats exposed to 50 ppm 1-bromopropane on 
post-exposure days 1, 2, and 3 and in the group exposed to 200 ppm on post-exposure days 1, 2, 3, and 
4 (locomotor activity was not tested in rats exposed to 1,000 ppm 1-bromopropane).  The open field test
showed that exposure to 1-bromopropane reduced freezing time (all doses, but not significantly), 
significantly increased ambulation and rearing at 200 ppm, had no significant effect on preening, and 
significantly reduced defecation/urination at 1,000 ppm.  Exposure to 1-bromopropane did not affect
passive avoidance behavior.  1-Bromopropane increased latency time in the water maze test in the 
1,000 ppm group. In addition, 1-bromopropane at 200 and 1,000 ppm decreased traction performance 
indicating decreased muscle strength.  Performance in the rota-rod test (motor coordination) was not
significantly affected. Of all the parameters examined, locomotor activity appeared to be the most
sensitive and a NOAEL and LOAEL of 10 ppm and 50 ppm, respectively can be defined based on this
test.
Dose and end point used for MRL derivation: NOAEL of 10 ppm for neurological effects in male rats.
[X ] NOAEL   [ ] LOAEL
The spontaneous locomotor activity results were presented graphically; however, the data were not
amenable for extraction using GrabIt! Software (version XP2). Thus, the NOAEL/LOAEL approach was
used to identify the POD for the MRL. The data (Figure 3 in the study) are presented as changes in
spontaneous locomotor activity relative to pre-exposure levels (assigned as 100% activity) for each day
post-exposure that the test was performed (up to 6 days post-exposure).  The selection of which post-
exposure day (1–6) to model to compare treated and controls would have been entirely arbitrary.









   
      








   
 
 










    
 
   
    
    
      
   
  
    
  
     
      





Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustment
[X]  10 for human variability
MRL = 3.33 ppm / 30 (UF) = 0.1 ppm
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
NOAEL[HEC] =  NOAEL[ADJ] x (Hb/gA / Hb/gH)
where:
NOAEL[ADJ] = 10 ppm x 8 hours/24 hours = 3.33 ppm
Hb/gA = animal blood:air partition coefficient = 11.7 (NTP-CERHR 2004)
Hb/gH = human blood:air partition coefficient = 7.08 (NTP-CERHR 2004)
(Hb/gA / Hb/gH) = 11.7/7.08 = 1.653
Because the ratio of the partition coefficients is >1, a default value of 1 was used.
NOAELHEC] = 3.33 ppm x 1 = 3.33 ppm
Was a conversion used from intermittent to continuous exposure? Yes, see above.
Other additional studies or pertinent information that lend support to this MRL:  No human data suitable 
for MRL derivation.  However, the human data available suggests that the nervous system is a target for
1-bromopropane toxicity.  There are two publications of human cases exposed for intermediate durations
(from weeks to months) that provide exposure levels. A case discussed by Ichihara et al. (2002) (case 3)
was a woman who showed signs of staggering and numbness and paresthesias in the feet, thighs, lower
back, and hips, and complained of headaches after 2 months of using 1-bromopropane as a solvent with a 
spray gun.  Estimates of the exposure levels using a passive sampler indicated that the daily TWA
concentration ranged from 60 to 261 ppm with an average of 133±67 ppm (SD).  Raymond and Ford 
(2007) reported that four workers developed severe ataxia, sensory motor, and cognitive impairments
soon after the introduction of 1-bromopropane into their workplace as a furniture adhesive.  A survey
conducted by NIOSH 9 months after the four workers became ill showed that the workers could have
been exposed to a mean concentration of 1-bromopropane of 107 ppm (range 58–254 ppm). 
Agency Contact (Chemical Manager): Nickolette Roney
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Route: [X] Inhalation   [ ] Oral
Duration: [ ] Acute   [ ] Intermediate   [X] Chronic
Graph Key: 89
Species: Human
Minimal Risk Level: 0.02 [ ] mg/kg/day  [X] ppm
Reference: Li W, Shibata, E, Zhou Z, et al. 2010. Dose-dependent neurologic abnormalities in workers
exposed to 1-bromopropane. J Occup Environ Med 52(8):769-777.
Experimental design: The study examined the exposure-dependent effects of 1-bromopropane in a
population of workers and age-, sex-, and region-matched controls in three 1-bromopropane production 
plants in China.  The purity of the 1-bromopropane manufactured was >96% in one factory and ≥99% in 
the other two factories. The factories were evaluated at different times, but within the 2001–2005 year
period.  The final analysis comprised 120 women (60 exposed, 60 referents) and 52 men (26 exposed, 
26 referents).  The referents were randomly recruited from various factories not involved with 1-bromo-
propane; however, no monitoring data were available in the control factories. Workers from 1-bromo-
propane production plants could potentially be exposed to 1-bromopropane during: adding the chemical
into the reaction pots; sitting close to the reaction pots to observe and record the temperature; taking out
the crude product; adding hydroxy carbonate and stirring; or pouring the product into drums.  No 
protective masks were worn in any of the factories studied, but in one of the factories investigated in 
2001, the workers wore plastic gloves.  The exposure periods ranged from 35.9 to 47.0 months. Workers 
were asked to fill out a questionnaire that included age, sex, smoking or drinking habits, education, past
or present illnesses, and previous exposure to other chemicals and duration of exposure to 1-bromo-
propane. Electrophysiological studies measured motor nerve conduction velocity, distal latency, F-wave 
conduction velocity in the tibial nerve, sensory nerve conduction velocity in the sural nerve, and 
amplitude of the electromyography (EMG) elicited by stimulation of the motor nerve, and F-wave and 
potential of sensory nerve. Vibration sense was measured in the big toe, and reflexes and muscle strength 
were scored in four limbs.  Various neurobehavioral tests, including Santa Ana, simple reaction time, 
digit symbol, Benton test, digit span, and pursuit aiming tests, were conducted. The report, however, does
not indicate how often the tests were conducted. Comprehensive hematological and clinical tests were 
also conducted in addition to measuring serum TSH, LH, FSH, estradiol (females), and testosterone
(males).  Assessment of individual exposure to 1- and 2-bromopropane was done by analyzing the content
of passive samplers attached to each worker during one 8- or 12-hour shift.  This was done twice for two
shifts and the average exposure level was used as the representative exposure level. Individual TWA
exposure to 1-bromopropane ranged from 0.07 to 106.4 (median ± interquartile range, 6.6±16.3) ppm for
females and from 0.06 to 114.8 (median ± interquartile range, 4.6±11.6) ppm for males.  Females were 
classified into low-, mid-, and high-exposure groups (median exposures of 1.28, 6.6, and 22.58 ppm, 
respectively) and males into low- and high-exposure groups (median exposures of 1.05 and 12.5 ppm, 
respectively).  Data were analyzed in three different ways.  Continuous variables were analyzed with
ANOVA followed by Dunnett’s multiple comparison and scores of reflex and muscle strength were 
compared using nonparametric Wilcoxon test.  Linear regression analysis was performed to confirm the 
trend with the exposure level or the product of exposure level and period of exposure (cumulative
exposure).  The median value of each exposure group (rather than individual exposures) was used for
regression analysis or analysis of covariance (ANCOVA) on the exposure level.








   
 
     
        
       
      
 
      
  
       
    
  
  
    
   
  
   
    
     
     
 
     
   
     
  
   
 
    
   
   





   
       
  
   
    




    
   




Effect noted in study and corresponding doses: Dunnett's multiple comparison following ANOVA 
showed significant differences between controls and exposed female groups for tibial distal latency
(increase), sural sensory nerve conduction velocity (decrease), vibration sense threshold (increase), 
fatigue, serum LDH (increase), serum TSH (increase), serum FSH (increase), estradiol (decrease), white
blood cell (decrease), red blood cells (decrease), and hemoglobin and hematocrit (decrease). The most
sensitive effect was increased vibration sense threshold, which showed significant effects in all exposure
groups. No differences between controls and exposed men were seen except for increased BUN in 
exposed men.  Regression analysis adjusting for alcohol exposure and pair-matching for age, sex, and 
region in selecting controls showed significant trends in tibial distal latency, vibration sense in toes,
Benton test (test for visual perception and memory), BUN, LDH, TSH, red blood cells, hematocrit, and 
platelets in females.  In males, only BUN showed a significant trend. The same regression analysis on the
product of exposure levels and duration of exposure (cumulative exposure) showed significant increases
in tibial distal latency, vibration sense threshold, BUN, LDH, CK, TSH, MCV, MCH, red blood cells, and 
hematocrit in female workers and in BUN and Santa Ana non-preferred hand in male workers. Because 
estimation of vibration loss is influenced by the examining neurologist and body weight, which were not
controlled for in the regression analysis, an ANCOVA analysis on 1-bromopropane exposure level (or 1-
bromopropane cumulative exposure level), neurologist, age, height, body weight, and alcohol
consumption was conducted in female workers (n=60/group; body weight data was unavailable for five
age-matched pairs, so these pairs were assigned the average body weight of the group). The results 
showed that the effect of 1-bromopropane and cumulative 1-bromopropane were significant; however, the 
effect of examining neurologist was also significant.
This study has a number of limitations, some of which were identified by the investigators or pointed out
by others (Smith et al. 2011).  Of particular concern for the chronic inhalation MRL derivation are the
following limitations: (1) the cross-sectional study design; (2) potential selection bias for the control 
group; (3) potential underestimation of 1-bromopropane exposure levels; (4) lack of biomonitoring data
for controls; and (5) concerns regarding the vibration sense measurement method utilized in the study.
1. ATSDR acknowledges that use of a cross-sectional study design limits the ability to identify a
cause-effect relationship between 1-bromopropane and observed effects.  However, supporting
evidence from two other cross-sectional studies and several case-reports supported an association
between neurotoxic effects and exposure to 1-bromopropane (Ichihara et al. 2002; Majersik et al. 
2007; NIOSH 2002, 2003a; Raymond and Ford 2007; Samukawa et al. 2012; Sclar 1999; Wang 
et al. 2015).
2. ATSDR acknowledges that there may be selection bias in the identification of the age-, sex-, and 
region-matched controls. While the investigators stated that controls were “randomly” selected
from adjacent factories, it is unclear what methods were used to randomly select controls.
3. ATSDR acknowledges that estimated 1-bromopropane exposures provided by the study
investigators may be lower than actual exposures. The study authors indicated that windows and 
doors were wide open during the working hours, but it is reasonable to assume that windows
and/or doors may have been closed during rainy or cold weather.  If monitoring was conducted 
with windows and doors open, the exposure levels would be greater if windows and doors were
closed.  Study authors also indicate uncertainties in the cumulative exposure assessment, as 
measurements were taken over a 1–3-day period and presumed to be the same level for entire 
duration of employment.  Additionally, no details for the sampling rate on personal monitors was
provided and indoor air temperature during monitoring was not reported (temperature is essential
to convert the mass concentration in mg/m3 to ppm).  Furthermore, exposure levels were not
reported by factory or job description, which would have led to a more meaningful evaluation of
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results. Also, potential dermal exposure from lack of wearing gloves and oral exposure if hands 
were not properly washed prior to eating may have contributed to exposure levels beyond 
measured air levels (Smith et al. 2011).  In response, the study investigators clarified that plastic 
gloves were worn in at least one of the factories, decreasing the potential for dermal/oral exposure 
(Ichihara et al. 2011), but it does not appear that gloves were worn in other factories.  
4. Smith et al. (2011) raised concerns regarding lack of biomonitoring data for controls from nearby
factories not using 1-bromopropane, particularly the lack of exposure data for other potentially
neurotoxic chemicals.  However, ATSDR agrees with the study investigators, who proposed that
if neurotoxic chemical exposure did occur at control factories it would only serve to
underestimate the neurotoxic effects in the bromopropane-exposed group of workers (Ichihara et
al. 2011).
5. ATSDR acknowledges that the 128 Hz tuning fork is not the best choice for quantitative analysis 
of vibration sense between individuals, as more specialized equipment is available that would
have produced more quantitatively accurate results (such as the quantitative Rydel-Seiffer 64 Hz
tuning fork, bio/neurothesiometer, or Computer Assisted Sensation Examination IV [CASE IV]) 
(Burns et al. 2002; Levy 2010; Nizar et al. 2014; Pestronk et al. 2004; Willits et al. 2015).  
Identification of clinical vibration impairment using a tuning fork has been shown to overestimate
the quantitative vibration threshold (identified by the CASE IV system), and the discordance was 
associated with age, height, and body surface area of the subject (Burns et al. 2002).  However, 
the study authors acknowledged that clinical assessment of vibration threshold using a tuning fork
is inherently inaccurate due to examiner bias and subject characteristics (age, weight, height), and
reported that findings remained significant after statistical adjustment for examiner and subject
characteristics.  A follow-up letter to the editor by the study investigators clarified that examiners
were blinded to the exposure group (Ichihara et al. 2011), which was an initial concern raised by
Smith et al. (2011).  Other studies evaluating the 128 Hz tuning for the ability to accurately detect
loss of vibration sense in patients with diabetic neuropathy reported a sensitivity (ability to
diagnose condition if present) of 40–69% and a specificity (ability to diagnose lack of condition)
of 90–100%, compared with detection using the neurothesiometer (which is considered the
diagnostic tool of choice) (Nizar et al. 2014; Willits et al. 2015).  These values indicate that use of
a 128 Hz tuning fork to clinically identify loss of vibration sense will most likely underestimate
(rather than overestimate) the presence of dysfunction.  Additionally, by placing the tuning fork
on the examiner’s foot (once subjects indicated they could no longer feel vibration), the study
investigators deviated from the standard protocol (as described by Gilman 2002), which involves
removing the tuning fork from the subject and placing it on the examiner’s fingers (which are 
much more sensitive).  This deviation would also most likely underestimate (rather than 
overestimate) the presence of dysfunction. Taking into consideration all available evidence, 
while the 128 Hz tuning fork is not the most sensitive or quantitative assessment tool, it was able
to detect statistically significant differences between control and exposed groups after adjusting
for examiner and subject characteristics (age, weight, height).  Therefore, ATSDR considered 
data obtained using this method adequate for the derivation of the chronic inhalation MRL.
Other limitations of the study identified by Smith et al. (2011) or the study authors include: (1) lack of
control of the temperature of the skin of the legs may have impacted measurements of nerve conduction
velocity; (2) abnormally high control values for tibial nerve distal latency; (3) co-exposure to low levels 
of 2-bromopropane in the exposed group of workers (which has been shown to have reproductive and 
hematopoietic effects on workers and animals); and (4) no data on menstrual cycle of females (which
could have influenced some hematology and some clinical chemistry results).  While these limitations are 
acknowledged by ATSDR, they do not directly impact end points used in the MRL derivation because
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they relate either to neurological end points not selected as the basis for the MRL (limitations 1 and 2) or
to non-neurological end points (limitations 3 and 4).
Despite the limitations of this study, ATSDR still considers the study by Li et la. (2010) as the most
appropriate study for deriving the chronic inhalation MRL (see further discussion in Other additional
studies or pertinent information that lend support to this MRL section below).  However, it is noted that
the confidence in this MRL is low due to the acknowledged limitations. 
The results of the study by Li et al. (2010) suggest a minimal LOAEL of 1.28 ppm based on a statistically
significant increase in the vibration sense threshold in female workers.  Women in this exposure group 
also showed significantly slower sural nerve conduction velocity; however, this effect was not selected as 
the critical effect as it was not observed consistently in higher exposure groups and was not significant
based on regression analysis.  Other neurological effects observed in this study at higher exposures (≥6.6 
ppm) in female workers included increased tibial nerve distal latency.  Effects observed in hematology
and clinical chemistry are not considered by ATSDR to be biologically relevant because they were small
in magnitude and were generally within human reference ranges.  No NOAEL was identified for this 
study.  
Dose and end point used for MRL derivation: 1.28 ppm
[ ] NOAEL  [X] LOAEL
A minimal LOAEL of 1.28 ppm was identified for mild neurological impairment in females (increased
vibration sense threshold).  No NOAEL was identified.  BMD modeling was conducted on this end point; 
however, no models provided an adequate fit.
Uncertainty Factors used in MRL derivation:
[X]  3 for use of a minimal LOAEL
[ ]  10 for extrapolation from animals to humans
[X]  10 for human variability
MRL = 1.28 x 5 days/7 days x 12 hours/24 hours = 0.46 ppm
MRL = 0.46 ppm / 30 (UF) = 0.02 ppm
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? The exposure concentration was
adjusted to continuous exposure basis as shown above.  Although Li et al. (2010) report median exposure
levels based on TWA concentrations for 8- or 12-hour work shifts, the majority of workers (65%) had
12-hour work shifts.  
Other additional studies or pertinent information that lend support to this MRL: Candidate principal
studies considered for deriving the chronic inhalation MRL are shown in Table A-3.  Of the candidate
human studies, only the Li et al. (2010) study was adequate for consideration.  The NIOSH occupational
health surveys (2002, 2003a) did not contain a reference group.  Among the candidate animal studies, the
lowest LOAEL was for various histological alterations in the respiratory tract of mice (Morgan et al.
2011; NTP 2011); LOAELs from other available studies occur at much higher concentrations.  Therefore, 






   
    
     















































































both the Li et al. (2010) study in humans and the Morgan et al. (2011) study in mice were further
evaluated as potential principal studies. The critical effects, PODs, uncertainty factors, and candidate
MRL for each option are presented in Table A-4.  Candidate MRLs based on the key human and animal
studies are almost the same (0.02 and 0.03 ppm, respectively); rationale for selection of the human study
over the animal study as the critical study is discussed below.
Table A-3.  Studies Considered for Deriving the Chronic-Duration Inhalation MRL
Significant effects at NOAEL LOAEL
Study End point(s) evaluated LOAEL (ppm) (ppm)
Human studies
Li et al. (2010) Hematology, clinical chemistry Increased vibration threshold ND 1.28
Cross-sectional (including thyroid and 
occupational exposure reproductive hormones),
study; average neurological evaluation (nerve 
exposure duration conduction velocity, vibration 
~40 months sense, neurobehavioral
testing)
NIOSH (2003a) Hematology, clinical Subjective complaints of ND 45.7
Cross-sectional chemistry, questionnaire for neurotoxicity
occupational health neurological deficits, nerve 
survey; average conduction velocity
exposure duration 
~29 months
NIOSH (2002) Hematology, questionnaire for Subjective complaints of ND 117.1





Morgan et al. (2011); Comprehensive 2-year Various histological alterations ND 62.5
NTP (2011) bioassay; neurological in the nasal respiratory
B6C3F1 mice, function not assessed epithelium, larynx, trachea,
105 weeks and bronchioles
Morgan et al. (2011); Comprehensive 2-year Glandular hyperplasia in the ND 125
NTP (2011) bioassay; neurological nose (both sexes), chronic
F-344 rats, 105 weeks function not assessed active nasal inflammation 
(females)
BSOC (2001a) Comprehensive 2-generation Hepatocellular vacuolization in 100 250
Sprague-Dawley rats, reproductive toxicity study; F0 and F1 males, reduced 
2 generations (~16– neurological function not prostate weight in F0 males
18 weeks per assessed
generation)
LOAEL = lowest-observed-adverse-effect level; MRL = Minimal Risk Level; ND = not determined; NOAEL = no-
observed-adverse-effect level
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Table A-4.  Options for Derivation of Chronic-Duration Inhalation MRL Based on 
Principal Chronic Human and Animal Studies
Study Critical effect POD (ppm) UF MRL (ppm)
Human study






10 for human variability;













BMCL = lower limit on the benchmark concentration; CONV = converted to continuous exposure; HEC = human 
equivalent concentration; LOAEL = lowest-observed-adverse-effect level; MRL = Minimal Risk Level; POD = point of
departure; UF = uncertainty factor
Decreased vibration sense was identified as the most sensitive effect in the human occupational study by
Li et al. (2010).  As discussed above, there are numerous limitations to this study; however, the
identification of neurological impairment as the critical effect is supported by the NIOSH occupational
surveys and several human case reports of workers exposed to 1-bromopropane at workplace air
concentrations >45 ppm for weeks to years.  No other available study evaluated the reportedly low
exposure levels (median exposures of 4.6 ppm in men and 6.6 ppm in women) reported in the Li et al. 
(2010) study.  Reported neurological effects in workers in these other studies ranged from mild 
neurological impairments and complaints, such as numbness and tremors, to frank neurotoxic effects
requiring hospitalization, such as ataxia, spastic paraparesis, and symmetric demyelinating
polyneuropathy (Ichihara et al. 2002; Majersik et al. 2007; NIOSH 2002, 2003a; Raymond and Ford 
2007; Samukawa et al. 2012; Sclar 1999; Wang et al. 2015). Several of the case studies reported
decreased vibration sense, particularly in the lower extremities (Ichihara et al. 2002; Majersik et al. 2007;
Raymond and Ford 2007; Samukawa et al. 2012; Sclar 1999), supporting the selection of increased 
vibration sense threshold in the toe from the Li et al. (2010) study as the critical effect.  
Animal studies provide supporting evidence that exposure to 1-bromopropane can result in neurotoxicity.
Although neurological function has not been evaluated in animals following chronic exposure, observed 
effects in acute- and intermediate-duration inhalation rat studies at concentrations as low as 50 ppm
included changes in neurobehavior, muscle strength, electrophysiology, morphology, and biochemistry
(Fueta et al. 2002; Honma et al. 2003; Ichihara et al. 2000b; Kim et al. 1999; Mohideen et al. 2011, 2013;
Subramanian et al. 2012; Ueno et al. 2007; Wang et al. 2002, 2003; Yu et al. 2001).
In the chronic mouse study, lesions in the lung and nasal epithelium were the most sensitive effects
occurring at the lowest tested concentration, 62.5 ppm (Morgan et al. 2011; NTP 2011).  Lesions in the
lung and nasal epithelium were also found in F-344 rats at the lowest tested concentration, 125 ppm
(Morgan et al. 2011; NTP 2011).  In intermediate-duration animal studies, respiratory tract lesions were
found in mice exposed to concentrations as low as 125 ppm for 2–14 weeks (NTP 2011), but were not 
found in F-344 rats at concentrations up to 1000 ppm for 14 weeks (NTP 2011), Sprague-Dawley rats at
concentrations up to 1,800 ppm for 8–13 weeks (Albemarle Corporation 1997; Kim et al. 1999), or Wistar
rats at concentrations up to 800 ppm for 12 weeks (Ichihara et al. 2000a). These results suggest that mice 
are more sensitive to respiratory effects than rats following intermediate-duration inhalation exposure. 
Several acute and intermediate-duration rat studies found neurological effects at concentrations lower
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than those causing respiratory effects (as low as 50 ppm, see previous paragraph), providing support for
neurological effects as the critical effects following acute and intermediate-duration exposure.  In 
humans, the only evidence for respiratory effects was mild respiratory irritation reported in case studies of
workers experiencing frank neurotoxicity following exposure to >100 ppm 1-bromopropane (Ichihara et
al. 2002; Raymond and Ford 2007). The relative severities of the respiratory and neurotoxic effects in
these cases suggest that humans are more susceptible to neurotoxic effects from 1-bromopropane than 
respiratory effects.
Based on available data, neurological effects appear to be the most sensitive effect for workers repeatedly
exposed to 1-bromopropane and in animals exposed to 1-bromopropane for acute and intermediate
durations.  Neurological effects in chronically exposed animals, however, have not been adequately
studied to characterize the relative sensitivity of neurological effects versus respiratory effects.  In the 
absence of this information, a comparison was made of MRLs based on the minimal LOAEL for
neurological effects in workers in the Li et al. (2010) study and the LOAEL for respiratory tract lesions in
mice exposed for 2 years (Morgan et al. 2011; NTP 2011). The resultant MRLs were numerically
equivalent (Table 3).  Despite the limitations in the principal human study, ATSDR still considers Li et al. 
(2010) the best available study on which to base the MRL, principally because it is based on human data.  
ACGIH (2014) also used the same study to recommend a TLV-TWA of 0.1 ppm based on the LOAEL of
1.28 ppm for decreased vibration sense in toes from female workers in the Li et al. (2010) study. The
TLV-TWA is TWA concentration for a conventional 8-hour workday and a 40-hour workweek, to which 
it is believed that nearly all workers may be repeatedly exposed, day after day, for a working lifetime 
without adverse effect (AGCIH 2016). Confidence in the chronic MRL is low because of the limitations
of the principal study, but could be improved with additional and better-designed neurological evaluations 
(cross-sectional or prospective) of workers exposed to 1-bromopropane in workplace air.  
Agency Contact (Chemical Manager): Nickolette Roney
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Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 7
Species: Rat
Minimal Risk Level: 0.2 [X] mg/kg/day   [ ] ppm
Reference: Zhong Z, Zeng T, Xie K, et al. 2013. Elevation of 4-hydroxynonenal and malondialdehyde
modified protein levels in cerebral cortex with cognitive dysfunction in rats exposed to 1-bromopropane.
Toxicology 306:16-23.
Experimental design: The study examined the effects of 1-bromopropane on cognitive function in male
Wistar rats and the possible role of oxidative stress.  Groups of rats (10/group) were administered 0, 200, 
400, or 800 mg 1-bromopropane/kg/day by gavage in corn oil for 12 consecutive days.  On days 8–12, 
cognitive function (spatial learning and memory) was assessed with the Morris water maze test. Twenty-
four hours after the last dose, the rats were killed, and the cerebral cortex was removed.  The following
were measured in cerebral cortex homogenates: GSH, oxidized glutathione (GSSG), total thiol (total -SH)
content, GSH reductase and GSH peroxide (GSH-Px) activities, and MDA level, as well as 4-HNE and
MDA modified proteins.
Effect noted in study and corresponding doses: Some rats in the 400 and 800 mg 1-bromopropane/kg/day 
groups showed irritability at the start of dosing.  After 1 week of dosing, rats in the 800 mg 1-bromo-
propane/kg/day group showed slow response and sluggishness.  Final body weight was reduced about
13% in the high-dose group; no data on food consumption were provided. Dose-related impairments 
were observed in learning and memory measures of the Morris water maze.  During the 4-day learning
phase, the escape latency was significantly increased in the 800 mg 1-bromopropane/kg/day group and 
the total swimming distance was increased at ≥200 mg 1-bromopropane/kg/day. Time spent in different 
swimming “search” patterns (direct finding, approaching target, random searching, and thigmotaxis)
differed significantly in all exposed groups, compared with controls, with exposed animals showing
increased thigmotaxis (time spent in periphery of tank).  On day 5, when the escape platform was 
removed to assess memory, all exposure groups showed a significant decrease in the number of times 
they crossed the former location of the target platform; rats exposed to 800 mg 1-bromopropane/kg/day 
also showed a significant decrease in time spent in the target quadrant.  Assessment of biochemical
indices showed an increase in oxidative stress (increased MDA and GSSG, decreased GSH, and 
decreased GSH reductase activities), mostly observed in the mid- and high-dose groups.  Tests with 
specific monoclonal antibodies also showed increased total levels of reactive aldehyde modified proteins 
in the cerebral cortex.
A LOAEL of 200 mg/kg/day was identified for this study based on impaired spatial learning and memory
(increased swimming distance, altered search pattern, decreased number of crossings of the escape 
platform); no NOAEL was identified.  All data were presented graphically.  The SDs could not be 
extracted from day 1–4 figures either because they overlapped between dose-groups (total swimming
distance) or they were not reported (distribution of search patterns); therefore, these data could not be
used for BMD analysis.  However, the means and SDs for the number of crossing of the escape platform













    
    
    
    












     
  
    
   
        
  





(assessed on day 5) were extracted digitally using GrabIt! software (version XP2) for BMD analysis
(Table A-5).  Alternate data extraction of the means and SDs using DigitizeIt software resulted in BMDLs 
that differed by <17% on average, which would yield the same MRL.
Table A-5.  Digitized Dataset for Number of Crossings of Escape Platform
Location on Day 5a
Dose (mg/kg/day) Animal number Mean (number) Standard deviation
0 10 7.2 2.8
200 10 4.3b 2.6
400 10 3.7c 2
800 10 2.4c 2
aData extracted from Figure 3B in Zhong et al. (2013).
bp<0.05.
cp<0.01.
Dose and end point used for MRL derivation: 19.75 mg/kg/day
[ ] NOAEL   [ ] LOAEL [X] BMDL1SD
All models provided an adequate and nearly equivalent fits (see Table A-6) by the various statistical
criteria, but the BMDLs had a 15.4-fold range, indicating some model dependence of the BMDL
estimates. The range of results is judged to be reasonable, because the range of the absolute differences 
between the individual BMDs and their corresponding BMDLs was comparable, ranging from about
111 to 130 mg/kg/day. Because the BMDL estimates are not sufficiently close, selecting the model with
the lowest BMDL is recommended (EPA 2012b).  Thus, the BMDL of 19.75 mg/kg/day from the Hill
model is a reasonable conservative estimate. The Hill model calculates BMD1SD and BMDL1SD values of
148.37 and 19.75 mg/kg/day, respectively, for decreased spatial memory in rats on day 5 of the Morris
water test (see Figure A-2).






























         
 
 
         
 
 
         
 
 
         
          
          
 
 
         
 
 
         




    
  
    










Table A-6.  Model Predictions for Effects of 1-Bromopropane on the Spatial
Memory Ability of Rats
Scaled residualscTest for
significant Dose Dose BMD1SD BMDL1SD 
difference Variance Means below above Overall (mg/kg/ (mg/kg/ 
Model p-valuea p-valueb p-valueb BMD BMD largest AIC day) day)
All doses
Constant variance
Exponential 0.002 0.61 0.45 -0.9692 0.0365 0.579 112.63 266.03 154.01
(model 2)d 
Exponential 0.002 0.61 0.45 -0.9692 0.0365 0.579 112.63 266.04 154.01
(model 3)d 
Exponential 0.002 0.61 0.52 0.0777 -0.3698 0.4757 113.46 165.96 55.12
(model 4)d 
Exponential 0.002 0.61 0.52 0.0777 -0.3698 0.4757 113.46 165.96 55.12
(model 5)d 
Hilld,e 0.002 0.61 0.63 0.0291 -0.247 0.384 113.29 148.37 19.75
Linearr 0.002 0.61 0.15 -1.22 -0.573 1.2 114.85 435.59 305.49
Polynomial 0.002 0.61 0.15 -1.22 -0.573 1.2 114.85 435.59 305.49
(2-degree)r 
Polynomial 0.002 0.61 0.15 -1.22 -0.573 1.2 114.85 435.59 305.49
(3-degree)r 
Powerd 0.002 0.61 0.15 -1.22 -0.573 1.2 114.85 435.59 305.49
aValues >0.05 fail to meet conventional goodness-of-fit criteria.
bValues <0.10 fail to meet conventional goodness-of-fit criteria.
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.
dPower restricted to ≥1.
eSelected model. With constant variance applied, all the models provided an adequate fit to means. BMDLs for 
models providing adequate fit differed by >threefold, so the model with the lowest BMDL (Hill) was selected.  The Hill
model also provided the best fit in the low-dose range (based on scaled residuals).
fCoefficients restricted to be negative.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 1SD = exposure concentration associated to a change in the mean response equal to one
control standard deviation from the control mean)






    
  
 





   
    









    
 
    
  
 
    
A-201-BROMOPROPANE
APPENDIX A
Figure A-2. Selected Model (Hill) for Impaired Spatial Memory Following 
Exposure to 1-Bromopropane (Zhong et al. 2013)





















0  100  200  300  400  500  600  700  800 
dose 
15:59 10/21 2014 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
MRL = 19.75 mg/kg/day ÷ 100 = 0.2 mg/kg/day
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
Not applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Marked decreases in
spontaneous activity (sedation), piloerection, and dyspnea were reported in rats exposed once to 2,000 mg 
1-bromopropane/kg in a lethality study by Elf Atochem S.A. (1993).  Clinical signs were observed within 
4 hours of dosing; surviving animals (9/10) fully recovered by day 2 of the 14-day observation period. Of






       
   
   
     
     
    
    
        
      
    
   
 
 
    
      
    
   
  
 
    
   
  
     
      
 
  
      
 
 
   
 
    
  
   
   
   
   
      
     





direct relevance to the results of Zhong et al. (2013) are the results of a recent study by the same groups of
investigators, which confirmed the previous results and reported that treatment of male Wistar rats with
≥200 mg 1-bromopropane/kg/day for 12 days impaired spatial memory and spatial learning ability (Guo 
et al. 2015). In this study, rats exposed to ≥200 mg 1-bromopropane/kg/day tested in the Morris Water
Maze showed a significantly dose-related decreased percent of time at the target platform; the NOAEL
was 100 mg 1-bromopropane/kg/day.  Modeling these data yielded a BMDL1SD (POD) of 77.94 mg
1-bromopropane/kg/day, which is higher than the BMDL1SD of 19.75 mg 1-bromopropane/kg/day used to 
derive the current MRL. Therefore, it is still more appropriate (more protective) to use data from Zhong
et al. (2013) to derive an acute-duration oral MRL for 1-bromopropane. Also relevant is another study
from the same group of investigators that reported motor abnormalities in rats administered ≥200 mg
1-bromopropane/kg/day for up to 16 weeks (Wang et al. 2012).  Only limited data from this study were
available for review.
While evidence for neurotoxicity following oral exposure is limited, human and animal evidence from
inhalation studies indicate that the nervous system is a target for 1-bromopropane toxicity.  Mild
neurological symptoms have been reported in humans at median TWA workplace air levels as low as 
1.28 ppm (Li et al. 2010), and two NIOSH health surveys and several case reports of workers exposed for
months to years indicate that higher exposure levels (>45 ppm) can lead to more severe, even permanent,
effects (Ichihara et al. 2002; Majersik et al. 2007; NIOSH 2002; Raymond and Ford 2007; Samukawa et
al. 2012; Sclar 1999). Neurological effects ranged from mild neurological impairments and complaints
with acute exposure, such as headache, numbness and weakness, to frank neurotoxic effects requiring
hospitalization following exposure for months or years, such as ataxia, spastic paraparesis, and symmetric 
demyelinating polyneuropathy. Evidence from animal studies supports that exposure to 1-bromopropane
can result in neurotoxic effects. Observed effects in acute and intermediate-duration inhalation studies at
concentrations as low as 50 ppm included changes in neurobehavior, muscle strength, electrophysiology, 
morphology, and biochemistry (Fueta et al. 2002; Honma et al. 2003; Ichihara et al. 2002; Kim et al.
1999; Mohideen et al. 2011, 2013; Subramanian et al. 2012; Suda et al. 2008; Ueno et al. 2007; Wang et
al. 2002, 2003; Yu et al. 2001; Zhang et al. 2013).  
All other effects observed in acute studies occurred at or above the LOAEL of 200 mg 1-bromo-
propane/kg/day identified in the neurobehavioral study by Zhong et al. (2013).  Observed effects included 
reduced antibody responses to the T-dependent SRBC antigen at ≥200 mg 1-bromopropane/kg/day (Lee
et al. 2007); congestion, hemorrhage, cellular swelling and vacuolization of hepatocytes in mouse liver at
≥500 mg 1-bromopropane/kg/day, but not 200 mg 1-bromopropane/kg/day (Lee et al. 2007); degeneration 
of spermatocytes in mouse testes at 600 mg 1-bromopropane/kg/day (only dose tested) (Yu et al. 2008);
and a 13% decrease in body weight at 800 mg 1-bromopropane/kg/day, but not ≤400 mg 1-bromo-
propane/kg/day (Zhong et al. 2013).  While the LOAEL of 200 mg 1-bromopropane/kg/day for immune
effects was considered as the basis of the MRL, the evidence supporting that 1-bromopropane is an
immunosuppressant (Anderson et al. 2010; Lee et al. 2007) is far less than the evidence indicating that
1-bromopropane is a neurotoxicant (discussed above).
Agency Contact (Chemical Manager): Nickolette Roney
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B-11-BROMOPROPANE
APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.






   
      
    
 
 
    
     
     
 
 
   
  
     
 
 
    
  
  
    
    
    
    
  
 
      
    









    
     
  
   
  
    




   





MRLs should help physicians and public health officials determine the safety of a community living near
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily
dose in water. MRLs are based largely on toxicological studies in animals and on reports of human
occupational exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.










     
   
  
  
   
 
 
      




    
       
   
 
 
   
  
  
   
 






   
    
   
  
    
 
 
    
 




     






See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures include 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7) System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").







    
       
    
    
      
    
 
 
    
 
     













   
 
 
   
  
 
   
      
 
   
   





      
      
     
 
     





(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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APPENDIX B
(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).






     
 













    
      

















































































































































1 → Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to frequency/ NOAEL



































10 (CEL, lung tumors,
nasal tumors)




Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
12 → a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 






    

























Chronic (≥ 365 days) Intermediate (15-364 days)
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C-11-BROMOPROPANE
APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
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APPENDIX C
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
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APPENDIX C
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
mt metric ton
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances












   
   









   
  
  
   
  
   
   
   
   
  
  
















   
  
  










OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
PEL-C permissible exposure limit-ceiling value
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
REL-C recommended exposure level-ceiling value
RfC reference concentration (inhalation)
RfD reference dose (oral)
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TLV-C threshold limit value-ceiling value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell














   
  
  
















WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
